
<html lang="en"     class="pb-page"  data-request-id="15a5283e-fbd9-4cf9-839c-acf5e22ac444"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-21;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b00971;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy" /></meta><meta name="dc.Creator" content="Zhangjian  Huang" /></meta><meta name="dc.Creator" content="Yi  Mou" /></meta><meta name="dc.Creator" content="Xiaojun  Xu" /></meta><meta name="dc.Creator" content="Di  Zhao" /></meta><meta name="dc.Creator" content="Yisheng  Lai" /></meta><meta name="dc.Creator" content="Yuwen  Xu" /></meta><meta name="dc.Creator" content="Cen  Chen" /></meta><meta name="dc.Creator" content="Ping  Li" /></meta><meta name="dc.Creator" content="Sixun  Peng" /></meta><meta name="dc.Creator" content="Jide  Tian" /></meta><meta name="dc.Creator" content="Yihua  Zhang" /></meta><meta name="dc.Description" content="Currently, no effective and safe medicines are available to treat diabetic nephropathy (DN). Bardoxolone methyl (CDDO-Me) has displayed promising anti-DN activity as well as serious side effects in..." /></meta><meta name="Description" content="Currently, no effective and safe medicines are available to treat diabetic nephropathy (DN). Bardoxolone methyl (CDDO-Me) has displayed promising anti-DN activity as well as serious side effects in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 19, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00971" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00971" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00971" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00971" /></link>
        
    
    

<title>Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00971" /></meta><meta property="og:title" content="Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0009.jpeg" /></meta><meta property="og:description" content="Currently, no effective and safe medicines are available to treat diabetic nephropathy (DN). Bardoxolone methyl (CDDO-Me) has displayed promising anti-DN activity as well as serious side effects in clinical trials, probably because the highly reactive α-cyano-α,β-unsaturated ketone (CUK) in ring A of CDDO-Me can covalently bind to thiol functionalities in many biomacromolecules. In this study, we designed and synthesized a γ-glutamyl transpeptidase (GGT)-based and CUK-modified derivative of CDDO-Me (2) to address this issue. 2 can be specifically cleaved by GGT, which is highly expressed in the kidney, to liberate CDDO-Me in situ. It should be noted that 2 exhibited anti-DN efficacy comparable to that of CDDO-Me with much less toxicity in cells and db/db mice, suggesting that its safety is better than CDDO-Me. Our findings not only reveal the therapeutic potential of 2 but also provide a strategy to optimize other synthetic molecules or natural products bearing a pharmacophore like CUK to achieve safer pharmaceutical drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00971"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00971">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00971&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00971&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00971&amp;href=/doi/10.1021/acs.jmedchem.7b00971" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 8847-8857</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00924" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00979" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhangjian++Huang">Zhangjian Huang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>#</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6409-8535" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Mou">Yi Mou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaojun++Xu">Xiaojun Xu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Di++Zhao">Di Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yisheng++Lai">Yisheng Lai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuwen++Xu">Yuwen Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cen++Chen">Cen Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ping++Li">Ping Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sixun++Peng">Sixun Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jide++Tian">Jide Tian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihua++Zhang">Yihua Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-2378-7064" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff6"><span class="aff-text"><sup>†</sup>State Key Laboratory of Natural Medicines, <sup>‡</sup>Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, and <sup>§</sup>Center of Drug Metabolism and Pharmacokinetics, College of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Crystal Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California 90095, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1c66747d727b76757d7274697d727b5c7f6c6932797869327f72"><span class="__cf_email__" data-cfemail="29534148474e43404847415c48474e694a595c074c4d5c074a47">[email protected]</span></a> (Z.H.).</div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#c8b0a1a9a7a2bda6b0bdfaf8f8f888f9fefbe6aba7a5"><span class="__cf_email__" data-cfemail="661e0f07090c13081e1354565656265750554805090b">[email protected]</span></a> (X.X.).</div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#7d070415091a193d4c4b4e531e1210"><span class="__cf_email__" data-cfemail="106a6978647774502126233e737f7d">[email protected]</span></a> (Y.Z.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00971&amp;href=/doi/10.1021%2Facs.jmedchem.7b00971" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 8847–8857</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 10, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 July 2017</li><li><span class="item_label"><b>Published</b> online</span>19 October 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 November 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00971" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00971</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8847%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DZhangjian%2BHuang%252C%2BYi%2BMou%252C%2BXiaojun%2BXu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D21%26contentID%3Dacs.jmedchem.7b00971%26title%3DNovel%2BDerivative%2Bof%2BBardoxolone%2BMethyl%2BImproves%2BSafety%2Bfor%2Bthe%2BTreatment%2Bof%2BDiabetic%2BNephropathy%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8857%26publicationDate%3DNovember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00971"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2251</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">19</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00971" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zhangjian&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Mou&quot;},{&quot;first_name&quot;:&quot;Xiaojun&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Di&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Yisheng&quot;,&quot;last_name&quot;:&quot;Lai&quot;},{&quot;first_name&quot;:&quot;Yuwen&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Cen&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Ping&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Sixun&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Jide&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Yihua&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8847-8857&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00971&quot;},&quot;abstract&quot;:&quot;Currently, no effective and safe medicines are available to treat diabetic nephropathy (DN). Bardoxolone methyl (CDDO-Me) has displayed promising anti-DN activity as well as serious side effects in clinical trials, probably because the highly reactive α-cyano-α,β-unsaturated ketone (CUK) in ring A of CDDO-Me can covalently bind to thiol functionalities in many biomacromolecules. In this study, we designed and synthesized a γ-glutamyl transpeptidase (GGT)-based and CUK-modified derivative of CDDO-Me (2) to address this issue. 2 can be specifically cleaved by GGT, which is highly expressed in the kidney, to liberate CDDO-Me in situ. It should be noted that 2 exhibited anti-DN efficacy comparable to that of CDDO-Me with much less toxicity in cells and db/db mice, suggesting that its safety is better than CDDO-Me. Our findings not only reveal the therapeutic potential of 2 but also provide a strategy to optimize other synthetic molecules or natural products bearing a pharmacophore like CUK to achieve safer pharma&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00971&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00971" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00971&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00971" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00971&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00971" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00971&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00971&amp;href=/doi/10.1021/acs.jmedchem.7b00971" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00971" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00971" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00971%26sid%3Dliteratum%253Aachs%26pmid%3D28994286%26genre%3Darticle%26aulast%3DHuang%26date%3D2017%26atitle%3DNovel%2BDerivative%2Bof%2BBardoxolone%2BMethyl%2BImproves%2BSafety%2Bfor%2Bthe%2BTreatment%2Bof%2BDiabetic%2BNephropathy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D21%26spage%3D8847%26epage%3D8857%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/jmcmar.2017.60.issue-21/20171109/jmcmar.2017.60.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Currently, no effective and safe medicines are available to treat diabetic nephropathy (DN). Bardoxolone methyl (CDDO-Me) has displayed promising anti-DN activity as well as serious side effects in clinical trials, probably because the highly reactive α-cyano-α,β-unsaturated ketone (CUK) in ring A of CDDO-Me can covalently bind to thiol functionalities in many biomacromolecules. In this study, we designed and synthesized a γ-glutamyl transpeptidase (GGT)-based and CUK-modified derivative of CDDO-Me (<b>2</b>) to address this issue. <b>2</b> can be specifically cleaved by GGT, which is highly expressed in the kidney, to liberate CDDO-Me in situ. It should be noted that <b>2</b> exhibited anti-DN efficacy comparable to that of CDDO-Me with much less toxicity in cells and <i>db</i>/<i>db</i> mice, suggesting that its safety is better than CDDO-Me. Our findings not only reveal the therapeutic potential of <b>2</b> but also provide a strategy to optimize other synthetic molecules or natural products bearing a pharmacophore like CUK to achieve safer pharmaceutical drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65147" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65147" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">α,β-Unsaturated ketone is an important pharmacophore in many natural products and synthetic small molecules that reacts with a variety of thiols in biomacromolecules via Michael addition. These reactions may modulate signaling pathways and lead to various biological activities in vivo.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Synthetic derivatives of the natural product oleanolic acid (OA),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> such as 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its ester (CDDO-Me, i.e., bardoxolone methyl) and amide (CDDO-Im) forms (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) with two α,β-unsaturated ketone moieties in rings A and C, respectively, display potent anti-inflammatory and antioxidant activities through activating the Kelch-like ECH-associated protein 1 (Keap1)–nuclear factor E2 related factor 2 (Nrf2)/antioxidant response element (ARE) signaling pathway.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> It has been reported that α-cyano-substituted α,β-unsaturated ketone (CUK) in ring A instead of α,β-unsaturated ketone in ring C of CDDO-Me attacks Cys151 in the BTB domain of Keap1 protein through Michael addition,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> resulting in the dissociation of Keap1 and Nrf2 and preventing the proteolysis of Nrf2. The free Nrf2 then translocates into the nucleus and binds to the ARE, inducing the expression of Nrf2 target genes, including NAD(P)H:quinoneoxidoreductase 1 (NQO1), glutathione-S-transferases (GSTs), and heme-oxygenase-1 (HO-1).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Similarly, CDDO-Me also attacks Cys-179 of inhibitor of nuclear factor kappa-B kinase (IKK) and thus inhibits NF-κB signaling.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Given that oxidative stress and inflammation are major risk factors for the development of diabetic nephropathy (DN),<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> CDDO-Me has already been clinically investigated for its anti-DN effects. Treatment with CDDO-Me in an amorphous spray-dried dispersion formulation initially improved the estimated glomerular filtration rate (eGFR) in patients with DN at stages 3b–4;<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> however, CDDO-Me increased the hospitalization rate and mortality due to heart failure in patients with stage 4 DN in a phase III clinical trial,<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> leading to the termination of the clinical trial. Currently, the mechanism underlying the detrimental adverse effects of CDDO-Me is still elusive. Notably, mitochondrial function is essential for maintaining myocardial tissue homeostasis, and many anticancer drugs such as doxorubicin, herceptin, and cisplatin directly or indirectly deteriorate cardiac mitochondrial function, leading to serious cardiotoxic effects.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> It was reported that a rapid and selective depletion of mitochondrial glutathione induced by CDDO-Me may be responsible, at least in part, for its cytotoxic effects.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Furthermore, it is known that CDDO-Me is a potent antiangiogenesis agent,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and impaired angiogenesis may bring about the transition from cardiac hypertrophy to heart failure.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> It is also known that diabetic patients with a higher risk of heart dysfunction may be more sensitive to CDDO-Me.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> Accordingly, although a phase II clinical trial of CDDO-Me for the treatment of DN has been reinitiated in Japan,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> the cardiac safety of CDDO-Me remains a serious concern.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Rationale for the design of a GGT-based and CUK-modified derivative of CDDO-Me (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since CDDO-Me interacts with 577 cellular proteins, as revealed by a proteomic analysis,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> the side effects of CDDO-Me may be attributed to its highly reactive CUK moiety in ring A, which reacts with thiol(s) in other proteins besides Keap1 and IKKβ through Michael addition. Accordingly, we envisioned that rational structural modification of CUK in CDDO-Me might reduce its off-target effects. However, the ordinary, simple modification of α,β-unsaturated ketone compounds<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> is not suitable for use with CDDO-Me. The major issue is that the 1,4-addition reaction of CUK results in a reversible product.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> Indeed, we have found that the 1,4-addition product, enol <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), obtained by reaction of the CUK with sodium hydroxide was easily converted back to CDDO-Me through a 1,4-elimination reaction. Nevertheless, it has been reported that the enol, generated from the 1,4-addition of a CUK-containing compound to a Grignard reagent, could be etherified by a substituted chlorosilane to generate a stable siloxane compound.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These successful conversions of CUK to the enol and then to the siloxane suggested the possibility of designing a new derivative of CDDO-Me by a similar structural modification of its CUK. Considering the fact that γ-glutamyl transpeptidase (GGT) is expressed mainly in the kidney and has been utilized for GGT-based renal targeting drugs,<a onclick="showRef(event, 'ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36">(29-36)</a> we designed a GGT-based and CUK-modified derivative of CDDO-Me (<b>2</b>) by coupling enol <b>1</b> with 4-glutamylbenzyl bromide, and we hypothesized that <b>2</b> would be relatively stable in circulation and other organs but could be specifically cleaved by GGT in the kidney, followed by 1,6-elimination<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> to generate intermediate <b>1</b> in situ, which may subsequently produce CDDO-Me via 1,4-elimination, as depicted in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>.</div><div class="NLM_p last">To verify this hypothesis, we synthesized compound <b>2</b>, investigated its stability, pharmacokinetics, and tissue distribution, and compared its therapeutic efficacy and safety with those of CDDO-Me in vitro and in vivo.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Synthesis of Compound <b>2</b></h3><div class="NLM_p">N-Fmoc glutamic acid monomethyl ester <b>3</b> was condensed with 4-aminophenylmethanol <b>4</b> in the presence of 2-ethoxy-1(2<i>H</i>)-quinoline carboxylic acid ethyl ester (EEDQ) to give amide <b>5</b>. Bromination of <b>5</b> in the presence of phosphorus tribromide furnished benzyl bromide <b>6</b>. Meanwhile, CDDO-Me was treated with NaOH in DMF to offer enol <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Without further purification, <b>1</b> was etherified with <b>6</b> to give enol ether <b>7</b>. Finally, removal of the N-protective group in <b>7</b> provided target compound <b>2</b>. Compound <b>8</b> could be generated by hydrolysis of <b>2</b> in the presence of plasma or liver homogenate (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions and reagents: (a) EEDQ, CH<sub>2</sub>Cl<sub>2</sub>, rt for 12 h; (b) PBr<sub>3</sub>, anhydrous THF, 0 °C for 0.5 h; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C for 12 h; (d) NHEt<sub>2</sub>, anhydrous CH<sub>2</sub>Cl<sub>2</sub>; (e) plasma or liver homogenate.</p></p></figure></div><div id="sec2-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Absolute Configuration of C1 in <b>2</b></h3><div class="NLM_p last">As mentioned above, the 1,4-addition of sodium hydroxide to the 1,2-double bond in CDDO-Me generates enol <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) with chirality at C1. Since the methyl group with a large amount of steric hindrance at C10 is present on the plane of ring A, the OH<sup>–</sup> should theoretically attack C1 (ortho to C10) under the plane, finally generating C1 with an R configuration in compounds <b>1</b>, <b>2</b>, <b>7</b>, and <b>8</b>. Initially, we tried to prepare a single crystal of compound <b>2</b> to confirm this, but we failed after several attempts over period of months. Eventually, analogue <b>9</b> [(1-hydroxyl-2-cyano-3-benzyloxy)-12-oxo-oleana-2(3),9(11)-dien-28-oic acid methyl ester, CCDC1471081, see the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf" class="ext-link">Supporting Information</a>] with the same configuration of C1 as that of <b>2</b> was synthesized and analyzed by X-ray diffraction. The absolute configuration of C1 in <b>9</b> was successfully assigned as R, thus establishing the R configuration of C1 in compound <b>2</b>.</div></div><div id="sec2-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> <b>2</b> Has Improved Solubility Compared to CDDO-Me</h3><div class="NLM_p last">Because the introduction of both hydroxyl and glutamic acid moieties at C1 and C3 in ring A of CDDO-Me, respectively, may improve aqueous solubility, we determined the solubility of <b>2</b> by using a well-established HPLC method.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> We found that its solubility was 0.0089 mg/mL in saline, which increased significantly to 12.23 mg/mL in mixed solvents of saline with 1% 1,3-propylene glycol and 1% Tween 80. In contrast, CDDO-Me could not be dissolved in these solvents.</div></div><div id="sec2-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Release of CDDO-Me from <b>2</b> Promoted by GGT in Vitro</h3><div class="NLM_p">Next, we investigated the stability of <b>2</b> in different medium by HPLC. After incubating <b>2</b> in PBS (pH = 7.4) at 37 °C for 8 h, around 20% of it was turned over (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A) with no CDDO-Me detected. To determine whether <b>2</b> could release CDDO-Me in the presence of GGT, incubation of <b>2</b> in Krebs buffer (pH = 7.4) with GGT (1 U/mL) at 37 °C for 8 h resulted in around 54% of <b>2</b> converted to CDDO-Me (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). Subsequently, incubation of <b>2</b> with GGT (1 U/mL) and a porcine liver esterase (2 U/mL) under the same conditions increased the conversion of <b>2</b> to CDDO-Me up to 88% (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C). We reasoned that GGT might preferentially recognize <b>8</b> with a free glutamine acid moiety, which was produced via hydrolysis of <b>2</b> by the esterase to generate CDDO-Me. Furthermore, incubation of <b>2</b> with rat kidney homogenates at 37 °C for 8 h caused 66% of <b>2</b> to be converted to CDDO-Me (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>D). In addition, we found that over 60% of <b>2</b> in rat plasma was converted into <b>8</b>, and only 4.2% was hydrolyzed to CDDO-Me (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>E); 32% of <b>2</b> was converted to CDDO-Me in the liver homogenates (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>F). As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B–D, <b>8</b> might be easily transferred to CDDO-Me in the presence of GGT, a combination of GGT and esterase, and rat kidney homogenate. Collectively, <b>2</b> was relatively stable in aqueous buffers, plasma, and liver homogenates, whereas it was labile, liberating CDDO-Me through the action of GGT in kidney homogenate.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Stability of <b>2</b> in various media. <b>2</b> was incubated in (A) PBS (pH = 7.4), (B) PBS (pH = 7.4) with (1 U/mL) GGT, (C) PBS (pH = 7.4) with (1 U/mL) GGT and (2 U/mL) esterase from porcine liver, (D) rat kidney homogenate, (E) rat plasma, and (F) rat liver homogenate. The conversion of <b>2</b> to <b>8</b> or further to CDDO-Me was measured by HPLC. Results in panels B–F are expressed as the mean ± SD from three individual experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> <b>2</b> Activates Keap1–Nrf2–ARE Signaling More Strongly than CDDO-Me</h3><div class="NLM_p">It is known that CDDO-Me can activate the Keap1–Nrf2–ARE signaling axis and exhibit a potent cytoprotective effect.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Additionally, <b>2</b> was found to be converted to CDDO-Me in the presence of GGT, as well as in rat kidney homogenate, plasma, and liver homogenate (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B–F, respectively). It was therefore of interest to determine whether <b>2</b> possesses the ability to activate Nrf2 signaling. Human embryonic kidney 293 (HEK293) cells were transfected with a Nrf2/ARE luciferase reporter and then treated with <b>2</b> or CDDO-Me. Treatment with <b>2</b> stimulated the activity of Nrf2 in HEK293 cells, which was similar to treatment with CDDO-Me (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). Next, the effect of <b>2</b> on Nrf2 activation was assessed by quantitative RT-PCR and western blot assays. Treatment with <b>2</b> or CDDO-Me did not change the relative levels of the <i>Nrf2</i> mRNA transcript (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B), but it significantly increased the relative levels of <i>HO-1</i> and <i>NQO1</i> mRNA transcripts in HEK293 cells (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C,D). Furthermore, treatment with <b>2</b> or CDDO-Me significantly increased the ratio of nuclear to cytosolic Nrf2 protein and the relative levels of HO-1 and NQO1 in HEK293 cells. Interestingly, the effect of <b>2</b> on stimulating Nrf2 signaling was stronger than that of CDDO-Me and tended to be dose-dependent (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>E–I).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>2</b> activates Nrf2 signaling. (A) HEK293 cells were transfected with an ARE-dependent luciferase reporter plasmid and subsequently treated in triplicate with CDDO-Me or <b>2</b> at the indicated concentrations for 48 h. Luciferase activity was measured to assess Nrf2 activity. HEK293 cells were treated in triplicate with <b>2</b> (200, 1000 nM) or CDDO-Me (200, 1000 nM) for 48 h, and the relative levels of <i>Nrf2</i> (B), <i>HO-1</i> (C), and <i>NQO1</i> (D) mRNA transcripts were analyzed by quantitative RT-PCR. Furthermore, the relative levels of nuclear and cytosolic Nrf2 (E), the ratio of nuclear to cytosolic Nrf2 (G), HO-1 (F, H), and cytoplasmic NQO1 (F, I) expression were analyzed by western blot assay. Results are representative images and expressed as the mean ± SD of each group from three individual experiments. *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <b>2</b> Exhibits Antioxidant and Anti-Inflammatory Activities Comparable to CDDO-Me</h3><div class="NLM_p">As mentioned previously, CDDO-Me can inhibit inflammation and NF-κB activation by inhibiting IκBα kinase β (IKKβ) activity to prevent IκB phosphorylation and degradation.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> To determine whether <b>2</b> has anti-inflammatory activity, HEK293 cells were transfected with an NF-κB luciferase reporter plasmid to test the impact of <b>2</b> on TNF-α stimulated NF-κB activation and luciferase activity. Treatment with TNF-α alone significantly increased the luciferase activity in HEK293 cells, whereas treatment with either <b>2</b> or CDDO-Me significantly reduced TNF-α induced luciferase activity (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Similarly, treatment with TNF-α alone significantly increased the relative levels of <i>iNOS</i>, <i>COX2</i>, <i>MCP-1</i>, and <i>TNF-α</i> mRNA transcripts, whereas treatment with <b>2</b> or CDDO-Me significantly decreased the TNF-α induced upregulation of NF-κB target genes such as <i>iNOS</i>, <i>COX2</i>, and <i>MCP-1</i> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B–E). In addition, treatment with <b>2</b> or CDDO-Me significantly mitigated the TNF-α induced increase in the ratio of nuclear to cytosolic p65, as well as the expression of NF-κB target genes in HEK293 cells (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>F–J). In conclusion, <b>2</b> exhibited antioxidant and anti-inflammatory activities in HEK293 cells, comparable to those of CDDO-Me.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>2</b> on NF-κB signaling. (A) HEK293 cells were transfected with an NF-κB driven luciferase reporter plasmid, and the effects of <b>2</b> on TNF-α induced NF-κB activity were determined. Furthermore, HEK293 cells were pretreated with TNF-α (10 ng/mL) for 6 h and then incubated in triplicate with <b>2</b> (200, 1000 nM) or CDDO-Me (200, 1000 nM) for 24 h. The relative levels of <i>iNOS</i> (B), <i>COX2</i> (C), <i>MCP-1</i> (D), and <i>TNF-α</i> (E) mRNAs to the control <i>GAPDH</i> mRNA in HEK293 cells were detected by quantitative RT-PCR, whereas the relative levels of nuclear and cytosolic p65 (F, G) and the expression of NF-κB target genes iNOS (H, I) and COX2 (H, J) in HEK293 cells were measured by western blot assay. Results are representative images or expressed as the mean ± SD of each group of cells from three individual experiments. *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <b>2</b> Displays Anti-DN Effects Comparable to CDDO-Me</h3><div class="NLM_p">To examine the effect of <b>2</b> on DN,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><i>db/db</i> mice at 8 weeks of age were randomized and treated intraperitoneally with vehicle, <b>2</b> (1 or 2 mg/kg), or CDDO-Me (0.65 mg/kg) three times per week for 12 consecutive weeks. We found that there was no significant difference in the amount of food and water consumed among the different groups of mice (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf" class="ext-link">Table S10</a>). Furthermore, the vehicle-treated mice lost about 15% of their body weight by the end of experiment. Treatment with CDDO-Me significantly increased the body weight of the mice by 11.3%, but treatment with either dose of <b>2</b> did not significantly change the body weight of the mice. In comparison with the DN control mice, treatment with <b>2</b> or CDDO-Me significantly reduced the levels of plasma urea nitrogen (BUN) and uric acid (UA) and also slightly decreased the levels of plasma creatinine in mice. Treatment with <b>2</b> or CDDO-Me significantly reduced the 24 h urine volumes and the levels of urinary albumin, whereas it increased the levels of urinary creatinine and reduced the urine albumin to creatinine ratio (UACR) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A–D). These results indicate that the anti-DN effect of <b>2</b> was comparable to that of CDDO-Me.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Treatment with <b>2</b> significantly mitigates DN-related kidney damage in mice. The mice were treated with CDDO-Me (0.65 mg/kg, the same molar ratio as 1 mg/kg <b>2</b>) or <b>2</b> (1 or 2 mg/kg) for 12 weeks. At the 11th week, the 24 h urine volumes (A) and levels of urinary albumin (B) and creatinine (C) in individual mice were measured before the mice were sacrificed, and the urine albumin to creatinine ratio (D) in individual mice was calculated. Furthermore, the kidney sections (5 μm) were stained with hematoxylin–eosin, Masson’s trichrome, and periodic acid Schiff (E, magnification ×400). The ultrathin kidney sections were subjected to TEM analysis (F–J). The thickness of the GBM in individual mice was measured, and a total of 30 locations for each mouse were calculated (K). Data are representative images and expressed as the mean ± SD of individual groups of mice (<i>n</i> = 6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Histological examination revealed moderate and severe fibrosis, reduced numbers of intraglomerular mesangial cells, and enlarged mesangial area with thickened capillary walls in the glomeruli of the model group of mice (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>E). In contrast, treatment with either <b>2</b> or CDDO-Me significantly reduced the pathogenic changes in the glomeruli of mice. Further transmission electron microscopy (TEM) analysis revealed that fused podocytes with a loss of foot processes and increased mesangial expansion and glomerular basement membrane (GBM) thickening, the hallmarks of DN,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> were detected in the kidney glomeruli of the model group of mice, whereas treatment with <b>2</b> or CDDO-Me improved the glomerular injury in mice (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>F–J).</div><div class="NLM_p last">Quantitative analysis indicated that treatment with either <b>2</b> or CDDO-Me significantly mitigated the DN-related GBM thickness in the kidney of the mice (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>K). Collectively, treatment with <b>2</b> significantly improved the kidney function in <i>db/db</i> mice, similar to that with CDDO-Me.</div></div><div id="sec2-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Pharmacokinetics of <b>2</b> in Rats</h3><div class="NLM_p">The pharmacokinetics of <b>2</b> was then evaluated in rats and compared with CDDO-Me. After intravenous administration of <b>2</b> (10 mg/kg) or CDDO-Me (10 mg/kg) to rats, blood samples were taken from the suborbital vein at 0, 2, 5, 15, 30, and 60 min and 1.5, 2, 4, 6, 8, 12, and 24 h and analyzed by LC-MS/MS. The corresponding plasma concentration–time profiles of <b>2</b> and CDDO-Me are shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A, and pharmacokinetic parameters are given in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. AUC<sub>0–∞</sub> (area under the concentration–time curve from time zero to infinity), <i>t</i><sub>1/2</sub> (half-life), and <i>C</i><sub>max</sub> (maximum plasma concentration) of <b>2</b> were 531.3 ± 178.2 μg·h/L, 1.3 ± 0.6 h, and 3020 ± 1361.7 μg/L, and for CDDO-Me, they were 2179.2 ± 370.5 μg·h/L, 4.4 ± 2.4 h, and 5016.7 ± 2631.8 μg/L, respectively. The CL (clearance rates) of <b>2</b> and CDDO-Me was 20.4 ± 7.2 and 4.7 ± 0.8 L/h/kg, respectively, and <i>V</i><sub>ss</sub> (distribution volumes) for <b>2</b> and CDDO-Me was 35.1 ± 12.4 and 29.1 ± 14.6 L/kg, respectively.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Plasma concentration–time profiles of <b>2</b> and CDDO-Me. After intravenous administration of <b>2</b> (10 mg/kg) or CDDO-Me (10 mg/kg) to rats, blood samples were taken from the suborbital vein at 0, 2, 5, 15, 30, and 60 min and 1.5, 2, 4, 6, 8, 12, and 24 h and analyzed by LC-MS/MS. (B–D) Tissue distribution study of <b>2</b> and CDDO-Me. Individual rats were injected intraperitoneally with CDDO-Me (0.04 mmol, 20 mg/kg) or <b>2</b> (0.04 mmol, 30 mg/kg), and their tissue (including heart, kidney, and liver) samples were collected longitudinally and analyzed by LC-MS/MS. (B) Tissue distribution of CDDO-Me, (C) tissue distribution of <b>2</b>, and (D) generation of CDDO-Me from <b>2</b> measured by LC-MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Plasma Pharmacokinetic Parameters after Intravenous Administration of <b>2</b> and CDDO-Me at a Dose of 10 mg/kg to Rats<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–t</sub> (μg·h/L)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0–∞</sub> (μg·h/L)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">CL (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μg/L)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">509.461 ± 169.171</td><td class="colsep0 rowsep0" align="char" char="±">531.346 ± 178.19</td><td class="colsep0 rowsep0" align="char" char="±">1.307 ± 0.602</td><td class="colsep0 rowsep0" align="char" char="±">20.398 ± 7.19</td><td class="colsep0 rowsep0" align="char" char="±">35.066 ± 12.377</td><td class="colsep0 rowsep0" align="char" char="±">3020 ± 1361.653</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDDO-Me</td><td class="colsep0 rowsep0" align="char" char="±">2057.201 ± 369.88</td><td class="colsep0 rowsep0" align="char" char="±">2179.198 ± 370.487</td><td class="colsep0 rowsep0" align="char" char="±">4.413 ± 2.372</td><td class="colsep0 rowsep0" align="char" char="±">4.683 ± 0.838</td><td class="colsep0 rowsep0" align="char" char="±">29.07 ± 14.552</td><td class="colsep0 rowsep0" align="char" char="±">5016.667 ± 2631.812</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Mean ± SD, <i>n</i> = 3.</p></div></div></div><div class="NLM_p last">Considering the fact that <b>2</b> could be rapidly converted to CDDO-Me and <b>8</b> in the presence of GGT as well as in rat kidney homogenate and plasma (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B–E) and that <b>8</b> as a precursor of CDDO-Me with a free glutamic acid moiety could be preferably recognized by GGT and quickly transferred to CDDO-Me (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B–D), it would be expected that <b>2</b> would possess a faster metabolic behavior relative to CDDO-Me, leading to the lower values of AUC<sub>0-∞</sub>, <i>t</i><sub>1/2</sub>, and <i>C</i><sub>max</sub> of <b>2</b> compared to those of CDDO-Me.</div></div><div id="sec2-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Liberation of CDDO-Me from <b>2</b> in the Kidney of Rats</h3><div class="NLM_p last">On the basis of the above pharmacokinetics results and the potent anti-DN effect of <b>2</b>, the tissue distributions of <b>2</b> and CDDO-Me were investigated. Individual rats were injected intraperitoneally with CDDO-Me (0.04 mmol, 20 mg/kg) or <b>2</b> (0.04 mmol, 30 mg/kg), and tissue (including heart, kidney, and liver) samples were collected longitudinally. LC-MS/MS analysis indicated that CDDO-Me was distributed preferably in the kidney (4.52 μg/g, 90 min), but was present in lower amounts in the liver (1.55 μg/g, 90 min) and heart (1.58 μg/g, 90 min) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A,B). In contrast, <b>2</b> was predominantly distributed in the liver (6.04 μg/g, 90 min), but was present in lower amounts in the heart (1.31 μg/g, 90 min) and kidney (1.23 μg/g, 10 min; 1.0 μg/g, 30 min; 0.8 μg/g, 90 min) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C). Importantly, after administration of <b>2</b>, CDDO-Me liberated from <b>2</b> was detected exclusively in the kidney (0.04 μg/g, 10 min; 0.09 μg/g, 30 min; and 0.18 μg/g, 90 min) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>D). Although the amount of CDDO-Me detected in the kidney of <b>2</b>-treated rats was relatively lower than that of CDDO-Me-treated rats, the ratio of CDDO-Me to <b>2</b> in the former case increased over 90 min (from 3.3 to 9% and then to 22.5%). Given that CDDO-Me reportedly exhibits potent anti-inflammatory and antioxidant activities at nanomolar levels,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> it would be expected that <b>2</b> would exert anti-DN activity at such low concentrations of CDDO-Me generated from <b>2</b> in the kidney. On the other hand, at higher concentrations (micromolar to millimolar), CDDO-Me could generate potent toxicity toward cancer and noncancer cells.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Accordingly, we believe that the gradual generation of CDDO-Me with lower concentrations from <b>2</b> in the kidney where GGT is highly expressed as well as the lack of CDDO-Me existing in the heart 90 min after the administration of <b>2</b> may be beneficial for the safety of <b>2</b>, especially cardiac safety.</div></div><div id="sec2-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <b>2</b> Is Less Cytotoxic and Relatively Safer than CDDO-Me</h3><div class="NLM_p">To determine the cytotoxicity of <b>2</b>, cardiomyocyte H9C2 and HEK293 cells were treated with or without <b>2</b> or CDDO-Me for 24 h. The cytotoxicity of each compound was measured by MTT assay, and the IC<sub>50</sub> values were calculated (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf" class="ext-link">Table S11</a>). Compound <b>2</b> was less toxic toward HEK293 cells than CDDO-Me (IC<sub>50</sub>: 56.5 vs 2.2 μM). Similarly, <b>2</b> had less toxicity against H9C2 cells than CDDO-Me (IC<sub>50</sub>: 112.5 vs 5.2 μM). The lower cytotoxicity of <b>2</b> may be attributed to its slow release of CDDO-Me by GGT in both types of cells, suggesting that <b>2</b> may be relatively safer than CDDO-Me.</div><div class="NLM_p">The human ether-a-go-go-related gene (hERG) encodes the α subunit of a potassium ion channel (Kv11.1), and inhibition of this channel can result in long QT syndrome, a fetal disorder associated with severe adverse effects of drugs.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Accordingly, we tested the potential effects of <b>2</b> and CDDO-Me on hERG channel activity by a patch-clamp assay in Chinese hamster ovary (CHO) cells that stably express hERG. Both <b>2</b> and CDDO-Me had very low hERG inhibitory activity (IC<sub>50</sub> > 200 μM), and treatment with <b>2</b> at 200 μM inhibited hERG activity by only 36.09%, which was significantly lower than the 45.72% inhibition observed by the same dose of CDDO-Me (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf" class="ext-link">Figure S5</a>). These results suggest that <b>2</b> may display less inhibition of hERG than CDDO-Me.</div><div class="NLM_p">To evaluate toxicity in vivo, we first performed an acute toxicity test. We found that intraperitoneal treatment with CDDO-Me up to 600 mg/kg or <b>2</b> up to 1000 mg/kg daily for 7 days resulted in a LD<sub>50</sub> value of <b>2</b> (886 mg/kg), which was over 2-fold higher than that of CDDO-Me (425 mg/kg) in ICR mice.</div><div class="NLM_p">Further TUNEL analysis indicated that a high frequency of apoptotic cells was detected in the cardiac tissue from aged <i>db</i>/<i>db</i> mice, and treatment with <b>2</b>, but not with CDDO-Me, significantly reduced the percentage of apoptotic cardiomyocytes (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A–F). These results further indicated that treatment with <b>2</b>, but not CDDO-Me, protected from long-term hyperglycemia-mediated cardiomyocyte apoptosis in aged <i>db</i>/<i>db</i> mice.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>2</b> is relatively safer than CDDO-Me. Control C57BL/6 mice (A) or 8 week old <i>db/db</i> mice were randomized and treated intraperitoneally with vehicle control (B), CDDO-Me (0.65 mg/kg, C), or <b>2</b> (1 mg/kg, D; 2 mg/kg, E) for 12 weeks. The apoptotic cells in the cardiac tissues were determined by TUNEL assay, and the percentage of apoptotic cardiomyocytes was calculated from three sections of each mouse (<i>n</i> = 6 per group, F). Data are representative images (magnification ×200) or expressed as the mean ± SD of each group from two separate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Long-term hyperglycemia is associated with the development of complications such as DN. Approximately, 20–40% of diabetic patients eventually develop DN.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Control of hyperglycemia and hypertension can help slow the pathogenic process of DN, and a great number of drugs have already been developed for the treatment of DN in recent decades. However, the clinical efficacy and safety of these drugs are unsatisfactory, particularly in patients with later stage DN.<a onclick="showRef(event, 'ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48 ref49">(46-49)</a> Therefore, new drugs with an improved efficacy and safety profile are urgently needed for the treatment of patients with DN.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">Our previous studies focused on the anti-inflammation and anticancer properties of CDDO-Me and its derivatives.<a onclick="showRef(event, 'ref43 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref43 ref51 ref52">(43, 51, 52)</a> In this study, we presented a novel strategy to rationally mask the CUK moiety of CDDO-Me in the non-target organs and tissues, leading to a CUK-modified CDDO-Me derivative (<b>2</b>), which could be specifically cleaved into CDDO-Me in the kidney by GGT. Compound <b>2</b> displayed better water solubility than CDDO-Me due to the introduction of hydroxyl and amine moieties to C1 and C3 in ring A of CDDO-Me, respectively. Interestingly, <b>2</b> exhibited comparable anti-DN efficacy to CDDO-Me. In <i>db</i>/<i>db</i> mice, <b>2</b> decreased proteinuria, inhibited glomerular sclerosis, and mitigated DN-related GBM thickness and podocyte damage. Importantly, <b>2</b> has obvious advantages in term of safety as compared with CDDO-Me. The cytotoxicity of <b>2</b> against H9C2 and HEK293 cells was much less than that of CDDO-Me. In ICR mice, the LD<sub>50</sub> value of <b>2</b> was over 2-fold higher than that of CDDO-Me. Treatment with CDDO-Me greatly increased the frequency of apoptotic cardiomyocytes; in sharp contrast, treatment with <b>2</b> significantly mitigated long-term hyperglycemia-induced spontaneous cardiomyocyte apoptosis in aged <i>db</i>/<i>db</i> mice. These results strongly suggest that <b>2</b> may be a relatively safer agent for intervention of DN.</div><div class="NLM_p">Importantly, this CUK-modifying strategy may be valuable for other pharmacological applications of CDDO-Me to avoid off-target effects. Given that CDDO-Me possesses potent anticancer activity,<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53, 54)</a> 4-boronic acid pinacol ester-substituted benzyl<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55, 56)</a> may be employed to etherify the 3-hydroxy of <b>1</b> to generate a ROS-inducible compound, which can be oxidized in cancer cells where ROS abundantly exists,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> to produce a 4-hydroxyl benzyl moiety, initiating a 1,6-elimination reaction to form <b>1</b>. Subsequently, <b>1</b> may undergo 1,4-elimination to liberate CDDO-Me, exerting anticancer activity.</div><div class="NLM_p last">In addition to CDDO-Me, this CUK-modifying strategy can be extended to other active synthetic molecules or natural products bearing a Michael acceptor similar to CUK to avoid the off-target effects associated with these compounds.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86751" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86751" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we developed a novel GGT-based and CUK-modifying strategy by rationally masking the highly reactive pharmacophore CUK in CDDO-Me. The achieved compound <b>2</b> exhibited comparable activity against DN but much less cardiotoxicity than CDDO-Me. These findings together with the high sequence homology between rodent and human GGT<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> suggest that compound <b>2</b> may be a relatively safer and valuable candidate for the treatment of DN. In addition, we provide a new strategy to optimize other molecules with a pharmacophore like CUK to obtain safer pharmaceutical drugs.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20670" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20670" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The purity of all tested compounds was characterized by HPLC analysis (LC-10A HPLC system consisting of LC-10ATvp pumps and a SPD-10Avp UV detector). Individual compounds with a purity of >95% were used for subsequent experiments.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of <b>2</b> [1-Hydroxyl-2-cyano-3-(4-(methyl-<span class="smallcaps smallerCapital">l</span>-glutaminate-<i>N</i><sup>5</sup>-yl)-benzyloxy)-12-oxo-oleana-2(3),9(11)-dien-28-oic Acid Methyl Ester]</h3><div class="NLM_p last">HNEt<sub>2</sub> (4 mL) was added to a solution of <b>7</b> (720 mg, 0.72 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The mixture was stirred at ambient temperature for 30 min before it was neutralized with ice-cold saturated aqueous NaHCO<sub>3</sub> (10 mL) and further diluted with water (20 mL). The resulting opaque solution was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> and brine (20 mL × 3) and were then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The residue was purified by flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH, 2/1) to give <b>2</b> as an amorphous solid (396 mg, 71%). mp: 158–160 °C; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 7.59 (s, 2H, ArH), 7.38 (s, 2H, ArH), 5.87 (s, 1H, CDDO C<sub>11</sub>H), 5.40–5.44 (m, 2H, benzyl-CH<sub>2</sub>), 4.45 (s, 1H, CDDO C<sub>1</sub>H), 3.72 (s, 3H, OCH<sub>3</sub>), 3.70 (s, 3H, OCH<sub>3</sub>), 3.50–3.58 (m, 1H, Glu-α-CH), 2.22–2.38 (m, 2H, Glu-γ-CH<sub>2</sub>), 1.28 (s, 3H), 1.16 (s, 6H), 1.06 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H), 0.89 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 202.1, 179.9, 178.7, 176.9, 176.2, 172.5, 140.6, 132.9, 132.8, 130.1, 129.4, 126.3, 121.1, 88.5, 75.2, 75.0, 53.8, 53.5, 52.4, 51.0, 46.7, 45.8, 43.8, 42.4, 41.8, 37.2, 35.4, 34.0, 33.7, 33.3, 33.0, 31.9, 31.5, 30.8, 29.4, 28.7, 24.7, 24.3, 23.8, 23.5, 21.6, 20.8, 19.4; IR (neat, cm<sup>–1</sup>): 2978 (s), 2945 (s), 2208 (s), 1720 (s), 1662 (s), 1521 (s), 1219 (m), 1064 (m); ESI-MS (<i>m</i>/<i>z</i>): 772.5 [M + H]<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated C<sub>45</sub>H<sub>61</sub>N<sub>3</sub>O<sub>8</sub>Na 772.4537, found 772.4551, PPM error 1.8.</div></div><div id="sec5-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Stability of <b>2</b></h3><div class="NLM_p last">Compound <b>2</b> (100 μM) was incubated in triplicate in Krebs buffer (37 °C, pH 7.4) in the presence or absence of GGT (1 U/mL, MBS173093, MyBioSource) and the glutamyl acceptor Gly-Gly (5 mM, Energy Chemical). After hydrolysis by GGT, the reactions were diluted with two volumes of acetonitrile and centrifuged to remove the enzyme, followed by HPLC analysis. Similarly, the stability of <b>2</b> was assessed in Krebs buffer (37 °C, pH 7.4) with the addition of esterase from porcine liver (2 U/mL, E3019, Sigma-Aldrich), GGT (1 U/mL), and Gly-Gly (5 mM). The plasma samples were prepared from three Wistar rats, and their kidney and liver tissue homogenates were also prepared in PBS. Subsequently, <b>2</b> (100 μM) was mixed with the plasma or homogenates, and the amount of <b>8</b> was detected using HPLC at intervals of 60 min for 8 h.</div></div><div id="sec5-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Cell Culture, Luciferease Reporter Assay, Quantitative RT-PCR, Western Blot</h3><div class="NLM_p last">HEK293 and H9C2 cells were from ATCC and maintained in high-glucose DMEM supplemented with 10% FBS (Hyclone). HEK-293 cells were transfected with a plasmid encoding NF-κB-controlled luciferase expression (Promega) and treated in triplicate with <b>2</b> or CDDO-Me for 48 h. Subsequently, the luciferase activity in each group of cells was measured using the dual-luciferase reporter assay system, according to the manufacturer’s instruction. Furthermore, HEK293 cells were pretreated with or without TNF-α (10 ng/mL) for 6 h and then treated in triplicate with or without <b>2</b> or CDDO-Me for 48 h. Total RNA was extracted from individual groups of cells with TRIzol (Invitrogen) and reverse transcribed into cDNA using iScript reverse transcriptase (Bio-Rad). The levels of target gene mRNA transcripts relative to that of control GAPDH were determined by quantitative RT-PCR using specific primers (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf" class="ext-link">Table S8</a>) and SsoFast EvaGreen supermix (Bio-Rad) in a Roche LightCycler 96 system. The data were analyzed by the 2<sup>–ΔΔCt</sup> method. In addition, the relative levels of Nrf2, TBP, HO-1, NQO1, β-actin, iNOS, COX2, and nuclear and cytosolic NF-κB p65 in individual groups of cells were determined by western blot assays using specific antibodies (Cell Signaling Technology).</div></div><div id="sec5-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Animal Experiments</h3><div class="NLM_p last">All animal experiments were conducted according to the guidelines approved by the Ministry of Health of the People’s Republic of China (Document No. 55, 2001) as well as by the Science and Technology Department of Jiangsu Province (SYXK (SU) 2016-0011). Male <i>db</i>/<i>db</i> mice at 8 weeks of age were obtained from the National Resource Center of Model Mice, Nanjing, and housed in a specific pathogen-free facility with normal chow and filtered water ad libitum. The mice were randomized and treated intraperitoneally with vehicle (5% Tween-80 in 0.9% saline, the model group), <b>2</b> (1 or 2 mg/kg, <i>n</i> = 6 per group), or CDDO-Me (0.65 mg/kg) three times per week for 12 consecutive weeks. Their body weight and water and food consumption were measured every other day. Eleven weeks after drug administration, the 24 h urine samples were collected from individual mice for analysis of total volumes. Subsequently, blood samples from individual mice were obtained. The mice were sacrificed, and their kidneys, hearts, livers, and other major organs were collected. The levels of urine albumin and creatinine in individual mice were measured. The levels of plasma BUN, creatinine, and uric acid in individual mice were analyzed.</div></div><div id="sec5-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Histology</h3><div class="NLM_p last">The collected tissues were fixed with 4% paraformaldehyde (PFA) and embedded in paraffin. The kidney tissue sections (5 μm) were stained with hematoxylin–eosin (HE), periodic acid Schiff (PAS), or Masson’s trichrome. The frequency of cardiomyocytes in the heart tissue sections (5 μm) was determined by a terminal deoxynucleotidyl transferased UTP nick end labeling (TUNEL) assay using a specific kit, according to manufactory’s instructions (Beyotime). Some kidney tissues from each group were fixed with 3% glutaraldehyde, and ultramicrotome sections (80 nm) were prepared (Leica EM UC7) and examined in a JEM-1011 electron microscope (JEOL, Inc., Peabody, MA). The thickness of the glomerular basement membrane (GBM) in 30 different locations randomly selected from three sections of each kidney was measured using ImageJ software. The average thickness of the GBM in individual mice was calculated.</div></div><div id="sec5-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Statistical Analysis</h3><div class="NLM_p last">Data are expressed as the mean ± SD of each group, and differences among groups were analyzed by one-way ANOVA and Tukey’s post hoc test. The difference between two groups was determined by two-tailed Student’s <i>t</i>-tests. All statistical analyses were performed using GraphPad Prism 5.0. A <i>P</i>-value < 0.05 was considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00971">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00971" class="ext-link">10.1021/acs.jmedchem.7b00971</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic and experimental details; <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HRMS spectra of new compounds; crystallographic data for <b>9</b>; and additional biological data of <b>2</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf">jm7b00971_si_001.pdf (1.6 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_002.csv">jm7b00971_si_002.csv (0.74 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00971" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhangjian Huang</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6409-8535" title="Orcid link">http://orcid.org/0000-0001-6409-8535</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dda7b5bcb3bab7b4bcb3b5a8bcb3ba9dbeada8f3b8b9a8f3beb3"><span class="__cf_email__" data-cfemail="364c5e5758515c5f57585e435758517655464318535243185558">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaojun Xu</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dca4b5bdb3b6a9b2a4a9eeececec9cedeaeff2bfb3b1"><span class="__cf_email__" data-cfemail="146c7d757b7e617a6c6126242424542522273a777b79">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuwen Xu</span> - <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihua Zhang</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2378-7064" title="Orcid link">http://orcid.org/0000-0003-2378-7064</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8ff5f6e7fbe8ebcfbeb9bca1ece0e2"><span class="__cf_email__" data-cfemail="740e0d1c001310344542475a171b19">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Mou</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Di Zhao</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yisheng Lai</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cen Chen</span> - <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping Li</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sixun Peng</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Natural Medicines, ‡Jiangsu Key Laboratory of Drug Discovery
for Metabolic Diseases, and §Center of Drug Metabolism and Pharmacokinetics, College
of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Crystal
Pharmatech Co., Ltd., Suzhou 215123, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jide Tian</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular and Medical Pharmacology, University
of California, Los Angeles, California 90095, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Z.H. and Y.M. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from the National Natural Science Foundation of China (nos. 21372261, 81673305, and 21472244) and Jiangsu Province Funds for Distinguished Young Scientists (BK20160033). Part of the work was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Program for New Century Excellent Talents in University (NCET-13-1033), and Jiangsu Shuang Chuang team.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i27" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i27"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i28" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i28"> Abbreviations Used</h2><tr><td class="NLM_term">DN</td><td class="NLM_def"><p class="first last">diabetic nephropathy</p></td></tr><tr><td class="NLM_term">CUK</td><td class="NLM_def"><p class="first last">α-cyano-α,β-unsaturated ketone</p></td></tr><tr><td class="NLM_term">OA</td><td class="NLM_def"><p class="first last">oleanolic acid</p></td></tr><tr><td class="NLM_term">CDDO</td><td class="NLM_def"><p class="first last">2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid</p></td></tr><tr><td class="NLM_term">Nrf2</td><td class="NLM_def"><p class="first last">nuclear factor erythroid 2-related factor 2</p></td></tr><tr><td class="NLM_term">Keap1</td><td class="NLM_def"><p class="first last">Kelch-like ECH-associated protein</p></td></tr><tr><td class="NLM_term">ARE</td><td class="NLM_def"><p class="first last">antioxidant response element</p></td></tr><tr><td class="NLM_term">NQO1</td><td class="NLM_def"><p class="first last">NAD(P)H:quinone oxidoreductase-1</p></td></tr><tr><td class="NLM_term">GSTs</td><td class="NLM_def"><p class="first last">glutathione-S-transferases</p></td></tr><tr><td class="NLM_term">HO-1</td><td class="NLM_def"><p class="first last">heme-oxygenase-1</p></td></tr><tr><td class="NLM_term">eGFR</td><td class="NLM_def"><p class="first last">estimated glomerular filtration rate</p></td></tr><tr><td class="NLM_term">GGT</td><td class="NLM_def"><p class="first last">γ-glutamyl transpeptidase</p></td></tr><tr><td class="NLM_term">EEDQ</td><td class="NLM_def"><p class="first last">2-ethoxy-1(2<i>H</i>)-quinoline carboxylic acid ethyl ester</p></td></tr><tr><td class="NLM_term">AUC<sub>0–∞</sub></td><td class="NLM_def"><p class="first last">area under the concentration–time curve from time zero to infinity</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance rate</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">distribution volume</p></td></tr><tr><td class="NLM_term">IKKβ</td><td class="NLM_def"><p class="first last">IκBα kinase β</p></td></tr><tr><td class="NLM_term">BUN</td><td class="NLM_def"><p class="first last">plasma urea nitrogen</p></td></tr><tr><td class="NLM_term">UA</td><td class="NLM_def"><p class="first last">uric acid</p></td></tr><tr><td class="NLM_term">UACR</td><td class="NLM_def"><p class="first last">urine albumin to creatinine ratio</p></td></tr><tr><td class="NLM_term">TEM</td><td class="NLM_def"><p class="first last">transmission electron microscopy</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glomerular basement membrane</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">SDD</td><td class="NLM_def"><p class="first last">spray dried dispersion</p></td></tr><tr><td class="NLM_term">PFA</td><td class="NLM_def"><p class="first last">paraformaldehyde</p></td></tr><tr><td class="NLM_term">HE</td><td class="NLM_def"><p class="first last">hematoxylin–eosin</p></td></tr><tr><td class="NLM_term">PAS</td><td class="NLM_def"><p class="first last">periodic acid Schiff</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Johansson, M. H.</span><span> </span><span class="NLM_article-title">Reversible michael additions: covalent inhibitors and prodrugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span><span class="refDoi"> DOI: 10.2174/13895575112091330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.2174%2F13895575112091330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22625413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1330-1344&author=M.+H.+Johansson&title=Reversible+michael+additions%3A+covalent+inhibitors+and+prodrugs&doi=10.2174%2F13895575112091330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Michael additions: covalent inhibitors and prodrugs</span></div><div class="casAuthors">Johansson, Martin H.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1330-1344</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent inhibition is an efficient mol. mechanism for inhibiting enzymes or modulating the function of proteins and is found in the action of many drugs and biol. active natural products.  However, it is has been less appreciated that the formation of covalent bonds can be reversible or irreversible.  This review focuses on biol. active compds. that are Michael acceptors and how the reversible nature of the Michael addn. reaction influences biol. activity and how this can be exploited in designing prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9X1yh9k4q-7Vg90H21EOLACvtfcHk0lglp5uam1H7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ&md5=f90694162e39fe57915e888bbadbd2bb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F13895575112091330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13895575112091330%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%2BH.%26atitle%3DReversible%2520michael%2520additions%253A%2520covalent%2520inhibitors%2520and%2520prodrugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D1330%26epage%3D1344%26doi%3D10.2174%2F13895575112091330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Amslinger, S.</span><span> </span><span class="NLM_article-title">The tunable functionality of alpha,beta-unsaturated carbonyl compounds enables their differential application in biological systems</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1002/cmdc.200900499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1002%2Fcmdc.200900499" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=351-356&author=S.+Amslinger&title=The+tunable+functionality+of+alpha%2Cbeta-unsaturated+carbonyl+compounds+enables+their+differential+application+in+biological+systems&doi=10.1002%2Fcmdc.200900499"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900499%26sid%3Dliteratum%253Aachs%26aulast%3DAmslinger%26aufirst%3DS.%26atitle%3DThe%2520tunable%2520functionality%2520of%2520alpha%252Cbeta-unsaturated%2520carbonyl%2520compounds%2520enables%2520their%2520differential%2520application%2520in%2520biological%2520systems%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D351%26epage%3D356%26doi%3D10.1002%2Fcmdc.200900499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherrer, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robins, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, L. M.</span><span> </span><span class="NLM_article-title">Bioactive diterpenoid containing a reversible ″spring-loaded″ (E,Z)-dieneone Michael acceptor</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3920</span><span class="NLM_x">–</span> <span class="NLM_lpage">3923</span><span class="refDoi"> DOI: 10.1021/ol201443k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol201443k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=3920-3923&author=P.+Guptaauthor=U.+Sharmaauthor=T.+C.+Schulzauthor=E.+S.+Sherrerauthor=A.+B.+McLeanauthor=A.+J.+Robinsauthor=L.+M.+West&title=Bioactive+diterpenoid+containing+a+reversible+%E2%80%B3spring-loaded%E2%80%B3+%28E%2CZ%29-dieneone+Michael+acceptor&doi=10.1021%2Fol201443k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fol201443k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol201443k%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DU.%26aulast%3DSchulz%26aufirst%3DT.%2BC.%26aulast%3DSherrer%26aufirst%3DE.%2BS.%26aulast%3DMcLean%26aufirst%3DA.%2BB.%26aulast%3DRobins%26aufirst%3DA.%2BJ.%26aulast%3DWest%26aufirst%3DL.%2BM.%26atitle%3DBioactive%2520diterpenoid%2520containing%2520a%2520reversible%2520%25E2%2580%25B3spring-loaded%25E2%2580%25B3%2520%2528E%252CZ%2529-dieneone%2520Michael%2520acceptor%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D3920%26epage%3D3923%26doi%3D10.1021%2Fol201443k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Liu, J.</span><span> </span><span class="NLM_article-title">Pharmacology of oleanolic acid and ursolic acid</span> <span class="citation_source-journal">J. Ethnopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1016/0378-8741(95)90032-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2F0378-8741%2895%2990032-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=8847885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaK28Xht12gtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=57-68&author=J.+Liu&title=Pharmacology+of+oleanolic+acid+and+ursolic+acid&doi=10.1016%2F0378-8741%2895%2990032-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of oleanolic acid and ursolic acid</span></div><div class="casAuthors">Liu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">57-68</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with many refs.  Oleanolic acid and ursolic acid are triterpenoid compds. that exist widely in food, medicinal herbs and other plants.  This review summarizes the pharmacol. studies on these two triterpenoids.  Both oleanolic acid and ursolic acid are effective in protecting against chem. induced liver injury in lab. animals.  Oleanolic acid has been marketed in China as an oral drug for human liver disorders.  The mechanism of hepatoprotection by these two compds. may involve the inhibition of toxicant activation and the enhancement of the body defense systems.  Oleanolic acid and ursolic acid have also been long-recognized to have antiinflammatory and antihyperlipidemic properties in lab. animals, and more research is warranted to develop a therapy for patients.  Recently, both compds. have been noted for their antitumor-promotion effects, which are stimulating addnl. research in this field.  Oleanolic acid and ursolic acid are relatively non-toxic, and have been used in cosmetics and health products.  The possible mechanisms for the pharmacol. effects and the prospects for these two compds. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgToYQb0SebVg90H21EOLACvtfcHk0lgWtjdcwI-msg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xht12gtL4%253D&md5=95e420a3aaa6a0774105fcb174ee407e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0378-8741%2895%2990032-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-8741%252895%252990032-2%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DPharmacology%2520of%2520oleanolic%2520acid%2520and%2520ursolic%2520acid%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D1995%26volume%3D49%26spage%3D57%26epage%3D68%26doi%3D10.1016%2F0378-8741%2895%2990032-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Reisman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaassen, C. D.</span><span> </span><span class="NLM_article-title">CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.taap.2008.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.taap.2008.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=19371629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2009&pages=109-114&author=S.+A.+Reismanauthor=D.+B.+Buckleyauthor=Y.+Tanakaauthor=C.+D.+Klaassen&title=CDDO-Im+protects+from+acetaminophen+hepatotoxicity+through+induction+of+Nrf2-dependent+genes&doi=10.1016%2Fj.taap.2008.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes</span></div><div class="casAuthors">Reisman, Scott A.; Buckley, David B.; Tanaka, Yuji; Klaassen, Curtis D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-114</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CDDO-Im is a synthetic triterpenoid recently shown to induce cytoprotective genes through the Nrf2-Keap1 pathway, an important mechanism for the induction of cytoprotective genes in response to oxidative stress.  Upon oxidative or electrophilic insult, the transcription factor Nrf2 translocates to the nucleus, heterodimerizes with small Maf proteins, and binds to antioxidant response elements (AREs) in the upstream promoter regions of various cytoprotective genes.  To further elucidate the hepatoprotective effects of CDDO-Im, wild-type and Nrf2-null mice were pretreated with CDDO-Im (1 mg/kg, i.p.) or vehicle (DMSO), and then administered acetaminophen (500 mg/kg, i.p.).  Pretreatment of wild-type mice with CDDO-Im reduced liver injury caused by acetaminophen.  In contrast, hepatoprotection by CDDO-Im was not obsd. in Nrf2-null mice.  CDDO-Im increased Nrf2 protein expression and Nrf2-ARE binding in wild-type, but not Nrf2-null mice.  Furthermore, CDDO-Im increased the mRNA expression of the Nrf2 target genes NAD(P)H: quinone oxidoreductase-1 (Nqo1); glutamate-cysteine ligase, catalytic subunit (Gclc); and heme-oxygenase-1 (Ho-1), in both a dose- and time-dependent manner.  Conversely, CDDO-Im did not induce Nqo1, Gclc, and Ho-1 mRNA expression in Nrf2-null mice.  Collectively, the present study shows that CDDO-Im pretreatment induces Nrf2-dependent cytoprotective genes and protects the liver from acetaminophen-induced hepatic injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw2dPuqslcJbVg90H21EOLACvtfcHk0lgWtjdcwI-msg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKqt7k%253D&md5=432f16c5e684a71fef87459d93f28d6d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2008.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2008.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DReisman%26aufirst%3DS.%2BA.%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKlaassen%26aufirst%3DC.%2BD.%26atitle%3DCDDO-Im%2520protects%2520from%2520acetaminophen%2520hepatotoxicity%2520through%2520induction%2520of%2520Nrf2-dependent%2520genes%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2009%26volume%3D236%26spage%3D109%26epage%3D114%26doi%3D10.1016%2Fj.taap.2008.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Liby, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span> </span><span class="NLM_article-title">Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">972</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1124/pr.111.004846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1124%2Fpr.111.004846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22966038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=972-1003&author=K.+T.+Libyauthor=M.+B.+Sporn&title=Synthetic+oleanane+triterpenoids%3A+multifunctional+drugs+with+a+broad+range+of+applications+for+prevention+and+treatment+of+chronic+disease&doi=10.1124%2Fpr.111.004846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease</span></div><div class="casAuthors">Liby, Karen T.; Sporn, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">972-1003</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We review the rationale for the use of synthetic oleanane triterpenoids (SOs) for prevention and treatment of disease, as well as extensive biol. data on this topic resulting from both cell culture and in vivo studies.  Emphasis is placed on understanding mechanisms of action.  SOs are noncytotoxic drugs with an excellent safety profile.  Several hundred SOs have now been synthesized and in vitro have been shown to: 1) suppress inflammation and oxidative stress and therefore be cytoprotective, esp. at low nanomolar doses, 2) induce differentiation, and 3) block cell proliferation and induce apoptosis at higher micromolar doses.  Animal data on the use of SOs in neurodegenerative diseases and in diseases of the eye, lung, cardiovascular system, liver, gastrointestinal tract, and kidney, as well as in cancer and in metabolic and inflammatory/autoimmune disorders, are reviewed.  The importance of the cytoprotective Kelch-like erythroid cell-derived protein with CNC homol.-assocd. protein 1/nuclear factor (erythroid-derived 2)-like 2/antioxidant response element (Keap1/Nrf2/ARE) pathway as a mechanism of action is explained, but interactions with peroxisome proliferator-activated receptor γ (PARPγ), inhibitor of nuclear factor-κB kinase complex (IKK), janus tyrosine kinase/signal transducer and activator of transcription (JAK/STAT), human epidermal growth factor receptor 2 (HER2)/ErbB2/neu, phosphatase and tensin homolog (PTEN), the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, mammalian target of rapamycin (mTOR), and the thiol proteome are also described.  In these interactions, Michael addn. of SOs to reactive cysteine residues in specific mol. targets triggers biol. activity.  Ultimately, SOs are multifunctional drugs that regulate the activity of entire networks.  Recent progress in the earliest clin. trials with 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) Me ester (bardoxolone methyl) is also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozzGNihQsvrrVg90H21EOLACvtfcHk0lhRm2z0Yhbr4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaltQ%253D%253D&md5=5c0a741d089e6f6a504eae31a47d872c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fpr.111.004846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.111.004846%26sid%3Dliteratum%253Aachs%26aulast%3DLiby%26aufirst%3DK.%2BT.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26atitle%3DSynthetic%2520oleanane%2520triterpenoids%253A%2520multifunctional%2520drugs%2520with%2520a%2520broad%2520range%2520of%2520applications%2520for%2520prevention%2520and%2520treatment%2520of%2520chronic%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D972%26epage%3D1003%26doi%3D10.1124%2Fpr.111.004846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Cleasby, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickle, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweitzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span> </span><span class="NLM_article-title">Structure of the BTB domain of keap1 and its interaction with the triterpenoid antagonist CDDO</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e98896</span><span class="refDoi"> DOI: 10.1371/journal.pone.0098896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1371%2Fjournal.pone.0098896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=24896564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWlsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e98896&author=A.+Cleasbyauthor=J.+Yonauthor=P.+J.+Dayauthor=C.+Richardsonauthor=I.+J.+Tickleauthor=P.+A.+Williamsauthor=J.+F.+Callahanauthor=R.+Carrauthor=N.+Conchaauthor=J.+K.+Kernsauthor=H.+W.+Qiauthor=T.+Sweitzerauthor=P.+Wardauthor=T.+G.+Davies&title=Structure+of+the+BTB+domain+of+keap1+and+its+interaction+with+the+triterpenoid+antagonist+CDDO&doi=10.1371%2Fjournal.pone.0098896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO</span></div><div class="casAuthors">Cleasby, Anne; Yon, Jeff; Day, Philip J.; Richardson, Caroline; Tickle, Ian J.; Williams, Pamela A.; Callahan, James F.; Carr, Robin; Concha, Nestor; Kerns, Jeffrey K.; Qi, Hongwei; Sweitzer, Thomas; Ward, Paris; Davies, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e98896/1-e98896/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  The protein Keap1 is central to the regulation of the Nrf2-mediated cytoprotective response, and is increasingly recognized as an important target for therapeutic intervention in a range of diseases involving excessive oxidative stress and inflammation.  The BTB domain of Keap1 plays key roles in sensing environmental electrophiles and in mediating interactions with the Cul3/Rbx1 E3 ubiquitin ligase system, and is believed to be the target for several small mol. covalent activators of the Nrf2 pathway.  However, despite structural information being available for several BTB domains from related proteins, there have been no reported crystal structures of Keap1 BTB, and this has precluded a detailed understanding of its mechanism of action and interaction with antagonists.  We report here the first structure of the BTB domain of Keap1, which is thought to contain the key cysteine residue responsible for interaction with electrophiles, as well as structures of the covalent complex with the antagonist CDDO/bardoxolone, and of the constitutively inactive C151W BTB mutant.  In addn. to providing the first structural confirmation of antagonist binding to Keap1 BTB, we also present biochem. evidence that adduction of Cys 151 by CDDO is capable of inhibiting the binding of Cul3 to Keap1, and discuss how this class of compd. might exert Nrf2 activation through disruption of the BTB-Cul3 interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe-yi4jSWD-bVg90H21EOLACvtfcHk0lhRm2z0Yhbr4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWlsr7I&md5=f9c6542ff2508a74313e996ccdafa0ae</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0098896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0098896%26sid%3Dliteratum%253Aachs%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DYon%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DWilliams%26aufirst%3DP.%2BA.%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DConcha%26aufirst%3DN.%26aulast%3DKerns%26aufirst%3DJ.%2BK.%26aulast%3DQi%26aufirst%3DH.%2BW.%26aulast%3DSweitzer%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26atitle%3DStructure%2520of%2520the%2520BTB%2520domain%2520of%2520keap1%2520and%2520its%2520interaction%2520with%2520the%2520triterpenoid%2520antagonist%2520CDDO%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De98896%26doi%3D10.1371%2Fjournal.pone.0098896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Kensler, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakabayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswal, S.</span><span> </span><span class="NLM_article-title">Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.46.120604.141046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1146%2Fannurev.pharmtox.46.120604.141046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=16968214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1altrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=89-116&author=T.+W.+Kenslerauthor=N.+Wakabayashiauthor=S.+Biswal&title=Cell+survival+responses+to+environmental+stresses+via+the+Keap1-Nrf2-ARE+pathway&doi=10.1146%2Fannurev.pharmtox.46.120604.141046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway</span></div><div class="casAuthors">Kensler, Thomas W.; Wakabayashi, Nobunao; Biswal, Shyam</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-116</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Keap1-Nrf2-ARE signaling plays a significant role in protecting cells from endogenous and exogenous stresses.  The development of Nrf2 knockout mice has provided key insights into the toxicol. importance of this pathway.  These mice are more sensitive to the hepatic, pulmonary, ovarian, and neurotoxic consequences of acute exposures to environmental agents and drugs, inflammatory stresses, as well as chronic exposures to cigarette smoke and other carcinogens.  Under quiescent conditions, the transcription factor Nrf2 interacts with the actin-anchored protein Keap1, largely localized in the cytoplasm.  This quenching interaction maintains low basal expression of Nrf2-regulated genes.  However, upon recognition of chem. signals imparted by oxidative and electrophilic mols., Nrf2 is released from Keap1, escapes proteasomal degrdn., translocates to the nucleus, and transactivates the expression of several dozen cytoprotective genes that enhance cell survival.  This review highlights the key elements in this adaptive response to protection against acute and chronic cell injury provoked by environmental stresses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAmRpcXFLXq7Vg90H21EOLACvtfcHk0lhRm2z0Yhbr4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1altrg%253D&md5=eee9260ebe6186b82da647701a10c7e2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.46.120604.141046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.46.120604.141046%26sid%3Dliteratum%253Aachs%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DWakabayashi%26aufirst%3DN.%26aulast%3DBiswal%26aufirst%3DS.%26atitle%3DCell%2520survival%2520responses%2520to%2520environmental%2520stresses%2520via%2520the%2520Keap1-Nrf2-ARE%2520pathway%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2007%26volume%3D47%26spage%3D89%26epage%3D116%26doi%3D10.1146%2Fannurev.pharmtox.46.120604.141046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Shishodia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, B. B.</span><span> </span><span class="NLM_article-title">A synthetic triterpenoid, CDDO-Me, inhibits I kappa B alpha, kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappa B-regulated gene products in human leukemic cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1828</span><span class="NLM_x">–</span> <span class="NLM_lpage">1838</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F1078-0432.CCR-05-2044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=16551868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1CjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1828-1838&author=S.+Shishodiaauthor=G.+Sethiauthor=M.+Konoplevaauthor=M.+Andreeffauthor=B.+B.+Aggarwal&title=A+synthetic+triterpenoid%2C+CDDO-Me%2C+inhibits+I+kappa+B+alpha%2C+kinase+and+enhances+apoptosis+induced+by+TNF+and+chemotherapeutic+agents+through+down-regulation+of+expression+of+nuclear+factor+kappa+B-regulated+gene+products+in+human+leukemic+cells&doi=10.1158%2F1078-0432.CCR-05-2044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB-Regulated Gene Products in Human Leukemic Cells</span></div><div class="casAuthors">Shishodia, Shishir; Sethi, Gautam; Konopleva, Marina; Andreeff, Michael; Aggarwal, Bharat B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1828-1838</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The C-28 Me ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me), a synthetic triterpenoid based on naturally occurring ursolic and oleanolic acids, induces apoptosis in tumor cells, induces differentiation, and inhibits inflammatory response through a poorly understood mechanism.  Because the nuclear transcription factor nuclear factor κB (NF-κB) has been shown to suppress apoptosis and promote proliferation and is linked with inflammation and differentiation, we postulated that CDDO-Me modulates NF-κB activity and NF-κB-regulated gene expression.  Using human leukemia cell lines and patient samples, we show that CDDO-Me potently inhibits both constitutive and inducible NF-κB activated by tumor necrosis factor (TNF), interleukin (IL)-1{szligbeta}, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke.  CDDO-Me was more potent than CDDO and its imidazole deriv.  NF-κB suppression occurred through inhibition of IκBα kinase activation, IκBα phosphorylation, IκBα degrdn., p65 phosphorylation, p65 nuclear translocation, and NF-κB-mediated reporter gene transcription.  This inhibition correlated with suppression of NF-κB-dependent genes involved in antiapoptosis (IAP2, cFLIP, TRAF1, survivin, and bcl-2), proliferation (cyclin d1 and c-myc), and angiogenesis (VEGF, cox-2, and mmp-9).  CDDO-Me also potentiated the cytotoxic effects of TNF and chemotherapeutic agents.  Overall, our results suggest that CDDO-Me inhibits NF-κB through inhibition of IκBα kinase, leading to the suppression of expression of NF-κB-regulated gene products and enhancement of apoptosis induced by TNF and chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8LQa8tIlmE7Vg90H21EOLACvtfcHk0lh9ciX8xu7ROg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1CjsLY%253D&md5=de5e618ec5bd9c4984aa3894be850610</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2044%26sid%3Dliteratum%253Aachs%26aulast%3DShishodia%26aufirst%3DS.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3DA%2520synthetic%2520triterpenoid%252C%2520CDDO-Me%252C%2520inhibits%2520I%2520kappa%2520B%2520alpha%252C%2520kinase%2520and%2520enhances%2520apoptosis%2520induced%2520by%2520TNF%2520and%2520chemotherapeutic%2520agents%2520through%2520down-regulation%2520of%2520expression%2520of%2520nuclear%2520factor%2520kappa%2520B-regulated%2520gene%2520products%2520in%2520human%2520leukemic%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1828%26epage%3D1838%26doi%3D10.1158%2F1078-0432.CCR-05-2044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Singh, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winocour, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrington, K.</span><span> </span><span class="NLM_article-title">Oxidative stress in early diabetic nephropathy: fueling the fire</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1038/nrendo.2010.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnrendo.2010.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21151200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=176-184&author=D.+K.+Singhauthor=P.+Winocourauthor=K.+Farrington&title=Oxidative+stress+in+early+diabetic+nephropathy%3A+fueling+the+fire&doi=10.1038%2Fnrendo.2010.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress in early diabetic nephropathy: fueling the fire</span></div><div class="casAuthors">Singh, Dhruv K.; Winocour, Peter; Farrington, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">176-184</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This Review summarizes the role of reactive oxygen species and oxidative stress in diabetes mellitus and in the pathogenesis of endothelial cell dysfunction and diabetic nephropathy.  Furthermore, the authors explore possible therapeutic interventions to reduce oxidative stress and endothelial cell dysfunction and retard the progression of diabetic nephropathy.  Diabetic nephropathy is a major microvascular complication of diabetes mellitus and the most common cause of end-stage renal disease worldwide.  The treatment costs of diabetes mellitus and its complications represent a huge burden on health-care expenditures, creating a major need to identify modifiable factors concerned in the pathogenesis and progression of diabetic nephropathy.  Chronic hyperglycemia remains the primary cause of the metabolic, biochem. and vascular abnormalities in diabetic nephropathy.  Promotion of excessive oxidative stress in the vascular and cellular milieu results in endothelial cell dysfunction, which is one of the earliest and most pivotal metabolic consequences of chronic hyperglycemia.  These derangements are caused by excessive prodn. of advanced glycation end products and free radicals and by the subjugation of antioxidants and antioxidant mechanisms.  An increased understanding of the role of oxidative stress in diabetic nephropathy has lead to the exploration of a no. of therapeutic strategies, the success of which has so far been limited.  However, judicious and timely use of current therapies to maintain good glycemic control, adequate blood pressure and lipid levels, along with lifestyle measures such as regular exercise, optimization of diet and smoking cessation, may help to reduce oxidative stress and endothelial cell dysfunction and retard the progression of diabetic nephropathy until more definitive therapies become available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFT_0kFsXLabVg90H21EOLACvtfcHk0lh9ciX8xu7ROg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlaqtb8%253D&md5=5a72fe9d5cd00587a95276cad81800b6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2010.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2010.212%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%2BK.%26aulast%3DWinocour%26aufirst%3DP.%26aulast%3DFarrington%26aufirst%3DK.%26atitle%3DOxidative%2520stress%2520in%2520early%2520diabetic%2520nephropathy%253A%2520fueling%2520the%2520fire%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D7%26spage%3D176%26epage%3D184%26doi%3D10.1038%2Fnrendo.2010.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucherot, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichinger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitsche, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grone, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlondorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kretzler, M.</span><span> </span><span class="NLM_article-title">Modular activation of nuclear factor-kappa B transcriptional programs in human diabetic nephropathy</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2993</span><span class="NLM_x">–</span> <span class="NLM_lpage">3003</span><span class="refDoi"> DOI: 10.2337/db06-0477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.2337%2Fdb06-0477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2006&pages=2993-3003&author=H.+Schmidauthor=A.+Boucherotauthor=Y.+Yasudaauthor=A.+Hengerauthor=B.+Brunnerauthor=F.+Eichingerauthor=A.+Nitscheauthor=E.+Kissauthor=M.+Bleichauthor=H.+J.+Groneauthor=P.+J.+Nelsonauthor=D.+Schlondorffauthor=C.+D.+Cohenauthor=M.+Kretzler&title=Modular+activation+of+nuclear+factor-kappa+B+transcriptional+programs+in+human+diabetic+nephropathy&doi=10.2337%2Fdb06-0477"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2337%2Fdb06-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb06-0477%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DBoucherot%26aufirst%3DA.%26aulast%3DYasuda%26aufirst%3DY.%26aulast%3DHenger%26aufirst%3DA.%26aulast%3DBrunner%26aufirst%3DB.%26aulast%3DEichinger%26aufirst%3DF.%26aulast%3DNitsche%26aufirst%3DA.%26aulast%3DKiss%26aufirst%3DE.%26aulast%3DBleich%26aufirst%3DM.%26aulast%3DGrone%26aufirst%3DH.%2BJ.%26aulast%3DNelson%26aufirst%3DP.%2BJ.%26aulast%3DSchlondorff%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DC.%2BD.%26aulast%3DKretzler%26aufirst%3DM.%26atitle%3DModular%2520activation%2520of%2520nuclear%2520factor-kappa%2520B%2520transcriptional%2520programs%2520in%2520human%2520diabetic%2520nephropathy%26jtitle%3DDiabetes%26date%3D2006%26volume%3D55%26spage%3D2993%26epage%3D3003%26doi%3D10.2337%2Fdb06-0477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Navarro-Gonzalez, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mora-Fernandez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fuentes, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Perez, J.</span><span> </span><span class="NLM_article-title">Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy</span> <span class="citation_source-journal">Nat. Rev. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1038/nrneph.2011.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnrneph.2011.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21537349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms12lsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=327-340&author=J.+F.+Navarro-Gonzalezauthor=C.+Mora-Fernandezauthor=M.+M.+de+Fuentesauthor=J.+Garcia-Perez&title=Inflammatory+molecules+and+pathways+in+the+pathogenesis+of+diabetic+nephropathy&doi=10.1038%2Fnrneph.2011.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy</span></div><div class="casAuthors">Navarro-Gonzalez, Juan F.; Mora-Fernandez, Carmen; Muros de Fuentes, Mercedes; Garcia-Perez, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Nephrology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">327-340</span>CODEN:
                <span class="NLM_cas:coden">NRNABO</span>;
        ISSN:<span class="NLM_cas:issn">1759-5061</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inflammation has a key role in the pathogenesis and progression of diabetic nephropathy; however, the pathways, ligands and receptors involved in this condition are complex and only partially understood.  The authors of this Review discuss the mol. networks that are implicated in the development of diabetic nephropathy and describe how these pathways function in health and disease, as well as their importance in the identification and development of potential therapeutics.  Many lines of evidence, ranging from in vitro expts. and pathol. examns. to epidemiol. studies, show that inflammation is a cardinal pathogenetic mechanism in diabetic nephropathy.  Thus, modulation of inflammatory processes in the setting of diabetes mellitus is a matter of great interest for researchers today.  The relationships between inflammation and the development and progression of diabetic nephropathy involve complex mol. networks and processes.  This Review, therefore, focuses on key proinflammatory mols. and pathways implicated in the development and progression of diabetic nephropathy: the chemokines CCL2, CX3CL1 and CCL5 (also known as MCP-1, fractalkine and RANTES, resp.); the adhesion mols. intercellular adhesion mol. 1, vascular cell adhesion protein 1, endothelial cell-selective adhesion mol., E-selectin and α-actinin 4; the transcription factor nuclear factor κB; and the inflammatory cytokines IL-1, IL-6, IL-18 and tumor necrosis factor.  Advances in the understanding of the roles that these inflammatory pathways have in the context of diabetic nephropathy will facilitate the discovery of new therapeutic targets.  In the next few years, promising new therapeutic strategies based on anti-inflammatory effects could be successfully translated into clin. treatments for diabetic complications, including diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqeKIeooP0zLVg90H21EOLACvtfcHk0lhTrUwWRTwAXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms12lsLo%253D&md5=461d682d7bb8a411ea66ba860c029b1e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrneph.2011.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneph.2011.51%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DMora-Fernandez%26aufirst%3DC.%26aulast%3Dde%2BFuentes%26aufirst%3DM.%2BM.%26aulast%3DGarcia-Perez%26aufirst%3DJ.%26atitle%3DInflammatory%2520molecules%2520and%2520pathways%2520in%2520the%2520pathogenesis%2520of%2520diabetic%2520nephropathy%26jtitle%3DNat.%2520Rev.%2520Nephrol.%26date%3D2011%26volume%3D7%26spage%3D327%26epage%3D340%26doi%3D10.1038%2Fnrneph.2011.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pergola, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnock, D. G.</span><span> </span><span class="NLM_article-title">Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD</span> <span class="citation_source-journal">Am. J. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span><span class="refDoi"> DOI: 10.1159/000327599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1159%2F000327599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21508635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFyls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=469-476&author=P.+E.+Pergolaauthor=M.+Krauthauthor=J.+W.+Huffauthor=D.+A.+Fergusonauthor=S.+Ruizauthor=C.+J.+Meyerauthor=D.+G.+Warnock&title=Effect+of+bardoxolone+methyl+on+kidney+function+in+patients+with+T2D+and+stage+3b-4+CKD&doi=10.1159%2F000327599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b-4 CKD</span></div><div class="casAuthors">Pergola, Pablo E.; Krauth, Melissa; Huff, J. Warren; Ferguson, Deborah A.; Ruiz, Stacey; Meyer, Colin J.; Warnock, David G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-476</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Bardoxolone Me, a novel synthetic triterpenoid, induces Nrf2, a transcription factor known to play a key role in decreasing oxidative stress and the prodn. of pro-inflammatory mols.  This exploratory multi-center, open-label study assessed the clin. activity and safety of bardoxolone Me in 20 patients with moderate to severe chronic kidney disease and type 2 diabetes.  Patients received 25 mg of bardoxolone Me daily for 28 days, followed by 75 mg daily for another 28 days.  The study achieved its primary efficacy endpoint, as demonstrated by a significant increase from baseline in estd. glomerular filtration rate (eGFR) of 7.2 mL/min/1.73 m2 (p < 0.001).  Improvements were seen in approx. 90% of patients and showed a dose- and time-dependent increase in eGFR.  The eGFR change paralleled a significant redn. in serum creatinine (-0.3 mg/dL) and blood urea nitrogen (-4.9 mg/dL), along with an increase in creatinine clearance (+14.6 mL/min/1.73 m2), without a change in the 24-h creatinine excretion rate.  Markers of vascular injury and inflammation were improved by treatment with bardoxolone.  No life-threatening adverse events or drug-related serious adverse events were reported.  The results describe an apparent increase in kidney function following relatively short-term treatment with bardoxolone Me, a promising new agent that warrants placebo-controlled studies to define its long-term effects on renal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6lXQIYezO97Vg90H21EOLACvtfcHk0lhTrUwWRTwAXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFyls7w%253D&md5=79cc223ddcc75525c0547f4edbf02de7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1159%2F000327599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000327599%26sid%3Dliteratum%253Aachs%26aulast%3DPergola%26aufirst%3DP.%2BE.%26aulast%3DKrauth%26aufirst%3DM.%26aulast%3DHuff%26aufirst%3DJ.%2BW.%26aulast%3DFerguson%26aufirst%3DD.%2BA.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DC.%2BJ.%26aulast%3DWarnock%26aufirst%3DD.%2BG.%26atitle%3DEffect%2520of%2520bardoxolone%2520methyl%2520on%2520kidney%2520function%2520in%2520patients%2520with%2520T2D%2520and%2520stage%25203b-4%2520CKD%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2011%26volume%3D33%26spage%3D469%26epage%3D476%26doi%3D10.1159%2F000327599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akizawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audhya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakris, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ-Schmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsberry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerspink, H. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parving, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaziri, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrolstad, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chertow, G. M.</span><span> </span><span class="NLM_article-title">Bardoxolone methyl in Type 2 diabetes and stage 4 chronic kidney disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">2492</span><span class="NLM_x">–</span> <span class="NLM_lpage">2503</span><span class="refDoi"> DOI: 10.1056/NEJMoa1306033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa1306033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=24206459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=2492-2503&author=D.+de+Zeeuwauthor=T.+Akizawaauthor=P.+Audhyaauthor=G.+L.+Bakrisauthor=M.+Chinauthor=H.+Christ-Schmidtauthor=A.+Goldsberryauthor=M.+Houserauthor=M.+Krauthauthor=H.+J.+L.+Heerspinkauthor=J.+J.+McMurrayauthor=C.+J.+Meyerauthor=H.+H.+Parvingauthor=G.+Remuzziauthor=R.+D.+Totoauthor=N.+D.+Vaziriauthor=C.+Wannerauthor=J.+Wittesauthor=D.+Wrolstadauthor=G.+M.+Chertow&title=Bardoxolone+methyl+in+Type+2+diabetes+and+stage+4+chronic+kidney+disease&doi=10.1056%2FNEJMoa1306033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease</span></div><div class="casAuthors">de Zeeuw, Dick; Akizawa, Tadao; Audhya, Paul; Bakris, George L.; Chin, Melanie; Christ-Schmidt, Heidi; Goldsberry, Angie; Houser, Mark; Krauth, Melissa; Lambers Heerspink, Hiddo J.; McMurray, John J.; Meyer, Colin J.; Parving, Hans-Henrik; Remuzzi, Giuseppe; Toto, Robert D.; Vaziri, Nosratola D.; Wanner, Christoph; Wittes, Janet; Wrolstad, Danielle; Chertow, Glenn M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2492-2503</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high.  Whether nuclear I factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.  METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estd. glomerular filtration rate [GFR], 15 to <30 mL per min per 1.73 m2 of body-surface area) to bardoxolone Me, at a daily dose of 20 mg, or placebo.  The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes.  RESULTS: The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 mo.  A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone Me and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone Me group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P = 0.92).  In the bardoxolone Me group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed In 51 patients, and 19 patients died from cardiovascular causes.  A total of 96 patients in the bardoxolone Me group were hospitalized for heart failure or died from heart failure, as compared with 55 in the placebo group (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P < 0.001).  Estd. GFR, blood pressure, and the urinary albumin-to-creatinine ratio increased significantly and body wt. decreased significantly in the bardoxolone Me group, as compared with the placebo group.  CONCLUSIONS: Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone Me did not reduce the risk of ESRD or death from cardiovascular causes.  A higher rate of cardiovascular events with bardoxolone Me than with placebo prompted termination of the trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomI6Z9q4C0LLVg90H21EOLACvtfcHk0lhTrUwWRTwAXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKqs74%253D&md5=1bcc997b57ba700423e0549a617231b5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306033%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DAkizawa%26aufirst%3DT.%26aulast%3DAudhya%26aufirst%3DP.%26aulast%3DBakris%26aufirst%3DG.%2BL.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DChrist-Schmidt%26aufirst%3DH.%26aulast%3DGoldsberry%26aufirst%3DA.%26aulast%3DHouser%26aufirst%3DM.%26aulast%3DKrauth%26aufirst%3DM.%26aulast%3DHeerspink%26aufirst%3DH.%2BJ.%2BL.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DMeyer%26aufirst%3DC.%2BJ.%26aulast%3DParving%26aufirst%3DH.%2BH.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DToto%26aufirst%3DR.%2BD.%26aulast%3DVaziri%26aufirst%3DN.%2BD.%26aulast%3DWanner%26aufirst%3DC.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DWrolstad%26aufirst%3DD.%26aulast%3DChertow%26aufirst%3DG.%2BM.%26atitle%3DBardoxolone%2520methyl%2520in%2520Type%25202%2520diabetes%2520and%2520stage%25204%2520chronic%2520kidney%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D2492%26epage%3D2503%26doi%3D10.1056%2FNEJMoa1306033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Pergola, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raskin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audhya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ-Schmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnock, D. G.</span><span> </span><span class="NLM_article-title">Bardoxolone methyl and kidney function in CKD with type 2 diabetes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1056/NEJMoa1105351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa1105351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21699484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslSnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=327-336&author=P.+E.+Pergolaauthor=P.+Raskinauthor=R.+D.+Totoauthor=C.+J.+Meyerauthor=J.+W.+Huffauthor=E.+B.+Grossmanauthor=M.+Krauthauthor=S.+Ruizauthor=P.+Audhyaauthor=H.+Christ-Schmidtauthor=J.+Wittesauthor=D.+G.+Warnock&title=Bardoxolone+methyl+and+kidney+function+in+CKD+with+type+2+diabetes&doi=10.1056%2FNEJMoa1105351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Bardoxolone methyl and kidney function in CKD with type 2 diabetes</span></div><div class="casAuthors">Pergola, Pablo E.; Raskin, Philip; Toto, Robert D.; Meyer, Colin J.; Huff, J. Warren; Grossman, Eric B.; Krauth, Melissa; Ruiz, Stacey; Audhya, Paul; Christ-Schmidt, Heidi; Wittes, Janet; Warnock, David G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Chronic kidney disease (CKD) assocd. with type 2 diabetes is the leading cause of kidney failure, with both inflammation and oxidative stress contributing to disease progression.  Bardoxolone Me, an oral antioxidant inflammation modulator, has shown efficacy in patients with CKD and type 2 diabetes in short-term studies, but longer-term effects sand dose response have not been detd.  Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned 227 adults with CKD (defined as an estd. glomerular filtration rate [GFR] of 20 to 45 mL per min per 1.73 m2 of body-surface area) in a 1:1:1:1 ratio to receive placebo or bardoxolone Me at a target dose of 25, 75, or 150 mg once daily.  The primary outcome was the change from baseline in the estd. GFR with bardoxolone Me, as compared with placebo, at 24 wk; a secondary outcome was the change at 52 wk.  Results: Patients receiving bardoxolone Me had significant increases in the mean (±SD) estd. GFR, as compared with placebo, at 24 wk (with between-group differences per min per 1.73 m2 of 8.2 ± 1.5 mL in the 25-mg group, 11.4 ± 1.5 mL in the 75-mg group, and 10.4 ± 1.5 mL in the 150-mg group; P < 0.001).  The increases were maintained through week 52, with significant differences per min per 1.73 m2 of 5.8 ± 1.8 mL, 10.5 ± 1.8 mL, and 9.3 ± 1.9 mL, resp.  Muscle spasms, were generally mild and dose-related.  Hypomagnesemia, mild increases in alanine aminotransferase levels, and gastrointestinal effects were more common among patients receiving bardoxolone Me.  Conclusions: Bardoxolone Me was assocd. with improvement in the estd. GFR in patients with advanced CKD and type 2 diabetes at 24 wk.  The improvement persisted at 52 wk, suggesting that bardoxolone Me may have promise for the treatment of CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcbGTG2V2X9LVg90H21EOLACvtfcHk0li5obCh6_Zh0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslSnsrs%253D&md5=9f4f2bb5e020129e58dc47437fcab8a7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105351%26sid%3Dliteratum%253Aachs%26aulast%3DPergola%26aufirst%3DP.%2BE.%26aulast%3DRaskin%26aufirst%3DP.%26aulast%3DToto%26aufirst%3DR.%2BD.%26aulast%3DMeyer%26aufirst%3DC.%2BJ.%26aulast%3DHuff%26aufirst%3DJ.%2BW.%26aulast%3DGrossman%26aufirst%3DE.%2BB.%26aulast%3DKrauth%26aufirst%3DM.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DAudhya%26aufirst%3DP.%26aulast%3DChrist-Schmidt%26aufirst%3DH.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DWarnock%26aufirst%3DD.%2BG.%26atitle%3DBardoxolone%2520methyl%2520and%2520kidney%2520function%2520in%2520CKD%2520with%2520type%25202%2520diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D327%26epage%3D336%26doi%3D10.1056%2FNEJMoa1105351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Varga, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferdinandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span> </span><span class="NLM_article-title">Drug-induced mitochondrial dysfunction and cardiotoxicity</span> <span class="citation_source-journal">Am. J. Physiol. Heart Circ. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">H1453</span><span class="NLM_x">–</span> <span class="NLM_lpage">H1467</span><span class="refDoi"> DOI: 10.1152/ajpheart.00554.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1152%2Fajpheart.00554.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=26386112" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=H1453-H1467&author=Z.+V.+Vargaauthor=P.+Ferdinandyauthor=L.+Liaudetauthor=P.+Pacher&title=Drug-induced+mitochondrial+dysfunction+and+cardiotoxicity&doi=10.1152%2Fajpheart.00554.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00554.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00554.2015%26sid%3Dliteratum%253Aachs%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DFerdinandy%26aufirst%3DP.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DPacher%26aufirst%3DP.%26atitle%3DDrug-induced%2520mitochondrial%2520dysfunction%2520and%2520cardiotoxicity%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2015%26volume%3D309%26spage%3DH1453%26epage%3DH1467%26doi%3D10.1152%2Fajpheart.00554.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Samudio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurinna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruvolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korchin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span> </span><span class="NLM_article-title">Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1, 9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1130</span><span class="NLM_x">–</span> <span class="NLM_lpage">1139</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F1535-7163.MCT-07-0553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18483301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFanu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1130-1139&author=I.+Samudioauthor=S.+Kurinnaauthor=P.+Ruvoloauthor=B.+Korchinauthor=H.+Kantarjianauthor=M.+Beranauthor=K.+Dunnerauthor=S.+Kondoauthor=M.+Andreeffauthor=M.+Konopleva&title=Inhibition+of+mitochondrial+metabolism+by+methyl-2-cyano-3%2C12-dioxooleana-1%2C+9-diene-28-oate+induces+apoptotic+or+autophagic+cell+death+in+chronic+myeloid+leukemia+cells&doi=10.1158%2F1535-7163.MCT-07-0553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells</span></div><div class="casAuthors">Samudio, Ismael; Kurinna, Svitlana; Ruvolo, Peter; Korchin, Borys; Kantarjian, Hagop; Beran, Miloslav; Dunner, Kenneth, Jr.; Kondo, Seiji; Andreeff, Michael; Konopleva, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1130-1139</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The initial success of the first synthetic bcr-abl kinase inhibitor imatinib has been dampened by the emergence of imatinib-resistant disease in blast crisis chronic myeloid leukemia.  Here, we report that the novel triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me) potently induced cytotoxicity in imatinib-resistant KBM5 cells expressing the T315I mutation of bcr-abl (24-h EC50, 540 nmol/L).  In long-term culture, CDDO-Me abrogated the growth of human parental KBM5 and KBM5-STI cells with 96-h IC50 of 205 and 221 nmol/L, resp.  In addn., CDDO-Me rapidly decreased the viability of murine lymphoid Ba/F3 cells expressing wild-type p210 as well as the imatinib-resistant E255K and T315I mutations of bcr-abl.  The low-dose effects of CDDO-Me are assocd. with inhibition of mitochondrial oxygen consumption, whereas the cytotoxic effects appear to be mediated by a rapid and selective depletion of mitochondrial glutathione that accompanies the increased generation of reactive oxygen species and mitochondrial dysfunction.  Interestingly, the mitochondriotoxic effects of CDDO-Me are followed by the rapid autophagocytosis of intracellular organelles or the externalization of phosphatidylserine in different cell types.  We conclude that alterations in mitochondrial function by CDDO-Me can result in autophagy or apoptosis of chronic myeloid leukemia cells regardless of the mutational status of bcr-abl.  CDDO-Me is in clin. trials and shows signs of clin. activity, with minimal side effects and complete lack of cardiotoxicity.  Studies in leukemias are in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqRX0lPsqvBbVg90H21EOLACvtfcHk0li5obCh6_Zh0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFanu7g%253D&md5=3600b693af70f14a98b12c04158a083b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0553%26sid%3Dliteratum%253Aachs%26aulast%3DSamudio%26aufirst%3DI.%26aulast%3DKurinna%26aufirst%3DS.%26aulast%3DRuvolo%26aufirst%3DP.%26aulast%3DKorchin%26aufirst%3DB.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DDunner%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKonopleva%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520mitochondrial%2520metabolism%2520by%2520methyl-2-cyano-3%252C12-dioxooleana-1%252C%25209-diene-28-oate%2520induces%2520apoptotic%2520or%2520autophagic%2520cell%2520death%2520in%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1130%26epage%3D1139%26doi%3D10.1158%2F1535-7163.MCT-07-0553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Vannini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cammarota, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noonan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albini, A.</span><span> </span><span class="NLM_article-title">The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3139</span><span class="NLM_x">–</span> <span class="NLM_lpage">3146</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F1535-7163.MCT-07-0451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18065492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3139-3146&author=N.+Vanniniauthor=G.+Lorussoauthor=R.+Cammarotaauthor=M.+Barberisauthor=D.+M.+Noonanauthor=M.+B.+Spornauthor=A.+Albini&title=The+synthetic+oleanane+triterpenoid%2C+CDDO-methyl+ester%2C+is+a+potent+antiangiogenic+agent&doi=10.1158%2F1535-7163.MCT-07-0451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent</span></div><div class="casAuthors">Vannini, Nicola; Lorusso, Girieca; Cammarota, Rosaria; Barberis, Massimo; Noonan, Douglas M.; Sporn, Michael B.; Albini, Adriana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3139-3146</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that the synthetic oleanane triterpenoid, CDDO-Me ester (CDDO-Me; Me 2-cyano-3,12-dioxoolean-1,9-dien-28-oate) is an effective agent for suppressing angiogenesis, both in cell culture and in vivo.  The potency of CDDO-Me is particularly striking when dosed in vivo to inhibit the angiogenic effects of vascular endothelial growth factor and tumor necrosis factor-α in Matrigel sponge assays; activity is seen at i.p. doses of CDDO-Me as low as 0.003 mg/kg of body wt.  If the Matrigel sponges are impregnated with CDDO-Me just before implantation in the mice, picomolar doses of CDDO-Me will suppress angiogenesis.  CDDO-Me also inhibits growth of endothelial cells in monolayer cultures and suppresses neovascular morphogenesis in three-dimensional cultures, but significantly higher doses (50-200 nmol/L) are required.  We also show antiangiogenic effects of CDDO-Me on xenografts of Kaposi's sarcoma cells in immunocompromised mice, using CD31 as a marker.  Several known individual mol. targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-κB signaling, signal transducers and activators of transcription signaling, and transforming growth factor-β signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2.  However, the particularly potent antiangiogenic activity seen in vivo in the present expts. suggest that CDDO-Me, as an angioprevention agent, may be interacting with an entire network of mol. and cellular targets, rather than at a single mol. locus or in a single-cell type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqGTbQoBtC7Vg90H21EOLACvtfcHk0likkKtJPP3bCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrzE&md5=752a46ca8ece347f695a70652f7b1112</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0451%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DN.%26aulast%3DLorusso%26aufirst%3DG.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DBarberis%26aufirst%3DM.%26aulast%3DNoonan%26aufirst%3DD.%2BM.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DAlbini%26aufirst%3DA.%26atitle%3DThe%2520synthetic%2520oleanane%2520triterpenoid%252C%2520CDDO-methyl%2520ester%252C%2520is%2520a%2520potent%2520antiangiogenic%2520agent%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3139%26epage%3D3146%26doi%3D10.1158%2F1535-7163.MCT-07-0451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orimo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molkentin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komuro, I.</span><span> </span><span class="NLM_article-title">p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1038/nature05602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnature05602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=17334357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2007&pages=444-448&author=M.+Sanoauthor=T.+Minaminoauthor=H.+Tokoauthor=H.+Miyauchiauthor=M.+Orimoauthor=Y.+Qinauthor=H.+Akazawaauthor=K.+Tatenoauthor=Y.+Kayamaauthor=M.+Haradaauthor=I.+Shimizuauthor=T.+Asaharaauthor=H.+Hamadaauthor=S.+Tomitaauthor=J.+D.+Molkentinauthor=Y.+Zouauthor=I.+Komuro&title=p53-Induced+inhibition+of+Hif-1+causes+cardiac+dysfunction+during+pressure+overload&doi=10.1038%2Fnature05602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload</span></div><div class="casAuthors">Sano, Masanori; Minamino, Tohru; Toko, Haruhiro; Miyauchi, Hideyuki; Orimo, Masayuki; Qin, Yingjie; Akazawa, Hiroshi; Tateno, Kaoru; Kayama, Yosuke; Harada, Mutsuo; Shimizu, Ippei; Asahara, Takayuki; Hamada, Hirofumi; Tomita, Shuhei; Molkentin, Jeffrey D.; Zou, Yunzeng; Komuro, Issei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">7134</span>),
    <span class="NLM_cas:pages">444-448</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cardiac hypertrophy occurs as an adaptive response to increased workload to maintain cardiac function.  However, prolonged cardiac hypertrophy causes heart failure, and its mechanisms are largely unknown.  Here we show that cardiac angiogenesis is crucially involved in the adaptive mechanism of cardiac hypertrophy and that p53 accumulation is essential for the transition from cardiac hypertrophy to heart failure.  Pressure overload initially promoted vascular growth in the heart by hypoxia-inducible factor-1 (Hif-1)-dependent induction of angiogenic factors, and inhibition of angiogenesis prevented the development of cardiac hypertrophy and induced systolic dysfunction.  Sustained pressure overload induced an accumulation of p53 that inhibited Hif-1 activity and thereby impaired cardiac angiogenesis and systolic function.  Conversely, promoting cardiac angiogenesis by introducing angiogenic factors or by inhibiting p53 accumulation developed hypertrophy further and restored cardiac dysfunction under chronic pressure overload.  These results indicate that the anti-angiogenic property of p53 may have a crucial function in the transition from cardiac hypertrophy to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8UHX9LdjcrVg90H21EOLACvtfcHk0likkKtJPP3bCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1WqsL8%253D&md5=81f9e1bada37ef80a463b3bddee5f6e1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature05602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05602%26sid%3Dliteratum%253Aachs%26aulast%3DSano%26aufirst%3DM.%26aulast%3DMinamino%26aufirst%3DT.%26aulast%3DToko%26aufirst%3DH.%26aulast%3DMiyauchi%26aufirst%3DH.%26aulast%3DOrimo%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DAkazawa%26aufirst%3DH.%26aulast%3DTateno%26aufirst%3DK.%26aulast%3DKayama%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DI.%26aulast%3DAsahara%26aufirst%3DT.%26aulast%3DHamada%26aufirst%3DH.%26aulast%3DTomita%26aufirst%3DS.%26aulast%3DMolkentin%26aufirst%3DJ.%2BD.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DKomuro%26aufirst%3DI.%26atitle%3Dp53-Induced%2520inhibition%2520of%2520Hif-1%2520causes%2520cardiac%2520dysfunction%2520during%2520pressure%2520overload%26jtitle%3DNature%26date%3D2007%26volume%3D446%26spage%3D444%26epage%3D448%26doi%3D10.1038%2Fnature05602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rosengren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosiborod, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawshani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivodic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudbjornsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lind, M.</span><span> </span><span class="NLM_article-title">Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study</span> <span class="citation_source-journal">Lancet Diabetes Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1016/S2213-8587(15)00292-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2FS2213-8587%2815%2900292-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=26388415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A280%3ADC%252BC283ktVKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=876-885&author=A.+Rosengrenauthor=D.+Vestbergauthor=A.+M.+Svenssonauthor=M.+Kosiborodauthor=M.+Clementsauthor=A.+Rawshaniauthor=A.+Pivodicauthor=S.+Gudbjornsdottirauthor=M.+Lind&title=Long-term+excess+risk+of+heart+failure+in+people+with+type+1+diabetes%3A+a+prospective+case-control+study&doi=10.1016%2FS2213-8587%2815%2900292-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study</span></div><div class="casAuthors">Rosengren Annika; Vestberg Daniel; Lind Marcus; Svensson Ann-Marie; Kosiborod Mikhail; Clements Mark; Rawshani Araz; Pivodic Aldina; Gudbjornsdottir Soffia</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Diabetes & endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">876-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Diabetes is an established risk factor for heart failure, but because nearly all heart failure occurs in older individuals, the excess risk and risk factors for heart failure in individuals with type 1 diabetes are not known.  We aimed to determine the excess risk of heart failure in individuals with type 1 diabetes overall and by different levels of glycaemic control and albuminuria.  METHODS:  In this prospective case-control study, we identified all individuals with type 1 diabetes registered in the Swedish National Diabetes Registry between Jan 1, 1998, and Dec 31, 2011, and five controls randomly selected from the general population for each patient, matched according to age, sex, and county, and compared them with respect to subsequent hospital admissions for heart failure, with hazard ratios calculated with Cox regression.  FINDINGS:  In a cohort of 33 402 patients (mean age at baseline 35 years [SD 14], 15 058 [45%] women, and mean duration of diabetes 20·1 years [SD 14·5]), over a mean follow-up of 7·9 years, 1062 (3%) patients were admitted to hospital with a diagnosis of heart failure, compared with 1325 (1%) of 166 228 matched controls over 8·3 years, giving a HR 4·69 (95% CI 3·64-6·04), after adjustment for time-updated age, sex, time-updated diabetes duration, birth in Sweden, educational level, and baseline comorbidities.  Worse glycaemic control was associated with increased risk of heart failure in a graded fashion, and so was the presence of albuminuria.  Risk of heart failure was also increased among those with well controlled diabetes (adjusted HR 2·16 [95% CI 1·55-3·01]) and in those with no albuminuria (3·38 [2·51-4·57]), but not in the subgroup both well-controlled and with normoalbuminuria (1·59 [0·70-3·58]).  INTERPRETATION:  Individuals with type 1 diabetes had a four-times increase in the risk of being admitted to hospital with heart failure compared with population-based controls.  Poor glycaemic control and impaired renal function substantially increased the risk of heart failure.  FUNDING:  The Swedish state, Swedish Society for Physicians, the Health & Medical Care Committee of the Regional Executive Board (Region Vastra Gotaland, Sweden), the Swedish Heart-Lung Foundation, Diabetes Wellness, Novo Nordisk Foundation (PI M Lind), the Swedish Research Council, and the Swedish Council for working life and social research (Epilife).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgDrp-IV1H8f_I8Jvzw4xCfW6udTcc2eYKhqSR_Ic5ILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ktVKgug%253D%253D&md5=cdd5239fb0f9851257ccf972f77d0d2f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2815%2900292-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252815%252900292-2%26sid%3Dliteratum%253Aachs%26aulast%3DRosengren%26aufirst%3DA.%26aulast%3DVestberg%26aufirst%3DD.%26aulast%3DSvensson%26aufirst%3DA.%2BM.%26aulast%3DKosiborod%26aufirst%3DM.%26aulast%3DClements%26aufirst%3DM.%26aulast%3DRawshani%26aufirst%3DA.%26aulast%3DPivodic%26aufirst%3DA.%26aulast%3DGudbjornsdottir%26aufirst%3DS.%26aulast%3DLind%26aufirst%3DM.%26atitle%3DLong-term%2520excess%2520risk%2520of%2520heart%2520failure%2520in%2520people%2520with%2520type%25201%2520diabetes%253A%2520a%2520prospective%2520case-control%2520study%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2015%26volume%3D3%26spage%3D876%26epage%3D885%26doi%3D10.1016%2FS2213-8587%2815%2900292-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gilbert, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krum, H.</span><span> </span><span class="NLM_article-title">Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">2107</span><span class="NLM_x">–</span> <span class="NLM_lpage">2117</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61402-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2FS0140-6736%2814%2961402-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=2107-2117&author=R.+E.+Gilbertauthor=H.+Krum&title=Heart+failure+in+diabetes%3A+effects+of+anti-hyperglycaemic+drug+therapy&doi=10.1016%2FS0140-6736%2814%2961402-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961402-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961402-1%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DR.%2BE.%26aulast%3DKrum%26aufirst%3DH.%26atitle%3DHeart%2520failure%2520in%2520diabetes%253A%2520effects%2520of%2520anti-hyperglycaemic%2520drug%2520therapy%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D2107%26epage%3D2117%26doi%3D10.1016%2FS0140-6736%2814%2961402-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span>The Phase II Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study. <a href="https://www.clinicaltrials.gov/ct2/show/NCT02316821" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02316821</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Phase+II+Study+of+Bardoxolone+Methyl+in+Patients+with+Chronic+Kidney+Disease+and+Type+2+Diabetes%3B+TSUBAKI+Study.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02316821."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Phase%2520II%2520Study%2520of%2520Bardoxolone%2520Methyl%2520in%2520Patients%2520with%2520Chronic%2520Kidney%2520Disease%2520and%2520Type%25202%2520Diabetes%253B%2520TSUBAKI%2520Study" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Yore, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettenbach, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liby, K. T.</span><span> </span><span class="NLM_article-title">Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e22862</span><span class="refDoi"> DOI: 10.1371/journal.pone.0022862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1371%2Fjournal.pone.0022862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21818401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e22862&author=M.+M.+Yoreauthor=A.+N.+Kettenbachauthor=M.+B.+Spornauthor=S.+A.+Gerberauthor=K.+T.+Liby&title=Proteomic+analysis+shows+synthetic+oleanane+triterpenoid+binds+to+mTOR&doi=10.1371%2Fjournal.pone.0022862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR</span></div><div class="casAuthors">Yore, Mark M.; Kettenbach, Arminja N.; Sporn, Michael B.; Gerber, Scott A.; Liby, Karen T.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e22862</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">New multifunctional drugs that target multiple disease-relevant networks offer a novel approach to the prevention and treatment of many diseases.  New synthetic oleanane triterpenoids (SO), such as CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) and its derivs., are multifunctional compds. originally developed for the prevention and treatment of inflammation and oxidative stress.  However, the protein binding partners and mechanisms of action of these SO are not yet fully understood.  Here we characterize the putative target profile of one SO, CDDO-Imidazolide (CDDO-Im), by combining affinity purifn. with mass spectroscopic proteomic anal. to identify 577 candidate binding proteins in whole cells.  This SO pharmaco-interactome consists of a diverse but interconnected set of signaling networks; bioinformatic anal. of the protein interactome identified canonical signaling pathways targeted by the SO, including retinoic acid receptor (RAR), estrogen receptor (ER), insulin receptor (IR), janus kinase/signal transducers and activators of transcription (JAK/STAT), and phosphatase and tensin homolog (PTEN).  Pull-down studies then further validated a subset of the putative targets.  In addn., we now show for the first time that the mammalian target of rapamycin (mTOR) is a direct target of CDDO-Im.  We also show that CDDO-Im blocks insulin-induced activation of this pathway by binding to mTOR and inhibiting its kinase activity.  Our basic studies confirm that the SO, CDDO-Im, acts on a protein network to elicit its pharmacol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xaGX_jtP5rVg90H21EOLACvtfcHk0ljOUhxzBDSM1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbfI&md5=6a92c2cdd3bfa0720a8b80f0f48fd5e7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0022862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0022862%26sid%3Dliteratum%253Aachs%26aulast%3DYore%26aufirst%3DM.%2BM.%26aulast%3DKettenbach%26aufirst%3DA.%2BN.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DGerber%26aufirst%3DS.%2BA.%26aulast%3DLiby%26aufirst%3DK.%2BT.%26atitle%3DProteomic%2520analysis%2520shows%2520synthetic%2520oleanane%2520triterpenoid%2520binds%2520to%2520mTOR%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De22862%26doi%3D10.1371%2Fjournal.pone.0022862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Woods, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieberich, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavanja, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, D. A.</span><span> </span><span class="NLM_article-title">Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as F-19 NMR probes in deuterium-free environments</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7934</span><span class="NLM_x">–</span> <span class="NLM_lpage">7941</span><span class="refDoi"> DOI: 10.1021/jm201114t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201114t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7934-7941&author=J.+R.+Woodsauthor=H.+P.+Moauthor=A.+A.+Bieberichauthor=T.+Alavanjaauthor=D.+A.+Colby&title=Fluorinated+amino-derivatives+of+the+sesquiterpene+lactone%2C+parthenolide%2C+as+F-19+NMR+probes+in+deuterium-free+environments&doi=10.1021%2Fjm201114t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm201114t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201114t%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BR.%26aulast%3DMo%26aufirst%3DH.%2BP.%26aulast%3DBieberich%26aufirst%3DA.%2BA.%26aulast%3DAlavanja%26aufirst%3DT.%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DFluorinated%2520amino-derivatives%2520of%2520the%2520sesquiterpene%2520lactone%252C%2520parthenolide%252C%2520as%2520F-19%2520NMR%2520probes%2520in%2520deuterium-free%2520environments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7934%26epage%3D7941%26doi%3D10.1021%2Fjm201114t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Oakley, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoBello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caccuri, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federici, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M. W.</span><span> </span><span class="NLM_article-title">The three-dimensional structure of the human Pi class glutathione transferase P1–1 in complex with the inhibitor ethacrynic acid and its glutathione</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span><span class="refDoi"> DOI: 10.1021/bi962316i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi962316i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=576-585&author=A.+J.+Oakleyauthor=J.+Rossjohnauthor=M.+LoBelloauthor=A.+M.+Caccuriauthor=G.+Federiciauthor=M.+W.+Parker&title=The+three-dimensional+structure+of+the+human+Pi+class+glutathione+transferase+P1%E2%80%931+in+complex+with+the+inhibitor+ethacrynic+acid+and+its+glutathione&doi=10.1021%2Fbi962316i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi962316i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi962316i%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DA.%2BJ.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLoBello%26aufirst%3DM.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DThe%2520three-dimensional%2520structure%2520of%2520the%2520human%2520Pi%2520class%2520glutathione%2520transferase%2520P1%25E2%2580%25931%2520in%2520complex%2520with%2520the%2520inhibitor%2520ethacrynic%2520acid%2520and%2520its%2520glutathione%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D576%26epage%3D585%26doi%3D10.1021%2Fbi962316i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frodin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span><span class="refDoi"> DOI: 10.1038/nchembio.925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Frodinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles&doi=10.1038%2Fnchembio.925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0lilb3952WGx2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFrodin%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476%26doi%3D10.1038%2Fnchembio.925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Couch, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A. C.</span><span> </span><span class="NLM_article-title">Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2215</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.bmcl.2005.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=15837296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlWqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2215-2219&author=R.+D.+Couchauthor=R.+G.+Browningauthor=T.+Hondaauthor=G.+W.+Gribbleauthor=D.+L.+Wrightauthor=M.+B.+Spornauthor=A.+C.+Anderson&title=Studies+on+the+reactivity+of+CDDO%2C+a+promising+new+chemopreventive+and+chemotherapeutic+agent%3A+implications+for+a+molecular+mechanism+of+action&doi=10.1016%2Fj.bmcl.2005.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action</span></div><div class="casAuthors">Couch, Robin D.; Browning, R. Greg; Honda, Tadashi; Gribble, Gordon W.; Wright, Dennis L.; Sporn, Michael B.; Anderson, Amy C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2215-2219</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CDDO, a semi-synthetic triterpenoid derived from oleanolic acid, has the potential to be used as a chemopreventive and chemotherapeutic agent.  The structure of CDDO contains two α,β-unsatd. carbonyl moieties, suggesting a mechanism of action involving a conjugate nucleophilic addn.  Spectroscopic evaluation with thiol nucleophiles illustrates that an addn. does indeed occur, but this addn. is selective and reversible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSEly4KE1L3bVg90H21EOLACvtfcHk0lilb3952WGx2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlWqs78%253D&md5=403474a7b33ce6f42e93ad3f9bbd84b0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DCouch%26aufirst%3DR.%2BD.%26aulast%3DBrowning%26aufirst%3DR.%2BG.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DGribble%26aufirst%3DG.%2BW.%26aulast%3DWright%26aufirst%3DD.%2BL.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DAnderson%26aufirst%3DA.%2BC.%26atitle%3DStudies%2520on%2520the%2520reactivity%2520of%2520CDDO%252C%2520a%2520promising%2520new%2520chemopreventive%2520and%2520chemotherapeutic%2520agent%253A%2520implications%2520for%2520a%2520molecular%2520mechanism%2520of%2520action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2215%26epage%3D2219%26doi%3D10.1016%2Fj.bmcl.2005.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Fleming, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tercek, F.</span><span> </span><span class="NLM_article-title">Unsaturated nitriles: conjugate addition-silylation with grignard reagents</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4883</span><span class="NLM_x">–</span> <span class="NLM_lpage">4885</span><span class="refDoi"> DOI: 10.1021/jo9705430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9705430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=4883-4885&author=F.+F.+Flemingauthor=Y.+F.+Puauthor=F.+Tercek&title=Unsaturated+nitriles%3A+conjugate+addition-silylation+with+grignard+reagents&doi=10.1021%2Fjo9705430"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo9705430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9705430%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DPu%26aufirst%3DY.%2BF.%26aulast%3DTercek%26aufirst%3DF.%26atitle%3DUnsaturated%2520nitriles%253A%2520conjugate%2520addition-silylation%2520with%2520grignard%2520reagents%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D4883%26epage%3D4885%26doi%3D10.1021%2Fjo9705430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Albert, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczuk, A.</span><span> </span><span class="NLM_article-title">Histochemical demonstration of gamma-glutamyl transpeptidase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1961</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1038/191767a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2F191767a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=1961&pages=767-768&author=Z.+Albertauthor=M.+Orlowskiauthor=A.+Szewczuk&title=Histochemical+demonstration+of+gamma-glutamyl+transpeptidase&doi=10.1038%2F191767a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F191767a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F191767a0%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DZ.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DSzewczuk%26aufirst%3DA.%26atitle%3DHistochemical%2520demonstration%2520of%2520gamma-glutamyl%2520transpeptidase%26jtitle%3DNature%26date%3D1961%26volume%3D191%26spage%3D767%26epage%3D768%26doi%3D10.1038%2F191767a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. E.</span><span> </span><span class="NLM_article-title">Human kidney gamma-glutamyl transpeptidase. Catalytic properties, subunit structure, and localization of the gamma-glutamyl binding site on the light subunit</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">252</span><span class="NLM_x">, </span> <span class="NLM_fpage">6042</span><span class="NLM_x">–</span> <span class="NLM_lpage">6045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1977&pages=6042-6045&author=S.+S.+Tateauthor=M.+E.+Ross&title=Human+kidney+gamma-glutamyl+transpeptidase.+Catalytic+properties%2C+subunit+structure%2C+and+localization+of+the+gamma-glutamyl+binding+site+on+the+light+subunit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTate%26aufirst%3DS.%2BS.%26aulast%3DRoss%26aufirst%3DM.%2BE.%26atitle%3DHuman%2520kidney%2520gamma-glutamyl%2520transpeptidase.%2520Catalytic%2520properties%252C%2520subunit%2520structure%252C%2520and%2520localization%2520of%2520the%2520gamma-glutamyl%2520binding%2520site%2520on%2520the%2520light%2520subunit%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1977%26volume%3D252%26spage%3D6042%26epage%3D6045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Worth, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span> </span><span class="NLM_article-title">gamma-L-Glutamyl-L-dopa is a dopamine pro-drug, relatively specific for the kidney in normal subjects</span> <span class="citation_source-journal">Clin. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span><span class="refDoi"> DOI: 10.1042/cs0690207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1042%2Fcs0690207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=3933890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaL2MXltFGqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1985&pages=207-214&author=D.+P.+Worthauthor=J.+N.+Harveyauthor=J.+Brownauthor=M.+R.+Lee&title=gamma-L-Glutamyl-L-dopa+is+a+dopamine+pro-drug%2C+relatively+specific+for+the+kidney+in+normal+subjects&doi=10.1042%2Fcs0690207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">γ-L-Glutamyl-L-dopa is a dopamine prodrug, relatively specific for the kidney in normal subjects</span></div><div class="casAuthors">Worth, D. P.; Harvey, J. N.; Brown, J.; Lee, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-14</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    </div><div class="casAbstract">γ-L-Glutamyl-L-dopa (I)  [52370-58-8] was given by i.v. infusion to normal subjects at doses of 12.5 and 100 μg/min/kg.  Both doses of I resulted in an increase in mean urinary Na+ excretion.  The mean effective renal plasma flow rose at both doses, but mean glomerular filtration rate increased only at the lower dose.  There was a fall in mean plasma renin  [9015-94-5] activity after infusion at both rates.  Mean urine free dopamine  [51-61-6] excretion increased by 280- and 2500-fold at infusion rates of 12.5 and 100 μg/min/kg, resp.  Mean plasma free dopamine rose at both doses but the increase at 12.5 μg/min/kg was not to a level previously assocd. with systemic effects of the catecholamine.  On administration of I at 12.5 μg/min/kg there were no changes in blood pressure or heart rate, but at the higher does there was a fall in diastolic blood pressure.  At a dose of 12.5 μg/min/kg in man, there is kidney-specific conversion of I to dopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7fgPKPPT2uLVg90H21EOLACvtfcHk0ljg7XG4dleK-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltFGqu7s%253D&md5=87b4e0982b8ae5f7bbe88e12a882c0f5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1042%2Fcs0690207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fcs0690207%26sid%3Dliteratum%253Aachs%26aulast%3DWorth%26aufirst%3DD.%2BP.%26aulast%3DHarvey%26aufirst%3DJ.%2BN.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26atitle%3Dgamma-L-Glutamyl-L-dopa%2520is%2520a%2520dopamine%2520pro-drug%252C%2520relatively%2520specific%2520for%2520the%2520kidney%2520in%2520normal%2520subjects%26jtitle%3DClin.%2520Sci.%26date%3D1985%26volume%3D69%26spage%3D207%26epage%3D214%26doi%3D10.1042%2Fcs0690207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milliken, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulczynska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slawin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkby, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botting, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megson, I. L.</span><span> </span><span class="NLM_article-title">Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5321</span><span class="NLM_x">–</span> <span class="NLM_lpage">5334</span><span class="refDoi"> DOI: 10.1021/jm400146r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400146r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5321-5334&author=Q.+Zhangauthor=P.+Millikenauthor=A.+Kulczynskaauthor=A.+M.+Slawinauthor=A.+Gordonauthor=N.+S.+Kirkbyauthor=D.+J.+Webbauthor=N.+P.+Bottingauthor=I.+L.+Megson&title=Development+and+characterization+of+glutamyl-protected+N-hydroxyguanidines+as+reno-active+nitric+oxide+donor+drugs+with+therapeutic+potential+in+acute+renal+failure&doi=10.1021%2Fjm400146r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm400146r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400146r%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMilliken%26aufirst%3DP.%26aulast%3DKulczynska%26aufirst%3DA.%26aulast%3DSlawin%26aufirst%3DA.%2BM.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DKirkby%26aufirst%3DN.%2BS.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DBotting%26aufirst%3DN.%2BP.%26aulast%3DMegson%26aufirst%3DI.%2BL.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520glutamyl-protected%2520N-hydroxyguanidines%2520as%2520reno-active%2520nitric%2520oxide%2520donor%2520drugs%2520with%2520therapeutic%2520potential%2520in%2520acute%2520renal%2520failure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5321%26epage%3D5334%26doi%3D10.1021%2Fjm400146r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Barthelmebs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caillette, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrhardt, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbs, J. L.</span><span> </span><span class="NLM_article-title">Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1414</span><span class="NLM_x">–</span> <span class="NLM_lpage">1422</span><span class="refDoi"> DOI: 10.1038/ki.1990.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fki.1990.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1972967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaK3cXkslSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1990&pages=1414-1422&author=M.+Barthelmebsauthor=A.+Cailletteauthor=J.+D.+Ehrhardtauthor=J.+Vellyauthor=J.+L.+Imbs&title=Metabolism+and+vascular+effects+of+gamma-L-glutamyl-L-dopa+on+the+isolated+rat+kidney&doi=10.1038%2Fki.1990.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney</span></div><div class="casAuthors">Barthelmebs, Mariette; Caillette, Agnes; Ehrhardt, Jean Daniel; Velly, Jeanne; Imbs, Jean Louis</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1414-22</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    </div><div class="casAbstract">Gamma-L-glutamyl-L-dopa (gludopa), a dopamine (DA) prodrug, is selectively metabolized in vivo by the kidney through the sequential action of two renal enzymes, gamma-glutamyl transpeptidase (gamma-GT) and arom. L-amino acid decarboxylase (AADC).  The factors regulating gludopa metab. and its renal vascular effects were studied in vitro.  Rat kidneys were perfused with a buffer contg. 6% bovine serum albumin (BSA).  Adding gludopa (final concn. 10-5 M in the perfusate) led to the release of DA both into urine and perfusate (0.53 and 1.38 nmol/min/g kidney wt., resp., during the first 5 min after substrate addn.).  Total DA release (urine plus perfusate) was 73.7 nmol/g kidney wt. within 30 min of recirculation.  In non-filtering kidneys, the total DA release in the recirculating medium was 12.5 nmol/g kidney wt.  Glomerular filtration and access to the gamma-GT on the brush border membrane of proximal tubular cells are required for the maximal conversion of gludopa.  On filtering kidneys, L-dopa was also converted to DA, but at a higher rate than gludopa (total DA formed within 30 min of recirculation = 131.2 nmol/g kidney wt.) and this rate was not reduced in non-filtering kidneys (224.2 nmol DA/g kidney wt. formed within 30 min).  Metabolic conversion of L-dopa by AADC is thus preserved in the case of an approach via the basolateral side of the proximal tubular cells.  The renal vascular effects of gludopa were studied after vascular tone had been restored by continuous perfusion of PGF2α and after the inhibition of alpha- and beta-adrenoceptors.  Gludopa (3·10-6 to 4·10-5 M) elicited concn.-dependent renal vasodilation.  At 4·10-5 M, the renal response was similar to that elicited by DA and L-dopa at concns. resp. 20- and 2-times lower.  These responses were abolished by the DA-1 receptor antagonist SCH 23390.  Inhibition of gamma-GT by AT-125 (10-6 M) reduced gludopa-induced renal vasodilatation, as did carbidopa (10-4 M), on the L-dopa-induced renal response.  Gludopa- and L-dopa-induced renal vasodilatations are directly linked to endorenal release of DA which interacts with vascular DA-1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_yt5__Og3I7Vg90H21EOLACvtfcHk0ljsoadEd-zaWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslSltb0%253D&md5=c6aadad02db6445c20141c4de78abd93</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fki.1990.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.1990.131%26sid%3Dliteratum%253Aachs%26aulast%3DBarthelmebs%26aufirst%3DM.%26aulast%3DCaillette%26aufirst%3DA.%26aulast%3DEhrhardt%26aufirst%3DJ.%2BD.%26aulast%3DVelly%26aufirst%3DJ.%26aulast%3DImbs%26aufirst%3DJ.%2BL.%26atitle%3DMetabolism%2520and%2520vascular%2520effects%2520of%2520gamma-L-glutamyl-L-dopa%2520on%2520the%2520isolated%2520rat%2520kidney%26jtitle%3DKidney%2520Int.%26date%3D1990%26volume%3D37%26spage%3D1414%26epage%3D1422%26doi%3D10.1038%2Fki.1990.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wilk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizoguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, M.</span><span> </span><span class="NLM_article-title">gamma-Glutamyl dopa: a kidney-specific dopamine precursor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=660553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaE1cXlsVSnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1978&pages=227-232&author=S.+Wilkauthor=H.+Mizoguchiauthor=M.+Orlowski&title=gamma-Glutamyl+dopa%3A+a+kidney-specific+dopamine+precursor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Glutamyl dopa:  a kidney-specific dopamine precursor</span></div><div class="casAuthors">Wilk, Sherwin; Mizoguchi, Haruko; Orlowski, Marian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">227-32</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">γ-Glutamyl dopa (I)  [52370-58-8] was synthesized both chem. and enzymatically.  Injection of this deriv. into mice led to a selective generation of dopamine  [51-61-6] in the kidney as a consequence of the sequential action of γ-glutamyl transpeptidase and arom. L-amino acid decarboxylase, 2 enzymes which are highly concd. in the kidney.  The concn. of dopamine in the kidney after I was almost 5 times higher than that after an equiv. dose of L-dopa.  Infusion of 10 nmol I/g/30 min to rats produced a 60% increase in renal plasma flow.  By contrast the same dose of L-dopa had no effect on renal plasma flow.  Only a small pressor effect was obsd. after the infusion dose of I was increased 20-fold, indicating that the systemic effects of this prodrug are slight.  Thus, the prodrug I can be used as a specific renal vasodilator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOyxYan2-L07Vg90H21EOLACvtfcHk0ljsoadEd-zaWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXlsVSnsb4%253D&md5=f9d5cb083dacf5f472fdf365f02701c3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilk%26aufirst%3DS.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DOrlowski%26aufirst%3DM.%26atitle%3Dgamma-Glutamyl%2520dopa%253A%2520a%2520kidney-specific%2520dopamine%2520precursor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1978%26volume%3D206%26spage%3D227%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Li Kam Wa, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freestone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span> </span><span class="NLM_article-title">Renal metabolism and effects of the glutamyl derivatives of L-dopa and 5-hydroxytryptophan in man</span> <span class="citation_source-journal">Clin. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1042/cs0910177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1042%2Fcs0910177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=8795441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaK28Xltlamsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1996&pages=177-185&author=T.+C.+Li+Kam+Waauthor=S.+Freestoneauthor=R.+R.+Samsonauthor=N.+R.+Johnstonauthor=M.+R.+Lee&title=Renal+metabolism+and+effects+of+the+glutamyl+derivatives+of+L-dopa+and+5-hydroxytryptophan+in+man&doi=10.1042%2Fcs0910177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Renal metabolism and effects of the glutamyl derivatives of L-dopa and 5-hydroxytryptophan in man</span></div><div class="casAuthors">Li Kam Wa, T. C.; Freestone, S.; Samson, R. R.; Johnston, N. R.; Lee, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-185</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    
            (<span class="NLM_cas:orgname">Portland Press</span>)
        </div><div class="casAbstract">Equimolar amts. of γ-L-glutamyl-L-3,4-dihydroxyphenylalanine (gludopa) and γ-L-glutamyl-5-hydroxy-L-tryptophan were infused sep. and together in eight healthy, salt-replete male subjects in a placebo-controlled, cross-over study to investigate whether the administration of one amine precursor affects the renal metab. of the other and to det. whether dopamine or 5-hydroxytryptamine would be generated preferentially.  The overall effect on sodium excretion was also measured when both precursors were administered simultaneously.  Administration of gludopa was assocd. with marked increases in the urinary excretion of L-dopa, dopamine and 3,4-dihydroxyphenylacetic acid, together with a rise in the urinary excretion of sodium.  γ-L-Glutamyl-5-hydroxy-L-tryptophan, produced marked increases in the urinary excretion of 5-hydroxy-L-tryptophan, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid, and this was accompanied by a slight, but non-significant, redn. in sodium excretion.  About 27% of the infused dose of gludopa (on a molar basis) was recovered in the urine as dopamine whereas 15% of the given dose of γ-L-glutamyl-5-hydroxy-L-tryptophan was excreted as 5-hydroxytryptamine.  The urinary excretion values of L-dopa, dopamine and 3,4-dihydroxyphenylacetic acid after the simultaneous infusion of gludopa and γ-L-glutamyl-5-hydroxy-L-tryptophan were not significantly different from those obsd. after infusion of gludopa only.  Similarly, the urinary excretion values of 5-hydroxy-L-tryptophan, 5-hydroxytryptamine and 5-hydroxy-indoleacetic acid during the co-infusion were similar to those measured after administration of γ-L-glutamyl-5-hydroxy-L-tryptophan only.  The net effect of the concomitant infusion of both glutamyl derivs. was an increase in urinary sodium excretion.  The authors' study in salt-replete individuals suggests that dopamine rather than 5-hydroxytryptamine was preferentially produced when equimolar amts. of their precursors were provided and that the natriuretic effect of dopamine, generated intrarenally from gludopa, was greater than the sodium retaining action of 5-hydroxytryptamine derived from γ-L-glutamyl-5-hydroxy-L-tryptophan.  Comparison of the urinary metabolite data after the sep. and concomitant infusion of the two glutamyl compds. provided no evidence of competitive inhibition of synthesis of either amine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn7Aez3H3jK7Vg90H21EOLACvtfcHk0liFMmdiM5aMxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xltlamsr0%253D&md5=677471b4d08bcac85bf61fe9accb5729</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1042%2Fcs0910177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fcs0910177%26sid%3Dliteratum%253Aachs%26aulast%3DLi%2BKam%2BWa%26aufirst%3DT.%2BC.%26aulast%3DFreestone%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DR.%2BR.%26aulast%3DJohnston%26aufirst%3DN.%2BR.%26aulast%3DLee%26aufirst%3DM.%2BR.%26atitle%3DRenal%2520metabolism%2520and%2520effects%2520of%2520the%2520glutamyl%2520derivatives%2520of%2520L-dopa%2520and%25205-hydroxytryptophan%2520in%2520man%26jtitle%3DClin.%2520Sci.%26date%3D1996%26volume%3D91%26spage%3D177%26epage%3D185%26doi%3D10.1042%2Fcs0910177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Yasushi, Y.; Keiko, S.; Setsuko, N.</span><span> </span><span class="NLM_article-title">Novel glutamic acid derivative and use thereof</span>. W.O. Patent 2,015,178,265, November 26,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Yasushi&author=S.+Keiko&author=N.+Setsuko&title=Novel+glutamic+acid+derivative+and+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYasushi%26aufirst%3DY.%26atitle%3DNovel%2520glutamic%2520acid%2520derivative%2520and%2520use%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Tranoy-Opalinski, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papot, S.</span><span> </span><span class="NLM_article-title">Design of self-immolative linkers for tumour-activated prodrug therapy</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span><span class="refDoi"> DOI: 10.2174/187152008785133065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.2174%2F187152008785133065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18690826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ogsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=618-637&author=I.+Tranoy-Opalinskiauthor=A.+Fernandesauthor=M.+Thomasauthor=J.+P.+Gessonauthor=S.+Papot&title=Design+of+self-immolative+linkers+for+tumour-activated+prodrug+therapy&doi=10.2174%2F187152008785133065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design of self-immolative linkers for tumour-activated prodrug therapy</span></div><div class="casAuthors">Tranoy-Opalinski, I.; Fernandes, A.; Thomas, M.; Gesson, J.-P.; Papot, S.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">618-637</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The main drawback of most cancer chemotherapy is its relatively low ability to target tumor cells vs. normal cells.  As a consequence, chemotherapy is usually connected with severe side effects due to the toxicity of traditional cytostatic agents towards normal tissues.  A few years ago, the site-specific activation of nontoxic prodrugs in tumors has been proposed in order to enhance the selectivity for the killing of cancer cells.  Within this framework, most of the prodrugs that have been designed were three part compds. comprising trigger, linker and effector units.  The main function of the linker is to release the effector unit after selective trigger activation via a spontaneous chem. breakdown.  However, its structure also affects significantly many prodrug properties such as stability, pharmacokinetic, organ distribution, bioavailability or trigger activation.  This review, focussed on the linker unit, is an update of the previous article published in 2002.  It deals with recent advances in the design of prodrug linkers including new delivery systems such as elongated linkers or self-immolative dendrimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeb-2jcsWQx7Vg90H21EOLACvtfcHk0liFMmdiM5aMxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ogsr8%253D&md5=c11a530c32537ef25c5789e0a8573d91</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2174%2F187152008785133065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152008785133065%26sid%3Dliteratum%253Aachs%26aulast%3DTranoy-Opalinski%26aufirst%3DI.%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DGesson%26aufirst%3DJ.%2BP.%26aulast%3DPapot%26aufirst%3DS.%26atitle%3DDesign%2520of%2520self-immolative%2520linkers%2520for%2520tumour-activated%2520prodrug%2520therapy%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D618%26epage%3D637%26doi%3D10.2174%2F187152008785133065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Dong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surana, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, R. B.</span><span> </span><span class="NLM_article-title">Solubilization and preformulation of poorly water soluble and hydrolysis susceptible N-epoxymethyl-1,8-naphthalimide (ENA) compound</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.ijpharm.2008.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18282672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2008&pages=130-136&author=Y.+Dongauthor=W.+K.+Ngauthor=U.+Suranaauthor=R.+B.+Tan&title=Solubilization+and+preformulation+of+poorly+water+soluble+and+hydrolysis+susceptible+N-epoxymethyl-1%2C8-naphthalimide+%28ENA%29+compound&doi=10.1016%2Fj.ijpharm.2008.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Solubilization and preformulation of poorly water soluble and hydrolysis susceptible N-epoxymethyl-1,8-naphthalimide</span></div><div class="casAuthors">Dong, Yuancai; Ng, Wai Kiong; Surana, Uttam; Tan, Reginald B. H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">130-136</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-Epoxymethyl-1,8-naphthalimide (ENA) is a novel antiproliferative drug candidate with potent anticancer and antifungal activity.  It has an aq. soly. of 0.0116 mg/mL and also exhibits hydrolytic instability with a first-order hydrolysis rate of 0.051 h-1.  The present preformulation study aimed to characterize the physicochem. properties of ENA and develop an early injectable soln. formulation for preclin. studies.  To minimize hydrolysis, ENA is proposed to be formulated as either lyophilized powders or nonaq. solns. followed by solubilization/reconstitution prior to administration.  ENA solubilization was investigated in both aq. media (by cosolvency, micellization and complexation) and nonaq. solns. (mixt. of Cremophor EL and ethanol).  It is found that none of the solubilization techniques in aq. media could increase ENA soly. to a desired level of several hundreds μg/mL at pharmaceutically acceptable excipient concns. (≤10%).  In contrast, a combination of 70% Cremophor EL and 30% ethanol (vol./vol.) proved effective in solubilizing ENA at 4 mg/mL, which exhibited good phys. and chem. stability on storage at both 4° and room temp. over 4 mo.  No pptn. was obsd. upon 5-20 times diln. by the saline; in addn., less than 5% of ENA was hydrolyzed in 4 h for the saline-dild. aq. solns.  This nonaq. ENA formulation is thus proposed for further preclin. studies, which can be reconstituted, prior to administration, by the 5-20 times infusion fluids (saline, 5% dextrose, etc.) to the desired drug dosing concn. at the acceptable excipient level.  The approach used in this work could serve as a useful ref. in formulating nonpolar drugs with hydrolytic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYu7dPcI3t77Vg90H21EOLACvtfcHk0ljnVF6ns4gXRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFClurc%253D&md5=fa221971b1689f088b7b11246a3061b9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DW.%2BK.%26aulast%3DSurana%26aufirst%3DU.%26aulast%3DTan%26aufirst%3DR.%2BB.%26atitle%3DSolubilization%2520and%2520preformulation%2520of%2520poorly%2520water%2520soluble%2520and%2520hydrolysis%2520susceptible%2520N-epoxymethyl-1%252C8-naphthalimide%2520%2528ENA%2529%2520compound%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D356%26spage%3D130%26epage%3D136%26doi%3D10.1016%2Fj.ijpharm.2008.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Ahmad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharbanda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufe, D.</span><span> </span><span class="NLM_article-title">Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">35764</span><span class="NLM_x">–</span> <span class="NLM_lpage">35769</span><span class="refDoi"> DOI: 10.1074/jbc.M607160200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1074%2Fjbc.M607160200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=35764-35769&author=R.+Ahmadauthor=D.+Rainaauthor=C.+Meyerauthor=S.+Kharbandaauthor=D.+Kufe&title=Triterpenoid+CDDO-Me+blocks+the+NF-kappaB+pathway+by+direct+inhibition+of+IKKbeta+on+Cys-179&doi=10.1074%2Fjbc.M607160200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M607160200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M607160200%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DRaina%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DKufe%26aufirst%3DD.%26atitle%3DTriterpenoid%2520CDDO-Me%2520blocks%2520the%2520NF-kappaB%2520pathway%2520by%2520direct%2520inhibition%2520of%2520IKKbeta%2520on%2520Cys-179%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D35764%26epage%3D35769%26doi%3D10.1074%2Fjbc.M607160200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Sharma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, S. R.</span><span> </span><span class="NLM_article-title">Diabetic kidney disease in the db/db mouse</span> <span class="citation_source-journal">Am. J. Physiol. Renal Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">F1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">F1144</span><span class="refDoi"> DOI: 10.1152/ajprenal.00315.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1152%2Fajprenal.00315.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=12736165" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=F1138-F1144&author=K.+Sharmaauthor=P.+McCueauthor=S.+R.+Dunn&title=Diabetic+kidney+disease+in+the+db%2Fdb+mouse&doi=10.1152%2Fajprenal.00315.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00315.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00315.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DMcCue%26aufirst%3DP.%26aulast%3DDunn%26aufirst%3DS.%2BR.%26atitle%3DDiabetic%2520kidney%2520disease%2520in%2520the%2520db%252Fdb%2520mouse%26jtitle%3DAm.%2520J.%2520Physiol.%2520Renal%2520Physiol.%26date%3D2003%26volume%3D284%26spage%3DF1138%26epage%3DF1144%26doi%3D10.1152%2Fajprenal.00315.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Alpers, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, K. L.</span><span> </span><span class="NLM_article-title">Mouse models of diabetic nephropathy</span> <span class="citation_source-journal">Curr. Opin. Nephrol. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1097/MNH.0b013e3283451901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1097%2FMNH.0b013e3283451901" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=278-284&author=C.+E.+Alpersauthor=K.+L.+Hudkins&title=Mouse+models+of+diabetic+nephropathy&doi=10.1097%2FMNH.0b013e3283451901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1097%2FMNH.0b013e3283451901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMNH.0b013e3283451901%26sid%3Dliteratum%253Aachs%26aulast%3DAlpers%26aufirst%3DC.%2BE.%26aulast%3DHudkins%26aufirst%3DK.%2BL.%26atitle%3DMouse%2520models%2520of%2520diabetic%2520nephropathy%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2011%26volume%3D20%26spage%3D278%26epage%3D284%26doi%3D10.1097%2FMNH.0b013e3283451901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liby, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yore, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopchuk, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, G. W.</span><span> </span><span class="NLM_article-title">New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1021/np100826q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np100826q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVWisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=537-545&author=M.+B.+Spornauthor=K.+T.+Libyauthor=M.+M.+Yoreauthor=L.+Fuauthor=J.+M.+Lopchukauthor=G.+W.+Gribble&title=New+synthetic+triterpenoids%3A+potent+agents+for+prevention+and+treatment+of+tissue+injury+caused+by+inflammatory+and+oxidative+stress&doi=10.1021%2Fnp100826q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress</span></div><div class="casAuthors">Sporn, Michael B.; Liby, Karen T.; Yore, Mark M.; Fu, Liangfeng; Lopchuk, Justin M.; Gribble, Gordon W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">We review the original rational for the development and the chem. of a series of new synthetic oleanane triterpenoids (SO), based on oleanolic acid (I) as a starting material.  Many of the new compds. that have been made, such as 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ["CDDO", (II; R = H)], are highly potent (activities found at levels below 1 nM) anti-inflammatory agents, as measured by their ability to block the cellular synthesis of the enzyme inducible nitric oxide synthase (iNOS) in activated macrophages.  Details of the org. synthesis of new SO and their chem. mechanisms of biol. activity are reviewed, as is formation of biotin conjugates for investigation of protein targets.  Finally, we give a brief summary of important biol. activities of SO in many organ systems in numerous animal models.  Clin. investigation of a new SO [Me 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate, "CDDO-Me", bardoxolone Me, (II; R = Me)] is currently in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWMDf2Fxc3LVg90H21EOLACvtfcHk0ljnVF6ns4gXRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVWisrg%253D&md5=a6b2efe5faaba6151472b0f5f654940e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fnp100826q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp100826q%26sid%3Dliteratum%253Aachs%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DLiby%26aufirst%3DK.%2BT.%26aulast%3DYore%26aufirst%3DM.%2BM.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLopchuk%26aufirst%3DJ.%2BM.%26aulast%3DGribble%26aufirst%3DG.%2BW.%26atitle%3DNew%2520synthetic%2520triterpenoids%253A%2520potent%2520agents%2520for%2520prevention%2520and%2520treatment%2520of%2520tissue%2520injury%2520caused%2520by%2520inflammatory%2520and%2520oxidative%2520stress%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2011%26volume%3D74%26spage%3D537%26epage%3D545%26doi%3D10.1021%2Fnp100826q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2452</span><span class="NLM_x">–</span> <span class="NLM_lpage">2464</span><span class="refDoi"> DOI: 10.1021/jm5019302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2452-2464&author=Y.+Aiauthor=F.+Kangauthor=Z.+Huangauthor=X.+Xueauthor=Y.+Laiauthor=S.+Pengauthor=J.+Tianauthor=Y.+Zhang&title=Synthesis+of+CDDO-amino+acid-nitric+oxide+donor+trihybrids+as+potential+antitumor+agents+against+both+drug-sensitive+and+drug-resistant+colon+cancer&doi=10.1021%2Fjm5019302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm5019302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019302%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520CDDO-amino%2520acid-nitric%2520oxide%2520donor%2520trihybrids%2520as%2520potential%2520antitumor%2520agents%2520against%2520both%2520drug-sensitive%2520and%2520drug-resistant%2520colon%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2452%26epage%3D2464%26doi%3D10.1021%2Fjm5019302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Fermini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossa, A. A.</span><span> </span><span class="NLM_article-title">The impact of drug-induced qt interval prolongation on drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1038/nrd1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnrd1108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=439-447&author=B.+Ferminiauthor=A.+A.+Fossa&title=The+impact+of+drug-induced+qt+interval+prolongation+on+drug+discovery+and+development&doi=10.1038%2Fnrd1108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrd1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1108%26sid%3Dliteratum%253Aachs%26aulast%3DFermini%26aufirst%3DB.%26aulast%3DFossa%26aufirst%3DA.%2BA.%26atitle%3DThe%2520impact%2520of%2520drug-induced%2520qt%2520interval%2520prolongation%2520on%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fnrd1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Nogueira, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souto, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho-Braga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, D.</span><span> </span><span class="NLM_article-title">Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease</span> <span class="citation_source-journal">Horm-Int. J. Endocrino.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.14310/horm.2002.1436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.14310%2Fhorm.2002.1436" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=483-494&author=C.+Nogueiraauthor=S.+B.+Soutoauthor=E.+Vinhaauthor=D.+Carvalho-Bragaauthor=D.+Carvalho&title=Oral+glucose+lowering+drugs+in+type+2+diabetic+patients+with+chronic+kidney+disease&doi=10.14310%2Fhorm.2002.1436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.14310%2Fhorm.2002.1436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14310%252Fhorm.2002.1436%26sid%3Dliteratum%253Aachs%26aulast%3DNogueira%26aufirst%3DC.%26aulast%3DSouto%26aufirst%3DS.%2BB.%26aulast%3DVinha%26aufirst%3DE.%26aulast%3DCarvalho-Braga%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DD.%26atitle%3DOral%2520glucose%2520lowering%2520drugs%2520in%2520type%25202%2520diabetic%2520patients%2520with%2520chronic%2520kidney%2520disease%26jtitle%3DHorm-Int.%2520J.%2520Endocrino.%26date%3D2013%26volume%3D12%26spage%3D483%26epage%3D494%26doi%3D10.14310%2Fhorm.2002.1436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Klahr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caggiula, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsicker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusek, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Striker, G.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The effects of dietary-protein restriction and blood-pressure control on the progression of chronic renal-disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">877</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span><span class="refDoi"> DOI: 10.1056/NEJM199403313301301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJM199403313301301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=8114857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A280%3ADyaK2c7lvFSisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1994&pages=877-884&author=S.+Klahrauthor=A.+S.+Leveyauthor=G.+J.+Beckauthor=A.+W.+Caggiulaauthor=L.+Hunsickerauthor=J.+W.+Kusekauthor=G.+Striker&title=The+effects+of+dietary-protein+restriction+and+blood-pressure+control+on+the+progression+of+chronic+renal-disease&doi=10.1056%2FNEJM199403313301301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group</span></div><div class="casAuthors">Klahr S; Levey A S; Beck G J; Caggiula A W; Hunsicker L; Kusek J W; Striker G</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">877-84</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Restricting protein intake and controlling hypertension delay the progression of renal disease in animals.  We tested these interventions in 840 patients with various chronic renal diseases.  METHODS:  In study 1, 585 patients with glomerular filtration rates of 25 to 55 ml per minute per 1.73 m2 of body-surface area were randomly assigned to a usual-protein diet or a low-protein diet (1.3 or 0.58 g of protein per kilogram of body weight per day) and to a usual- or a low-blood-pressure group (mean arterial pressure, 107 or 92 mm Hg).  In study 2, 255 patients with glomerular filtration rates of 13 to 24 ml per minute per 1.73 m2 were randomly assigned to the low-protein diet (0.58 g per kilogram per day) or a very-low-protein diet (0.28 g per kilogram per day) with a keto acid-amino acid supplement, and a usual- or a low-blood-pressure group (same values as those in study 1).  An 18-to-45-month follow-up was planned, with monthly evaluations of the patients.  RESULTS:  The mean follow-up was 2.2 years.  In study 1, the projected mean decline in the glomerular filtration rate at three years did not differ significantly between the diet groups or between the blood-pressure groups.  As compared with the usual-protein group and the usual-blood-pressure group, the low-protein group and the low-blood-pressure group had a more rapid decline in the glomerular filtration rate during the first four months after randomization and a slower decline thereafter.  In study 2, the very-low-protein group had a marginally slower decline in the glomerular filtration rate than did the low-protein group (P = 0.07).  There was no delay in the time to the occurrence of end-stage renal disease or death.  In both studies, patients in the low-blood-pressure group who had more pronounced proteinuria at base line had a significantly slower rate of decline in the glomerular filtration rate.  CONCLUSIONS:  Among patients with moderate renal insufficiency, the slower decline in renal function that started four months after the introduction of a low-protein diet suggests a small benefit of this dietary intervention.  Among patients with more severe renal insufficiency, a very-low-protein diet, as compared with a low-protein diet, did not significantly slow the progression of renal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBn-_i3rXoj3qj_yg7twvpfW6udTcc2ea8LhqijTqlerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7lvFSisg%253D%253D&md5=aec46f8160446b4fe98810b34260db13</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1056%2FNEJM199403313301301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199403313301301%26sid%3Dliteratum%253Aachs%26aulast%3DKlahr%26aufirst%3DS.%26aulast%3DLevey%26aufirst%3DA.%2BS.%26aulast%3DBeck%26aufirst%3DG.%2BJ.%26aulast%3DCaggiula%26aufirst%3DA.%2BW.%26aulast%3DHunsicker%26aufirst%3DL.%26aulast%3DKusek%26aufirst%3DJ.%2BW.%26aulast%3DStriker%26aufirst%3DG.%26atitle%3DThe%2520effects%2520of%2520dietary-protein%2520restriction%2520and%2520blood-pressure%2520control%2520on%2520the%2520progression%2520of%2520chronic%2520renal-disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1994%26volume%3D330%26spage%3D877%26epage%3D884%26doi%3D10.1056%2FNEJM199403313301301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdmann, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckardt, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyzi, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanovich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kewalramani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parfrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parving, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R.</span><span> </span><span class="NLM_article-title">A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">2019</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1056/NEJMoa0907845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa0907845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=19880844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A280%3ADC%252BD1MjmslSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=2019-2032&author=M.+A.+Pfefferauthor=E.+A.+Burdmannauthor=C.+Y.+Chenauthor=M.+E.+Cooperauthor=D.+de+Zeeuwauthor=K.+U.+Eckardtauthor=J.+M.+Feyziauthor=P.+Ivanovichauthor=R.+Kewalramaniauthor=A.+S.+Leveyauthor=E.+F.+Lewisauthor=J.+B.+McGillauthor=J.+J.+V.+McMurrayauthor=P.+Parfreyauthor=H.+H.+Parvingauthor=G.+Remuzziauthor=A.+K.+Singhauthor=S.+D.+Solomonauthor=R.+Toto&title=A+trial+of+darbepoetin+alfa+in+type+2+diabetes+and+chronic+kidney+disease&doi=10.1056%2FNEJMoa0907845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease</span></div><div class="casAuthors">Pfeffer Marc A; Burdmann Emmanuel A; Chen Chao-Yin; Cooper Mark E; de Zeeuw Dick; Eckardt Kai-Uwe; Feyzi Jan M; Ivanovich Peter; Kewalramani Reshma; Levey Andrew S; Lewis Eldrin F; McGill Janet B; McMurray John J V; Parfrey Patrick; Parving Hans-Henrik; Remuzzi Giuseppe; Singh Ajay K; Solomon Scott D; Toto Robert</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2019-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease.  Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested.  METHODS:  In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter.  The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease.  RESULTS:  Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17; P=0.41).  Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (hazard ratio, 1.06; 95% CI, 0.95 to 1.19; P=0.29).  Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68; P<0.001).  Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo (P<0.001).  There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group.  CONCLUSIONS:  The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke.  For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNrRccr0OgNthSDZx9hyjKfW6udTcc2ea8LhqijTqlerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjmslSltw%253D%253D&md5=904a3c1f4ae9a82d4476c9d3a1753a8b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0907845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0907845%26sid%3Dliteratum%253Aachs%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DBurdmann%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DEckardt%26aufirst%3DK.%2BU.%26aulast%3DFeyzi%26aufirst%3DJ.%2BM.%26aulast%3DIvanovich%26aufirst%3DP.%26aulast%3DKewalramani%26aufirst%3DR.%26aulast%3DLevey%26aufirst%3DA.%2BS.%26aulast%3DLewis%26aufirst%3DE.%2BF.%26aulast%3DMcGill%26aufirst%3DJ.%2BB.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DParfrey%26aufirst%3DP.%26aulast%3DParving%26aufirst%3DH.%2BH.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DToto%26aufirst%3DR.%26atitle%3DA%2520trial%2520of%2520darbepoetin%2520alfa%2520in%2520type%25202%2520diabetes%2520and%2520chronic%2520kidney%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D2019%26epage%3D2032%26doi%3D10.1056%2FNEJMoa0907845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Mann, J. F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamerson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruilope, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuranoff, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viberti, G.</span><span> </span><span class="NLM_article-title">Avosentan for overt diabetic nephropathy</span> <span class="citation_source-journal">J. Am. Soc. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">535</span><span class="refDoi"> DOI: 10.1681/ASN.2009060593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1681%2FASN.2009060593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=20167702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFClu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=527-535&author=J.+F.+E.+Mannauthor=D.+Greenauthor=K.+Jamersonauthor=L.+M.+Ruilopeauthor=S.+J.+Kuranoffauthor=T.+Littkeauthor=G.+Viberti&title=Avosentan+for+overt+diabetic+nephropathy&doi=10.1681%2FASN.2009060593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Avosentan for overt diabetic nephropathy</span></div><div class="casAuthors">Mann, Johannes F. E.; Green, Damian; Jamerson, Kenneth; Ruilope, Luis M.; Kuranoff, Susan J.; Littke, Thomas; Viberti, Giancarlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-535</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">In the short term, the endothelin antagonist avosentan reduces proteinuria, but whether this translates to protection from progressive loss of renal function is unknown.  We examd. the effects of avosentan on progression of overt diabetic nephropathy in a multicenter, multinational, double-blind, placebo-controlled trial.  We randomly assigned 1392 participants with type 2 diabetes to oral avosentan (25 or 50 mg) or placebo in addn. to continued angiotensin-converting enzyme inhibition and/or angiotensin receptor blockade.  The composite primary outcome was the time to doubling of serum creatinine, ESRD, or death.  Secondary outcomes included changes in albumin-to-creatinine ratio (ACR) and cardiovascular outcomes.  We terminated the trial prematurely after a median follow-up of 4 mo (max. 16 mo) because of an excess of cardiovascular events with avosentan.  We did not detect a difference in the frequency of the primary outcome between groups.  Avosentan significantly reduced ACR: In patients who were treated with avosentan 25 mg/d, 50 mg/d, and placebo, the median redn. in ACR was 44.3, 49.3, and 9.7%, resp.  Adverse events led to discontinuation of trial medication significantly more often for avosentan than for placebo (19.6 and 18.2 vs. 11.5% for placebo), dominated by fluid overload and congestive heart failure; death occurred in 21 (4.6%; P = 0.225), 17 (3.6%; P = 0.194), and 12 (2.6%), resp.  In conclusion, avosentan reduces albuminuria when added to std. treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDkVksju9Z7Vg90H21EOLACvtfcHk0ljt4pZ2MQIAsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFClu7k%253D&md5=65f0963d275019e74b10e0d59e259808</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1681%2FASN.2009060593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2009060593%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DJ.%2BF.%2BE.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DJamerson%26aufirst%3DK.%26aulast%3DRuilope%26aufirst%3DL.%2BM.%26aulast%3DKuranoff%26aufirst%3DS.%2BJ.%26aulast%3DLittke%26aufirst%3DT.%26aulast%3DViberti%26aufirst%3DG.%26atitle%3DAvosentan%2520for%2520overt%2520diabetic%2520nephropathy%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2010%26volume%3D21%26spage%3D527%26epage%3D535%26doi%3D10.1681%2FASN.2009060593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Parving, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolaides, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span> </span><span class="NLM_article-title">Cardiorenal end points in a trial of aliskiren for type 2 diabetes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2204</span><span class="NLM_x">–</span> <span class="NLM_lpage">2213</span><span class="refDoi"> DOI: 10.1056/NEJMoa1208799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa1208799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=23121378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVakt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2204-2213&author=H.+H.+Parvingauthor=B.+M.+Brennerauthor=J.+J.+McMurrayauthor=D.+de+Zeeuwauthor=S.+M.+Haffnerauthor=S.+D.+Solomonauthor=N.+Chaturvediauthor=F.+Perssonauthor=A.+S.+Desaiauthor=M.+Nicolaidesauthor=A.+Richardauthor=Z.+Xiangauthor=P.+Brunelauthor=M.+A.+Pfeffer&title=Cardiorenal+end+points+in+a+trial+of+aliskiren+for+type+2+diabetes&doi=10.1056%2FNEJMoa1208799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiorenal end points in a trial of aliskiren for type 2 diabetes</span></div><div class="casAuthors">Parving, Hans-Henrik; Brenner, Barry M.; McMurray, John J. V.; de Zeeuw, Dick; Haffner, Steven M.; Solomon, Scott D.; Chaturvedi, Nish; Persson, Frederik; Desai, Akshay S.; Nicolaides, Maria; Richard, Alexia; Xiang, Zhihua; Brunel, Patrick; Pfeffer, Marc A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2204-2213</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">This study was undertaken to det. whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.  In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker.  The primary end point was a composite of the time to cardiovascular death or a 1st occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline blood serum creatinine level.  The trial was stopped prematurely after the 2nd interim efficacy anal.  After a median follow-up of 32.9 mo, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20).  Effects on 2ndary renal end points were similar.  Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, resp.) and the mean redn. in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17).  The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per L) was significantly higher in the aliskiren group than in the placebo group (11.2 vs. 7.2%), as was the proportion with reported hypotension (12.1 vs. 8.3%).  The addn. of aliskiren to std. therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXET5pl999drVg90H21EOLACvtfcHk0ljt4pZ2MQIAsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVakt73F&md5=16882cb81d7f60e93f44b3cad9deca0b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1208799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1208799%26sid%3Dliteratum%253Aachs%26aulast%3DParving%26aufirst%3DH.%2BH.%26aulast%3DBrenner%26aufirst%3DB.%2BM.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DHaffner%26aufirst%3DS.%2BM.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DChaturvedi%26aufirst%3DN.%26aulast%3DPersson%26aufirst%3DF.%26aulast%3DDesai%26aufirst%3DA.%2BS.%26aulast%3DNicolaides%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DBrunel%26aufirst%3DP.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26atitle%3DCardiorenal%2520end%2520points%2520in%2520a%2520trial%2520of%2520aliskiren%2520for%2520type%25202%2520diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2204%26epage%3D2213%26doi%3D10.1056%2FNEJMoa1208799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Thomas, M. C.</span><span> </span><span class="NLM_article-title">Emerging drugs for managing kidney disease in patients with diabetes</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1517/14728214.2013.762356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1517%2F14728214.2013.762356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=23330907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=55-70&author=M.+C.+Thomas&title=Emerging+drugs+for+managing+kidney+disease+in+patients+with+diabetes&doi=10.1517%2F14728214.2013.762356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for managing kidney disease in patients with diabetes</span></div><div class="casAuthors">Thomas, Merlin C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-70</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The need for new approaches to manage the increasing nos. of patients with diabetes and their burden of complications is urgent.  Of these, chronic kidney disease imposes some of the highest costs, both in dollars and in terms of human suffering.  In individuals with diabetes, the presence and severity of kidney disease adversely affects their well-being, contributes to disease morbidity and increases their risk of a premature death.Areas covered: To collect information for the strategies previously or currently under investigation for managing kidney disease in patients with diabetes, a literature search was performed through the search engines PubMed and ClinicalTrials.gov.Expert opinion: Despite advancing knowledge on the pathogenesis of diabetic kidney disease, and promising effects in exptl. models, at present there are no new drugs that come close to providing the solns. we desire for our patients.  Even when used in combination with std. care, renal complications are at best only modestly reduced, at the considerable expense of addnl. pill burden and exposure to serious off-target effects.  Some of the most exciting advances over the last decade, including thiazolidinediones, direct renin inhibitors, endothelin antagonists and most recently bardoxolone Me have all fallen at this last hurdle.  Better targeted ( smarter') drugs appear to be the best hope for renoprotective therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokZWmPIkMpALVg90H21EOLACvtfcHk0ljt4pZ2MQIAsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKktbY%253D&md5=4c2caa89f6672ce3c2bce7162ef2a1ed</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1517%2F14728214.2013.762356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2013.762356%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BC.%26atitle%3DEmerging%2520drugs%2520for%2520managing%2520kidney%2520disease%2520in%2520patients%2520with%2520diabetes%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2013%26volume%3D18%26spage%3D55%26epage%3D70%26doi%3D10.1517%2F14728214.2013.762356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Ai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel olean-28,13beta-lactams as potential antiprostate cancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4506</span><span class="NLM_x">–</span> <span class="NLM_lpage">4520</span><span class="refDoi"> DOI: 10.1021/jm5020023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5020023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4506-4520&author=Y.+Aiauthor=Y.+Huauthor=F.+Kangauthor=Y.+Laiauthor=Y.+Jiaauthor=Z.+Huangauthor=S.+Pengauthor=H.+Jiauthor=J.+Tianauthor=Y.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+olean-28%2C13beta-lactams+as+potential+antiprostate+cancer+agents&doi=10.1021%2Fjm5020023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents</span></div><div class="casAuthors">Ai, Yong; Hu, Yang; Kang, Fenghua; Lai, Yisheng; Jia, Yanju; Huang, Zhangjian; Peng, Sixun; Ji, Hui; Tian, Jide; Zhang, Yihua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4506-4520</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">γ-Lactam is an important structural motif in a large no. of biol. active natural products and synthetic small pharmaceutical mols.  However, there is currently no effective approach to construct γ-lactam ring directly from natural rigid polycyclic amides.  Herein, we report a facile methodol. for synthesis of a new group of olean-28,13β-lactams from their corresponding amides, promoted by an easily available reagent 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), through an intramol. dehydrogenative C-N coupling reaction via a radical ion mechanism.  Biol. evaluation indicated that the most active lactam I displayed potent antiproliferative activity against human cancer cells but 13.84- to 16.92-fold less inhibitory activity on noncancer cells in vitro.  In addn., I significantly inhibited the growth of implanted prostate cancer in vivo.  Furthermore, I induced cell cycle arrest and apoptosis and down-regulated the AKT/mTOR signaling in DU-145 cells.  Finally, I was more stable in rat plasma and human liver microsomes than CDDO-Me and had little hERG channel inhibitory activity.  Collectively, I may be a potential antiprostate cancer agent for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFMGyzOutkVrVg90H21EOLACvtfcHk0li-WjTcZl8YcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVSntrc%253D&md5=2ba7a93f8fdec6be8156d01922f85338</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm5020023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5020023%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520olean-28%252C13beta-lactams%2520as%2520potential%2520antiprostate%2520cancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4506%26epage%3D4520%26doi%3D10.1021%2Fjm5020023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span> </span><span class="NLM_article-title">The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/j.intimp.2015.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.intimp.2015.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=25614226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ohsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=55-64&author=T.+Chenauthor=Y.+Mouauthor=J.+Tanauthor=L.+Weiauthor=Y.+Qiaoauthor=T.+Weiauthor=P.+Xiangauthor=S.+Pengauthor=Y.+Zhangauthor=Z.+Huangauthor=H.+Ji&title=The+protective+effect+of+CDDO-Me+on+lipopolysaccharide-induced+acute+lung+injury+in+mice&doi=10.1016%2Fj.intimp.2015.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice</span></div><div class="casAuthors">Chen, Tong; Mou, Yi; Tan, Jiani; Wei, Linlin; Qiao, Yixue; Wei, Tingting; Xiang, Pengjun; Peng, Sixun; Zhang, Yihua; Huang, Zhangjian; Ji, Hui</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-64</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CDDO-Me, initiated in a phase II clin. trial, is a potential useful therapeutic agent for cancer and inflammatory dysfunctions, whereas the therapeutic efficacy of CDDO-Me on LPS-induced acute lung injury (ALI) has not been reported as yet.  The purpose of the present study was to explore the protective effect of CDDO-Me on LPS-induced ALI in mice and to investigate its possible mechanism.  BalB/c mice received CDDO-Me (0.5 mg/kg, 2 mg/kg) or dexamethasone (5 mg/kg) i.p. 1 h before LPS stimulation and were sacrificed 6 h later.  W/D ratio, lung MPO activity, no. of total cells and neutrophils, pulmonary histopathol., IL-6, IL-1β, and TNF-α in the BALF were assessed.  Furthermore, we estd. iNOS, IL-6, IL-1β, and TNF-α mRNA expression and NO prodn. as well as the activation of the three main MAPKs, AkT, IκB-α and p65.  Pretreatment with CDDO-Me significantly ameliorated W/D ratio, lung MPO activity, inflammatory cell infiltration, and inflammatory cytokine prodn. in BALF from the in vivo study.  Addnl., CDDO-Me had beneficial effects on the intervention for pathogenesis process at mol., protein and transcriptional levels in vitro.  These anal. results provided evidence that CDDO-Me could be a potential therapeutic candidate for treating LPS-induced ALI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjLNCxbpkw7LVg90H21EOLACvtfcHk0li-WjTcZl8YcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ohsbo%253D&md5=06625d74528d5c4fe5d3733edcd8c5d9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2015.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2015.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DMou%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DP.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DThe%2520protective%2520effect%2520of%2520CDDO-Me%2520on%2520lipopolysaccharide-induced%2520acute%2520lung%2520injury%2520in%2520mice%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2015%26volume%3D25%26spage%3D55%26epage%3D64%26doi%3D10.1016%2Fj.intimp.2015.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Petronelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannitteri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, U.</span><span> </span><span class="NLM_article-title">Triterpenoids as new promising anticancer drugs</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e328330fd90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1097%2FCAD.0b013e328330fd90" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=880-892&author=A.+Petronelliauthor=G.+Pannitteriauthor=U.+Testa&title=Triterpenoids+as+new+promising+anticancer+drugs&doi=10.1097%2FCAD.0b013e328330fd90"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e328330fd90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e328330fd90%26sid%3Dliteratum%253Aachs%26aulast%3DPetronelli%26aufirst%3DA.%26aulast%3DPannitteri%26aufirst%3DG.%26aulast%3DTesta%26aufirst%3DU.%26atitle%3DTriterpenoids%2520as%2520new%2520promising%2520anticancer%2520drugs%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2009%26volume%3D20%26spage%3D880%26epage%3D892%26doi%3D10.1097%2FCAD.0b013e328330fd90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Liby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royce, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risingsong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yore, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dmitrovsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span> </span><span class="NLM_article-title">The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2414</span><span class="NLM_x">–</span> <span class="NLM_lpage">2419</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F0008-5472.CAN-06-4534" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2414-2419&author=K.+Libyauthor=D.+B.+Royceauthor=C.+R.+Williamsauthor=R.+Risingsongauthor=M.+M.+Yoreauthor=T.+Hondaauthor=G.+W.+Gribbleauthor=E.+Dmitrovskyauthor=T.+A.+Spornauthor=M.+B.+Sporn&title=The+synthetic+triterpenoids+CDDO-methyl+ester+and+CDDO-ethyl+amide+prevent+lung+cancer+induced+by+vinyl+carbamate+in+A%2FJ+mice&doi=10.1158%2F0008-5472.CAN-06-4534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4534%26sid%3Dliteratum%253Aachs%26aulast%3DLiby%26aufirst%3DK.%26aulast%3DRoyce%26aufirst%3DD.%2BB.%26aulast%3DWilliams%26aufirst%3DC.%2BR.%26aulast%3DRisingsong%26aufirst%3DR.%26aulast%3DYore%26aufirst%3DM.%2BM.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DGribble%26aufirst%3DG.%2BW.%26aulast%3DDmitrovsky%26aufirst%3DE.%26aulast%3DSporn%26aufirst%3DT.%2BA.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26atitle%3DThe%2520synthetic%2520triterpenoids%2520CDDO-methyl%2520ester%2520and%2520CDDO-ethyl%2520amide%2520prevent%2520lung%2520cancer%2520induced%2520by%2520vinyl%2520carbamate%2520in%2520A%252FJ%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D2414%26epage%3D2419%26doi%3D10.1158%2F0008-5472.CAN-06-4534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span> </span><span class="NLM_article-title">Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">19278</span><span class="NLM_x">–</span> <span class="NLM_lpage">19281</span><span class="refDoi"> DOI: 10.1021/ja2073824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja2073824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=19278-19281&author=Y.+Kuangauthor=K.+Balakrishnanauthor=V.+Gandhiauthor=X.+Peng&title=Hydrogen+peroxide+inducible+DNA+cross-linking+agents%3A+targeted+anticancer+prodrugs&doi=10.1021%2Fja2073824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs</span></div><div class="casAuthors">Kuang, Yunyan; Balakrishnan, Kumudha; Gandhi, Varsha; Peng, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">19278-19281</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The major concern for anticancer chemotherapeutic agents is the host toxicity.  The development of anticancer prodrugs targeting the unique biochem. alterations in cancer cells is an attractive approach to achieve therapeutic activity and selectivity.  We designed and synthesized a new type of nitrogen mustard prodrug that can be activated by high level of reactive oxygen species (ROS) found in cancer cells to release the active chemotherapy agent.  The activation mechanism was detd. by NMR anal.  The activity and selectivity of these prodrugs toward ROS was detd. by measuring DNA interstrand cross-links and/or DNA alkylations.  These compds. showed 60-90% inhibition toward various cancer cells, while normal lymphocytes were not affected.  To the best of our knowledge, this is the first example of H2O2-activated anticancer prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY5EVvl5gaabVg90H21EOLACvtfcHk0lh5QVO0ifyY0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqsLvE&md5=d907a75fa0e9c33185187cdfb85fda29</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja2073824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja2073824%26sid%3Dliteratum%253Aachs%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DBalakrishnan%26aufirst%3DK.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPeng%26aufirst%3DX.%26atitle%3DHydrogen%2520peroxide%2520inducible%2520DNA%2520cross-linking%2520agents%253A%2520targeted%2520anticancer%2520prodrugs%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D19278%26epage%3D19281%26doi%3D10.1021%2Fja2073824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Noh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span> </span><span class="NLM_article-title">Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">6907</span><span class="refDoi"> DOI: 10.1038/ncomms7907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fncomms7907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=25892552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6907&author=J.+Nohauthor=B.+Kwonauthor=E.+Hanauthor=M.+Parkauthor=W.+Yangauthor=W.+Choauthor=W.+Yooauthor=G.+Khangauthor=D.+Lee&title=Amplification+of+oxidative+stress+by+a+dual+stimuli-responsive+hybrid+drug+enhances+cancer+cell+death&doi=10.1038%2Fncomms7907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death</span></div><div class="casAuthors">Noh, Joungyoun; Kwon, Byeongsu; Han, Eunji; Park, Minhyung; Yang, Wonseok; Cho, Wooram; Yoo, Wooyoung; Khang, Gilson; Lee, Dongwon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6907</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells, compared with normal cells, are under oxidative stress assocd. with the increased generation of reactive oxygen species (ROS) including H2O2 and are also susceptible to further ROS insults.  Cancer cells adapt to oxidative stress by upregulating antioxidant systems such as glutathione to counteract the damaging effects of ROS.  Therefore, the elevation of oxidative stress preferentially in cancer cells by depleting glutathione or generating ROS is a logical therapeutic strategy for the development of anticancer drugs.  Here we report a dual stimuli-responsive hybrid anticancer drug QCA, which can be activated by H2O2 and acidic pH to release glutathione-scavenging quinone methide and ROS-generating cinnamaldehyde, resp., in cancer cells.  Quinone methide and cinnamaldehyde act in a synergistic manner to amplify oxidative stress, leading to preferential killing of cancer cells in vitro and in vivo.  We therefore anticipate that QCA has promising potential as an anticancer therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmpSt8k04fybVg90H21EOLACvtfcHk0lh5QVO0ifyY0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlaisrY%253D&md5=0f796d502d10b7e63a54cdab05287893</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fncomms7907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7907%26sid%3Dliteratum%253Aachs%26aulast%3DNoh%26aufirst%3DJ.%26aulast%3DKwon%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DCho%26aufirst%3DW.%26aulast%3DYoo%26aufirst%3DW.%26aulast%3DKhang%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DAmplification%2520of%2520oxidative%2520stress%2520by%2520a%2520dual%2520stimuli-responsive%2520hybrid%2520drug%2520enhances%2520cancer%2520cell%2520death%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6907%26doi%3D10.1038%2Fncomms7907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Lampiasi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzolina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervello, M.</span><span> </span><span class="NLM_article-title">The novel NF-kappaB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1016/j.canlet.2012.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.canlet.2012.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22343223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Kjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2012&pages=35-44&author=N.+Lampiasiauthor=A.+Azzolinaauthor=K.+Umezawaauthor=G.+Montaltoauthor=J.+A.+McCubreyauthor=M.+Cervello&title=The+novel+NF-kappaB+inhibitor+DHMEQ+synergizes+with+celecoxib+to+exert+antitumor+effects+on+human+liver+cancer+cells+by+a+ROS-dependent+mechanism&doi=10.1016%2Fj.canlet.2012.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism</span></div><div class="casAuthors">Lampiasi, Nadia; Azzolina, Antonina; Umezawa, Kazuo; Montalto, Giuseppe; McCubrey, James A.; Cervello, Melchiorre</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In a previous work of ours dehydroxymethyl-epoxyquinomicin (DHMEQ), an inhibitor of NF-κB, was shown to induce apoptosis through Reactive Oxygen Species (ROS) prodn. in hepatoma cells.  The present study demonstrated that DHMEQ cooperates with Celecoxib (CLX) to decrease NF-κB DNA binding and to inhibit cell growth and proliferation more effectively than treatment with these single agents alone in the hepatoma cell lines HA22T/VGH and Huh-6.  ROS prodn. induced by the DHMEQ-CLX combination in turn generated the expression of genes involved in endoplasmic reticulum (ER) stress and silencing TRB3 mRNA significantly decreased DHMEQ-CLX-induced cell growth inhibition.  Moreover, the DHMEQ-CLX combination was assocd. with induction of PARP cleavage and down-regulation of the anti-apoptotic proteins Bcl-2, Mcl-1 and survivin, as well as activated Akt.  CD95 and CD95 ligand expression increased synergistically in the combination treatment, which was reversed in the presence of NAC.  Knockdown of CD95 mRNA expression significantly decreased DHMEQ-CLX-induced cell growth inhibition in both cell lines.  These data suggest that the DHMEQ-CLX combination kills hepatoma cells via ROS prodn., ER stress response and the activation of intrinsic and extrinsic apoptotic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2Ybg0SJpHLVg90H21EOLACvtfcHk0lh5QVO0ifyY0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Kjtbk%253D&md5=6868d6ae8280e6294997393dbe8e3ed2</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DLampiasi%26aufirst%3DN.%26aulast%3DAzzolina%26aufirst%3DA.%26aulast%3DUmezawa%26aufirst%3DK.%26aulast%3DMontalto%26aufirst%3DG.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DCervello%26aufirst%3DM.%26atitle%3DThe%2520novel%2520NF-kappaB%2520inhibitor%2520DHMEQ%2520synergizes%2520with%2520celecoxib%2520to%2520exert%2520antitumor%2520effects%2520on%2520human%2520liver%2520cancer%2520cells%2520by%2520a%2520ROS-dependent%2520mechanism%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D322%26spage%3D35%26epage%3D44%26doi%3D10.1016%2Fj.canlet.2012.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Keillor, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castonguay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lherbet, C.</span><span> </span><span class="NLM_article-title">Gamma-glutamyl transpeptidase substrate specificity and catalytic mechanism</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1016/S0076-6879(05)01027-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2FS0076-6879%2805%2901027-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=2005&pages=449-467&author=J.+W.+Keillorauthor=R.+Castonguayauthor=C.+Lherbet&title=Gamma-glutamyl+transpeptidase+substrate+specificity+and+catalytic+mechanism&doi=10.1016%2FS0076-6879%2805%2901027-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2805%2901027-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252805%252901027-X%26sid%3Dliteratum%253Aachs%26aulast%3DKeillor%26aufirst%3DJ.%2BW.%26aulast%3DCastonguay%26aufirst%3DR.%26aulast%3DLherbet%26aufirst%3DC.%26atitle%3DGamma-glutamyl%2520transpeptidase%2520substrate%2520specificity%2520and%2520catalytic%2520mechanism%26jtitle%3DMethods%2520Enzymol.%26date%3D2005%26volume%3D401%26spage%3D449%26epage%3D467%26doi%3D10.1016%2FS0076-6879%2805%2901027-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 19 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jian Li, Tingting Wang, Feng Jiang, Zhangyong Hong, Xinhui Su, Shuang Li, <span class="NLM_string-name hlFld-ContribAuthor">Shoufa Han</span>. </span><span class="cited-content_cbyCitation_article-title">Activatable Dual ROS-Producing Probe for Dual Organelle-Engaged Photodynamic Therapy. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Bio Materials</span><span> <strong>2021,</strong> <em>4 </em>
                                    (5)
                                     , 4618-4628. <a href="https://doi.org/10.1021/acsabm.1c00354" title="DOI URL">https://doi.org/10.1021/acsabm.1c00354</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsabm.1c00354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsabm.1c00354%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Bio%2520Materials%26atitle%3DActivatable%252BDual%252BROS-Producing%252BProbe%252Bfor%252BDual%252BOrganelle-Engaged%252BPhotodynamic%252BTherapy%26aulast%3DLi%26aufirst%3DJian%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D23032021%26date%3D14042021%26date%3D27042021%26volume%3D4%26issue%3D5%26spage%3D4618%26epage%3D4628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qichao Bao, Liangying Zhang, Nan Wang, Brian Gabet, Weikang Yang, Xingyang Gao, Qidong You, <span class="NLM_string-name hlFld-ContribAuthor">Zhengyu Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2182-2189. <a href="https://doi.org/10.1021/acsmedchemlett.0c00323" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00323%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHydrogen%252BPeroxide%252BInducible%252BJAK3%252BCovalent%252BInhibitor%25253A%252BProdrug%252Bfor%252Bthe%252BTreatment%252Bof%252BRA%252Bwith%252BEnhanced%252BSafety%252BProfile%26aulast%3DBao%26aufirst%3DQichao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11062020%26date%3D01102020%26date%3D05102020%26volume%3D11%26issue%3D11%26spage%3D2182%26epage%3D2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Tingting  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhangyong  Hong</span>, <span class="hlFld-ContribAuthor ">Xinhui  Su</span>, <span class="hlFld-ContribAuthor ">Shuang  Li</span>, <span class="hlFld-ContribAuthor ">Shoufa  Han</span>. </span><span class="cited-content_cbyCitation_article-title">A fluorescence-activatable tumor-reporting probe for precise photodynamic therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2021,</strong> <em>9 </em>
                                    (29)
                                     , 5829-5836. <a href="https://doi.org/10.1039/D1TB00704A" title="DOI URL">https://doi.org/10.1039/D1TB00704A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1TB00704A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1TB00704A%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DA%252Bfluorescence-activatable%252Btumor-reporting%252Bprobe%252Bfor%252Bprecise%252Bphotodynamic%252Btherapy%26aulast%3DLi%26aufirst%3DJian%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D29%26spage%3D5829%26epage%3D5836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruifeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Jun  Ge</span>, <span class="hlFld-ContribAuthor ">Juanru  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">The protective effects of calycosin against diabetic nephropathy through Sirt3/SOD2/caspase-3 signaling pathway: In vitro. </span><span class="cited-content_cbyCitation_journal-name">Arabian Journal of Chemistry</span><span> <strong>2021,</strong> <em>14 </em>
                                    (3)
                                     , 102988. <a href="https://doi.org/10.1016/j.arabjc.2021.102988" title="DOI URL">https://doi.org/10.1016/j.arabjc.2021.102988</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.arabjc.2021.102988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.arabjc.2021.102988%26sid%3Dliteratum%253Aachs%26jtitle%3DArabian%2520Journal%2520of%2520Chemistry%26atitle%3DThe%252Bprotective%252Beffects%252Bof%252Bcalycosin%252Bagainst%252Bdiabetic%252Bnephropathy%252Bthrough%252BSirt3%25252FSOD2%25252Fcaspase-3%252Bsignaling%252Bpathway%25253A%252BIn%252Bvitro%26aulast%3DJiang%26aufirst%3DRuifeng%26date%3D2021%26volume%3D14%26issue%3D3%26spage%3D102988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kefei  Yuan</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative Stress and Antioxidant Strategies in Human Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-26. <a href="https://doi.org/10.1007/978-981-16-0522-2_1" title="DOI URL">https://doi.org/10.1007/978-981-16-0522-2_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0522-2_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0522-2_1%26sid%3Dliteratum%253Aachs%26atitle%3DOxidative%252BStress%252Band%252BAntioxidant%252BStrategies%252Bin%252BHuman%252BDiseases%26aulast%3DYuan%26aufirst%3DKefei%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D26%26pub%3DSpringer%2520Singapore%26atitle%3DOxidative%252BStress%26aulast%3DHuang%26aufirst%3DCanhua%26date%3D2021%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ewa  Szczesny-Malysiak</span>, <span class="hlFld-ContribAuthor ">Marta  Stojak</span>, <span class="hlFld-ContribAuthor ">Roberto  Campagna</span>, <span class="hlFld-ContribAuthor ">Marek  Grosicki</span>, <span class="hlFld-ContribAuthor ">Marek  Jamrozik</span>, <span class="hlFld-ContribAuthor ">Patrycja  Kaczara</span>, <span class="hlFld-ContribAuthor ">Stefan  Chlopicki</span>, . </span><span class="cited-content_cbyCitation_article-title">Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium. </span><span class="cited-content_cbyCitation_journal-name">Oxidative Medicine and Cellular Longevity</span><span> <strong>2020,</strong> <em>2020 </em>, 1-16. <a href="https://doi.org/10.1155/2020/4678252" title="DOI URL">https://doi.org/10.1155/2020/4678252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2020/4678252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2020%2F4678252%26sid%3Dliteratum%253Aachs%26jtitle%3DOxidative%2520Medicine%2520and%2520Cellular%2520Longevity%26atitle%3DBardoxolone%252BMethyl%252BDisplays%252BDetrimental%252BEffects%252Bon%252BEndothelial%252BBioenergetics%25252C%252BSuppresses%252BEndothelial%252BET-1%252BRelease%25252C%252Band%252BIncreases%252BEndothelial%252BPermeability%252Bin%252BHuman%252BMicrovascular%252BEndothelium%26aulast%3DSzczesny-Malysiak%26aufirst%3DEwa%26date%3D2020%26volume%3D2020%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shi-Sheng  Wang</span>, <span class="hlFld-ContribAuthor ">Qiao-Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Peng  Chu</span>, <span class="hlFld-ContribAuthor ">Ling-Qi  Kong</span>, <span class="hlFld-ContribAuthor ">Guang-Zhe  Li</span>, <span class="hlFld-ContribAuthor ">Yue-Qing  Li</span>, <span class="hlFld-ContribAuthor ">Li  Yang</span>, <span class="hlFld-ContribAuthor ">Wei-Jie  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiu-Han  Guo</span>, <span class="hlFld-ContribAuthor ">Ze-Yao  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antitumor activity of α,β-unsaturated carbonyl moiety- containing oleanolic acid derivatives targeting PI3K/AKT/mTOR signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 104036. <a href="https://doi.org/10.1016/j.bioorg.2020.104036" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104036%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B2-unsaturated%252Bcarbonyl%252Bmoiety-%252Bcontaining%252Boleanolic%252Bacid%252Bderivatives%252Btargeting%252BPI3K%25252FAKT%25252FmTOR%252Bsignaling%252Bpathway%26aulast%3DWang%26aufirst%3DShi-Sheng%26date%3D2020%26volume%3D101%26spage%3D104036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donna D.  Zhang</span>, <span class="hlFld-ContribAuthor ">Eli  Chapman</span>. </span><span class="cited-content_cbyCitation_article-title">The role of natural products in revealing NRF2 function. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Reports</span><span> <strong>2020,</strong> <em>37 </em>
                                    (6)
                                     , 797-826. <a href="https://doi.org/10.1039/C9NP00061E" title="DOI URL">https://doi.org/10.1039/C9NP00061E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NP00061E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NP00061E%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Reports%26atitle%3DThe%252Brole%252Bof%252Bnatural%252Bproducts%252Bin%252Brevealing%252BNRF2%252Bfunction%26aulast%3DZhang%26aufirst%3DDonna%2BD.%26date%3D2020%26date%3D2020%26volume%3D37%26issue%3D6%26spage%3D797%26epage%3D826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra  Rayego-Mateos</span>, <span class="hlFld-ContribAuthor ">José Luis  Morgado-Pascual</span>, <span class="hlFld-ContribAuthor ">Lucas  Opazo-Ríos</span>, <span class="hlFld-ContribAuthor ">Melania  Guerrero-Hue</span>, <span class="hlFld-ContribAuthor ">Cristina  García-Caballero</span>, <span class="hlFld-ContribAuthor ">Cristina  Vázquez-Carballo</span>, <span class="hlFld-ContribAuthor ">Sebastián  Mas</span>, <span class="hlFld-ContribAuthor ">Ana Belén  Sanz</span>, <span class="hlFld-ContribAuthor ">Carmen  Herencia</span>, <span class="hlFld-ContribAuthor ">Sergio  Mezzano</span>, <span class="hlFld-ContribAuthor ">Carmen  Gómez-Guerrero</span>, <span class="hlFld-ContribAuthor ">Juan Antonio  Moreno</span>, <span class="hlFld-ContribAuthor ">Jesús  Egido</span>. </span><span class="cited-content_cbyCitation_article-title">Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (11)
                                     , 3798. <a href="https://doi.org/10.3390/ijms21113798" title="DOI URL">https://doi.org/10.3390/ijms21113798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21113798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21113798%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPathogenic%252BPathways%252Band%252BTherapeutic%252BApproaches%252BTargeting%252BInflammation%252Bin%252BDiabetic%252BNephropathy%26aulast%3DRayego-Mateos%26aufirst%3DSandra%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D11%26spage%3D3798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhou  Li</span>, <span class="hlFld-ContribAuthor ">Qing  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Jin</span>, <span class="hlFld-ContribAuthor ">Yanhua  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Silencing of LncRNA PVT1 inhibits the proliferation, migration and fibrosis of high glucose-induced mouse mesangial cells via targeting microRNA-93-5p. </span><span class="cited-content_cbyCitation_journal-name">Bioscience Reports</span><span> <strong>2020,</strong> <em>40 </em>
                                    (5)
                                     <a href="https://doi.org/10.1042/BSR20194427" title="DOI URL">https://doi.org/10.1042/BSR20194427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BSR20194427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBSR20194427%26sid%3Dliteratum%253Aachs%26jtitle%3DBioscience%2520Reports%26atitle%3DSilencing%252Bof%252BLncRNA%252BPVT1%252Binhibits%252Bthe%252Bproliferation%25252C%252Bmigration%252Band%252Bfibrosis%252Bof%252Bhigh%252Bglucose-induced%252Bmouse%252Bmesangial%252Bcells%252Bvia%252Btargeting%252BmicroRNA-93-5p%26aulast%3DLi%26aufirst%3DJianzhou%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vicente  Galiano</span>, <span class="hlFld-ContribAuthor ">José A.  Encinar</span>, <span class="hlFld-ContribAuthor ">José  Villalaín</span>. </span><span class="cited-content_cbyCitation_article-title">Location, Orientation and Aggregation of Bardoxolone-ME, CDDO-ME, in a Complex Phospholipid Bilayer Membrane. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Membrane Biology</span><span> <strong>2020,</strong> <em>253 </em>
                                    (2)
                                     , 115-128. <a href="https://doi.org/10.1007/s00232-020-00106-5" title="DOI URL">https://doi.org/10.1007/s00232-020-00106-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00232-020-00106-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00232-020-00106-5%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Membrane%2520Biology%26atitle%3DLocation%25252C%252BOrientation%252Band%252BAggregation%252Bof%252BBardoxolone-ME%25252C%252BCDDO-ME%25252C%252Bin%252Ba%252BComplex%252BPhospholipid%252BBilayer%252BMembrane%26aulast%3DGaliano%26aufirst%3DVicente%26date%3D2020%26date%3D2020%26volume%3D253%26issue%3D2%26spage%3D115%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haishan  Zhou</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (3)
                                     , 209-225. <a href="https://doi.org/10.1080/13543776.2020.1715365" title="DOI URL">https://doi.org/10.1080/13543776.2020.1715365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1715365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1715365%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DRecent%252Bprogress%252Bin%252Bthe%252Bdevelopment%252Bof%252Bsmall%252Bmolecule%252BNrf2%252Bactivators%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhou%26aufirst%3DHaishan%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D3%26spage%3D209%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoke  Gu</span>, <span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Yinpeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingyu  Guan</span>, <span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Qingqing  Zhou</span>, <span class="hlFld-ContribAuthor ">Qinghua  Song</span>, <span class="hlFld-ContribAuthor ">Jingying  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and assessment of phenylacrylamide derivatives as potential anti-oxidant and anti-inflammatory agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>180 </em>, 62-71. <a href="https://doi.org/10.1016/j.ejmech.2019.07.020" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.020%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bassessment%252Bof%252Bphenylacrylamide%252Bderivatives%252Bas%252Bpotential%252Banti-oxidant%252Band%252Banti-inflammatory%252Bagents%26aulast%3DGu%26aufirst%3DXiaoke%26date%3D2019%26volume%3D180%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun-Mei  Liu</span>, <span class="hlFld-ContribAuthor ">Jia-Yan  Huang</span>, <span class="hlFld-ContribAuthor ">Li-Xin  Sheng</span>, <span class="hlFld-ContribAuthor ">Xiao-An  Wen</span>, <span class="hlFld-ContribAuthor ">Ke-Guang  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antitumor activity of fluorouracil – oleanolic acid/ursolic acid/glycyrrhetinic acid conjugates. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1370-1378. <a href="https://doi.org/10.1039/C9MD00246D" title="DOI URL">https://doi.org/10.1039/C9MD00246D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00246D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00246D%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DSynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Bfluorouracil%252B%2525E2%252580%252593%252Boleanolic%252Bacid%25252Fursolic%252Bacid%25252Fglycyrrhetinic%252Bacid%252Bconjugates%26aulast%3DLiu%26aufirst%3DChun-Mei%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1370%26epage%3D1378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nanfei  Yang</span>, <span class="hlFld-ContribAuthor ">Qing  Tang</span>, <span class="hlFld-ContribAuthor ">Wentao  Qin</span>, <span class="hlFld-ContribAuthor ">Zeyang  Li</span>, <span class="hlFld-ContribAuthor ">Dandan  Wang</span>, <span class="hlFld-ContribAuthor ">Weijie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Cao</span>, <span class="hlFld-ContribAuthor ">Yan  Lu</span>, <span class="hlFld-ContribAuthor ">Xiangyu  Ge</span>, <span class="hlFld-ContribAuthor ">Hongbin  Sun</span>, <span class="hlFld-ContribAuthor ">Pingping  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of obesity-related inflammation with a novel synthetic pentacyclic oleanane triterpenoids via modulation of macrophage polarization. </span><span class="cited-content_cbyCitation_journal-name">EBioMedicine</span><span> <strong>2019,</strong> <em>45 </em>, 473-486. <a href="https://doi.org/10.1016/j.ebiom.2019.06.053" title="DOI URL">https://doi.org/10.1016/j.ebiom.2019.06.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ebiom.2019.06.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ebiom.2019.06.053%26sid%3Dliteratum%253Aachs%26jtitle%3DEBioMedicine%26atitle%3DTreatment%252Bof%252Bobesity-related%252Binflammation%252Bwith%252Ba%252Bnovel%252Bsynthetic%252Bpentacyclic%252Boleanane%252Btriterpenoids%252Bvia%252Bmodulation%252Bof%252Bmacrophage%252Bpolarization%26aulast%3DYang%26aufirst%3DNanfei%26date%3D2019%26volume%3D45%26spage%3D473%26epage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. Allan  Butterfield</span>, <span class="hlFld-ContribAuthor ">Barry  Halliwell</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Neuroscience</span><span> <strong>2019,</strong> <em>20 </em>
                                    (3)
                                     , 148-160. <a href="https://doi.org/10.1038/s41583-019-0132-6" title="DOI URL">https://doi.org/10.1038/s41583-019-0132-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41583-019-0132-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41583-019-0132-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Neuroscience%26atitle%3DOxidative%252Bstress%25252C%252Bdysfunctional%252Bglucose%252Bmetabolism%252Band%252BAlzheimer%252Bdisease%26aulast%3DButterfield%26aufirst%3DD.%2BAllan%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D3%26spage%3D148%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoke  Gu</span>, <span class="hlFld-ContribAuthor ">Yanfei  Jiang</span>, <span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Yinpeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingyu  Guan</span>, <span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Qingqing  Zhou</span>, <span class="hlFld-ContribAuthor ">Qian  Lu</span>, <span class="hlFld-ContribAuthor ">Jingying  Qiu</span>, <span class="hlFld-ContribAuthor ">Xiaoxing  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of bifendate derivatives bearing acrylamide moiety as novel antioxidant agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>162 </em>, 59-69. <a href="https://doi.org/10.1016/j.ejmech.2018.11.003" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.003%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bbifendate%252Bderivatives%252Bbearing%252Bacrylamide%252Bmoiety%252Bas%252Bnovel%252Bantioxidant%252Bagents%26aulast%3DGu%26aufirst%3DXiaoke%26date%3D2019%26volume%3D162%26spage%3D59%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barry  Halliwell</span>, <span class="hlFld-ContribAuthor ">Irwin K.  Cheah</span>, <span class="hlFld-ContribAuthor ">Richard M. Y.  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Ergothioneine – a diet‐derived antioxidant with therapeutic potential. </span><span class="cited-content_cbyCitation_journal-name">FEBS Letters</span><span> <strong>2018,</strong> <em>592 </em>
                                    (20)
                                     , 3357-3366. <a href="https://doi.org/10.1002/1873-3468.13123" title="DOI URL">https://doi.org/10.1002/1873-3468.13123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/1873-3468.13123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F1873-3468.13123%26sid%3Dliteratum%253Aachs%26jtitle%3DFEBS%2520Letters%26atitle%3DErgothioneine%252B%2525E2%252580%252593%252Ba%252Bdiet%2525E2%252580%252590derived%252Bantioxidant%252Bwith%252Btherapeutic%252Bpotential%26aulast%3DHalliwell%26aufirst%3DBarry%26date%3D2018%26date%3D2018%26volume%3D592%26issue%3D20%26spage%3D3357%26epage%3D3366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.C.  Gutteridge</span>, <span class="hlFld-ContribAuthor ">Barry  Halliwell</span>. </span><span class="cited-content_cbyCitation_article-title">Mini-Review: Oxidative stress, redox stress or redox success ?. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2018,</strong> <em>502 </em>
                                    (2)
                                     , 183-186. <a href="https://doi.org/10.1016/j.bbrc.2018.05.045" title="DOI URL">https://doi.org/10.1016/j.bbrc.2018.05.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2018.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2018.05.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DMini-Review%25253A%252BOxidative%252Bstress%25252C%252Bredox%252Bstress%252Bor%252Bredox%252Bsuccess%252B%25253F%26aulast%3DGutteridge%26aufirst%3DJohn%2BM.C.%26date%3D2018%26volume%3D502%26issue%3D2%26spage%3D183%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Rationale for the design of a GGT-based and CUK-modified derivative of CDDO-Me (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reaction conditions and reagents: (a) EEDQ, CH<sub>2</sub>Cl<sub>2</sub>, rt for 12 h; (b) PBr<sub>3</sub>, anhydrous THF, 0 °C for 0.5 h; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C for 12 h; (d) NHEt<sub>2</sub>, anhydrous CH<sub>2</sub>Cl<sub>2</sub>; (e) plasma or liver homogenate.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Stability of <b>2</b> in various media. <b>2</b> was incubated in (A) PBS (pH = 7.4), (B) PBS (pH = 7.4) with (1 U/mL) GGT, (C) PBS (pH = 7.4) with (1 U/mL) GGT and (2 U/mL) esterase from porcine liver, (D) rat kidney homogenate, (E) rat plasma, and (F) rat liver homogenate. The conversion of <b>2</b> to <b>8</b> or further to CDDO-Me was measured by HPLC. Results in panels B–F are expressed as the mean ± SD from three individual experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>2</b> activates Nrf2 signaling. (A) HEK293 cells were transfected with an ARE-dependent luciferase reporter plasmid and subsequently treated in triplicate with CDDO-Me or <b>2</b> at the indicated concentrations for 48 h. Luciferase activity was measured to assess Nrf2 activity. HEK293 cells were treated in triplicate with <b>2</b> (200, 1000 nM) or CDDO-Me (200, 1000 nM) for 48 h, and the relative levels of <i>Nrf2</i> (B), <i>HO-1</i> (C), and <i>NQO1</i> (D) mRNA transcripts were analyzed by quantitative RT-PCR. Furthermore, the relative levels of nuclear and cytosolic Nrf2 (E), the ratio of nuclear to cytosolic Nrf2 (G), HO-1 (F, H), and cytoplasmic NQO1 (F, I) expression were analyzed by western blot assay. Results are representative images and expressed as the mean ± SD of each group from three individual experiments. *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>2</b> on NF-κB signaling. (A) HEK293 cells were transfected with an NF-κB driven luciferase reporter plasmid, and the effects of <b>2</b> on TNF-α induced NF-κB activity were determined. Furthermore, HEK293 cells were pretreated with TNF-α (10 ng/mL) for 6 h and then incubated in triplicate with <b>2</b> (200, 1000 nM) or CDDO-Me (200, 1000 nM) for 24 h. The relative levels of <i>iNOS</i> (B), <i>COX2</i> (C), <i>MCP-1</i> (D), and <i>TNF-α</i> (E) mRNAs to the control <i>GAPDH</i> mRNA in HEK293 cells were detected by quantitative RT-PCR, whereas the relative levels of nuclear and cytosolic p65 (F, G) and the expression of NF-κB target genes iNOS (H, I) and COX2 (H, J) in HEK293 cells were measured by western blot assay. Results are representative images or expressed as the mean ± SD of each group of cells from three individual experiments. *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Treatment with <b>2</b> significantly mitigates DN-related kidney damage in mice. The mice were treated with CDDO-Me (0.65 mg/kg, the same molar ratio as 1 mg/kg <b>2</b>) or <b>2</b> (1 or 2 mg/kg) for 12 weeks. At the 11th week, the 24 h urine volumes (A) and levels of urinary albumin (B) and creatinine (C) in individual mice were measured before the mice were sacrificed, and the urine albumin to creatinine ratio (D) in individual mice was calculated. Furthermore, the kidney sections (5 μm) were stained with hematoxylin–eosin, Masson’s trichrome, and periodic acid Schiff (E, magnification ×400). The ultrathin kidney sections were subjected to TEM analysis (F–J). The thickness of the GBM in individual mice was measured, and a total of 30 locations for each mouse were calculated (K). Data are representative images and expressed as the mean ± SD of individual groups of mice (<i>n</i> = 6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Plasma concentration–time profiles of <b>2</b> and CDDO-Me. After intravenous administration of <b>2</b> (10 mg/kg) or CDDO-Me (10 mg/kg) to rats, blood samples were taken from the suborbital vein at 0, 2, 5, 15, 30, and 60 min and 1.5, 2, 4, 6, 8, 12, and 24 h and analyzed by LC-MS/MS. (B–D) Tissue distribution study of <b>2</b> and CDDO-Me. Individual rats were injected intraperitoneally with CDDO-Me (0.04 mmol, 20 mg/kg) or <b>2</b> (0.04 mmol, 30 mg/kg), and their tissue (including heart, kidney, and liver) samples were collected longitudinally and analyzed by LC-MS/MS. (B) Tissue distribution of CDDO-Me, (C) tissue distribution of <b>2</b>, and (D) generation of CDDO-Me from <b>2</b> measured by LC-MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/medium/jm-2017-009714_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>2</b> is relatively safer than CDDO-Me. Control C57BL/6 mice (A) or 8 week old <i>db/db</i> mice were randomized and treated intraperitoneally with vehicle control (B), CDDO-Me (0.65 mg/kg, C), or <b>2</b> (1 mg/kg, D; 2 mg/kg, E) for 12 weeks. The apoptotic cells in the cardiac tissues were determined by TUNEL assay, and the percentage of apoptotic cardiomyocytes was calculated from three sections of each mouse (<i>n</i> = 6 per group, F). Data are representative images (magnification ×200) or expressed as the mean ± SD of each group from two separate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00971/20171103/images/large/jm-2017-009714_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00971&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i29">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Johansson, M. H.</span><span> </span><span class="NLM_article-title">Reversible michael additions: covalent inhibitors and prodrugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1330</span><span class="NLM_x">–</span> <span class="NLM_lpage">1344</span><span class="refDoi"> DOI: 10.2174/13895575112091330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.2174%2F13895575112091330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22625413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1330-1344&author=M.+H.+Johansson&title=Reversible+michael+additions%3A+covalent+inhibitors+and+prodrugs&doi=10.2174%2F13895575112091330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Michael additions: covalent inhibitors and prodrugs</span></div><div class="casAuthors">Johansson, Martin H.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1330-1344</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent inhibition is an efficient mol. mechanism for inhibiting enzymes or modulating the function of proteins and is found in the action of many drugs and biol. active natural products.  However, it is has been less appreciated that the formation of covalent bonds can be reversible or irreversible.  This review focuses on biol. active compds. that are Michael acceptors and how the reversible nature of the Michael addn. reaction influences biol. activity and how this can be exploited in designing prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9X1yh9k4q-7Vg90H21EOLACvtfcHk0ljDkvh7UO0RQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jJ&md5=f90694162e39fe57915e888bbadbd2bb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F13895575112091330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13895575112091330%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%2BH.%26atitle%3DReversible%2520michael%2520additions%253A%2520covalent%2520inhibitors%2520and%2520prodrugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D1330%26epage%3D1344%26doi%3D10.2174%2F13895575112091330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Amslinger, S.</span><span> </span><span class="NLM_article-title">The tunable functionality of alpha,beta-unsaturated carbonyl compounds enables their differential application in biological systems</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1002/cmdc.200900499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1002%2Fcmdc.200900499" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=351-356&author=S.+Amslinger&title=The+tunable+functionality+of+alpha%2Cbeta-unsaturated+carbonyl+compounds+enables+their+differential+application+in+biological+systems&doi=10.1002%2Fcmdc.200900499"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900499%26sid%3Dliteratum%253Aachs%26aulast%3DAmslinger%26aufirst%3DS.%26atitle%3DThe%2520tunable%2520functionality%2520of%2520alpha%252Cbeta-unsaturated%2520carbonyl%2520compounds%2520enables%2520their%2520differential%2520application%2520in%2520biological%2520systems%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D351%26epage%3D356%26doi%3D10.1002%2Fcmdc.200900499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherrer, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robins, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, L. M.</span><span> </span><span class="NLM_article-title">Bioactive diterpenoid containing a reversible ″spring-loaded″ (E,Z)-dieneone Michael acceptor</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3920</span><span class="NLM_x">–</span> <span class="NLM_lpage">3923</span><span class="refDoi"> DOI: 10.1021/ol201443k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol201443k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=3920-3923&author=P.+Guptaauthor=U.+Sharmaauthor=T.+C.+Schulzauthor=E.+S.+Sherrerauthor=A.+B.+McLeanauthor=A.+J.+Robinsauthor=L.+M.+West&title=Bioactive+diterpenoid+containing+a+reversible+%E2%80%B3spring-loaded%E2%80%B3+%28E%2CZ%29-dieneone+Michael+acceptor&doi=10.1021%2Fol201443k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fol201443k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol201443k%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DU.%26aulast%3DSchulz%26aufirst%3DT.%2BC.%26aulast%3DSherrer%26aufirst%3DE.%2BS.%26aulast%3DMcLean%26aufirst%3DA.%2BB.%26aulast%3DRobins%26aufirst%3DA.%2BJ.%26aulast%3DWest%26aufirst%3DL.%2BM.%26atitle%3DBioactive%2520diterpenoid%2520containing%2520a%2520reversible%2520%25E2%2580%25B3spring-loaded%25E2%2580%25B3%2520%2528E%252CZ%2529-dieneone%2520Michael%2520acceptor%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D3920%26epage%3D3923%26doi%3D10.1021%2Fol201443k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Liu, J.</span><span> </span><span class="NLM_article-title">Pharmacology of oleanolic acid and ursolic acid</span> <span class="citation_source-journal">J. Ethnopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1016/0378-8741(95)90032-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2F0378-8741%2895%2990032-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=8847885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaK28Xht12gtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=57-68&author=J.+Liu&title=Pharmacology+of+oleanolic+acid+and+ursolic+acid&doi=10.1016%2F0378-8741%2895%2990032-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of oleanolic acid and ursolic acid</span></div><div class="casAuthors">Liu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">57-68</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with many refs.  Oleanolic acid and ursolic acid are triterpenoid compds. that exist widely in food, medicinal herbs and other plants.  This review summarizes the pharmacol. studies on these two triterpenoids.  Both oleanolic acid and ursolic acid are effective in protecting against chem. induced liver injury in lab. animals.  Oleanolic acid has been marketed in China as an oral drug for human liver disorders.  The mechanism of hepatoprotection by these two compds. may involve the inhibition of toxicant activation and the enhancement of the body defense systems.  Oleanolic acid and ursolic acid have also been long-recognized to have antiinflammatory and antihyperlipidemic properties in lab. animals, and more research is warranted to develop a therapy for patients.  Recently, both compds. have been noted for their antitumor-promotion effects, which are stimulating addnl. research in this field.  Oleanolic acid and ursolic acid are relatively non-toxic, and have been used in cosmetics and health products.  The possible mechanisms for the pharmacol. effects and the prospects for these two compds. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgToYQb0SebVg90H21EOLACvtfcHk0lhcQw0uJ4SsRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xht12gtL4%253D&md5=95e420a3aaa6a0774105fcb174ee407e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2F0378-8741%2895%2990032-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-8741%252895%252990032-2%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DPharmacology%2520of%2520oleanolic%2520acid%2520and%2520ursolic%2520acid%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D1995%26volume%3D49%26spage%3D57%26epage%3D68%26doi%3D10.1016%2F0378-8741%2895%2990032-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Reisman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaassen, C. D.</span><span> </span><span class="NLM_article-title">CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.taap.2008.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.taap.2008.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=19371629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2009&pages=109-114&author=S.+A.+Reismanauthor=D.+B.+Buckleyauthor=Y.+Tanakaauthor=C.+D.+Klaassen&title=CDDO-Im+protects+from+acetaminophen+hepatotoxicity+through+induction+of+Nrf2-dependent+genes&doi=10.1016%2Fj.taap.2008.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes</span></div><div class="casAuthors">Reisman, Scott A.; Buckley, David B.; Tanaka, Yuji; Klaassen, Curtis D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-114</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CDDO-Im is a synthetic triterpenoid recently shown to induce cytoprotective genes through the Nrf2-Keap1 pathway, an important mechanism for the induction of cytoprotective genes in response to oxidative stress.  Upon oxidative or electrophilic insult, the transcription factor Nrf2 translocates to the nucleus, heterodimerizes with small Maf proteins, and binds to antioxidant response elements (AREs) in the upstream promoter regions of various cytoprotective genes.  To further elucidate the hepatoprotective effects of CDDO-Im, wild-type and Nrf2-null mice were pretreated with CDDO-Im (1 mg/kg, i.p.) or vehicle (DMSO), and then administered acetaminophen (500 mg/kg, i.p.).  Pretreatment of wild-type mice with CDDO-Im reduced liver injury caused by acetaminophen.  In contrast, hepatoprotection by CDDO-Im was not obsd. in Nrf2-null mice.  CDDO-Im increased Nrf2 protein expression and Nrf2-ARE binding in wild-type, but not Nrf2-null mice.  Furthermore, CDDO-Im increased the mRNA expression of the Nrf2 target genes NAD(P)H: quinone oxidoreductase-1 (Nqo1); glutamate-cysteine ligase, catalytic subunit (Gclc); and heme-oxygenase-1 (Ho-1), in both a dose- and time-dependent manner.  Conversely, CDDO-Im did not induce Nqo1, Gclc, and Ho-1 mRNA expression in Nrf2-null mice.  Collectively, the present study shows that CDDO-Im pretreatment induces Nrf2-dependent cytoprotective genes and protects the liver from acetaminophen-induced hepatic injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw2dPuqslcJbVg90H21EOLACvtfcHk0lhcQw0uJ4SsRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKqt7k%253D&md5=432f16c5e684a71fef87459d93f28d6d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2008.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2008.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DReisman%26aufirst%3DS.%2BA.%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKlaassen%26aufirst%3DC.%2BD.%26atitle%3DCDDO-Im%2520protects%2520from%2520acetaminophen%2520hepatotoxicity%2520through%2520induction%2520of%2520Nrf2-dependent%2520genes%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2009%26volume%3D236%26spage%3D109%26epage%3D114%26doi%3D10.1016%2Fj.taap.2008.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Liby, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span> </span><span class="NLM_article-title">Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">972</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1124/pr.111.004846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1124%2Fpr.111.004846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22966038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=972-1003&author=K.+T.+Libyauthor=M.+B.+Sporn&title=Synthetic+oleanane+triterpenoids%3A+multifunctional+drugs+with+a+broad+range+of+applications+for+prevention+and+treatment+of+chronic+disease&doi=10.1124%2Fpr.111.004846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease</span></div><div class="casAuthors">Liby, Karen T.; Sporn, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">972-1003</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We review the rationale for the use of synthetic oleanane triterpenoids (SOs) for prevention and treatment of disease, as well as extensive biol. data on this topic resulting from both cell culture and in vivo studies.  Emphasis is placed on understanding mechanisms of action.  SOs are noncytotoxic drugs with an excellent safety profile.  Several hundred SOs have now been synthesized and in vitro have been shown to: 1) suppress inflammation and oxidative stress and therefore be cytoprotective, esp. at low nanomolar doses, 2) induce differentiation, and 3) block cell proliferation and induce apoptosis at higher micromolar doses.  Animal data on the use of SOs in neurodegenerative diseases and in diseases of the eye, lung, cardiovascular system, liver, gastrointestinal tract, and kidney, as well as in cancer and in metabolic and inflammatory/autoimmune disorders, are reviewed.  The importance of the cytoprotective Kelch-like erythroid cell-derived protein with CNC homol.-assocd. protein 1/nuclear factor (erythroid-derived 2)-like 2/antioxidant response element (Keap1/Nrf2/ARE) pathway as a mechanism of action is explained, but interactions with peroxisome proliferator-activated receptor γ (PARPγ), inhibitor of nuclear factor-κB kinase complex (IKK), janus tyrosine kinase/signal transducer and activator of transcription (JAK/STAT), human epidermal growth factor receptor 2 (HER2)/ErbB2/neu, phosphatase and tensin homolog (PTEN), the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, mammalian target of rapamycin (mTOR), and the thiol proteome are also described.  In these interactions, Michael addn. of SOs to reactive cysteine residues in specific mol. targets triggers biol. activity.  Ultimately, SOs are multifunctional drugs that regulate the activity of entire networks.  Recent progress in the earliest clin. trials with 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) Me ester (bardoxolone methyl) is also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozzGNihQsvrrVg90H21EOLACvtfcHk0lhcQw0uJ4SsRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaltQ%253D%253D&md5=5c0a741d089e6f6a504eae31a47d872c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fpr.111.004846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.111.004846%26sid%3Dliteratum%253Aachs%26aulast%3DLiby%26aufirst%3DK.%2BT.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26atitle%3DSynthetic%2520oleanane%2520triterpenoids%253A%2520multifunctional%2520drugs%2520with%2520a%2520broad%2520range%2520of%2520applications%2520for%2520prevention%2520and%2520treatment%2520of%2520chronic%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D972%26epage%3D1003%26doi%3D10.1124%2Fpr.111.004846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Cleasby, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tickle, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweitzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span> </span><span class="NLM_article-title">Structure of the BTB domain of keap1 and its interaction with the triterpenoid antagonist CDDO</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e98896</span><span class="refDoi"> DOI: 10.1371/journal.pone.0098896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1371%2Fjournal.pone.0098896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=24896564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWlsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e98896&author=A.+Cleasbyauthor=J.+Yonauthor=P.+J.+Dayauthor=C.+Richardsonauthor=I.+J.+Tickleauthor=P.+A.+Williamsauthor=J.+F.+Callahanauthor=R.+Carrauthor=N.+Conchaauthor=J.+K.+Kernsauthor=H.+W.+Qiauthor=T.+Sweitzerauthor=P.+Wardauthor=T.+G.+Davies&title=Structure+of+the+BTB+domain+of+keap1+and+its+interaction+with+the+triterpenoid+antagonist+CDDO&doi=10.1371%2Fjournal.pone.0098896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO</span></div><div class="casAuthors">Cleasby, Anne; Yon, Jeff; Day, Philip J.; Richardson, Caroline; Tickle, Ian J.; Williams, Pamela A.; Callahan, James F.; Carr, Robin; Concha, Nestor; Kerns, Jeffrey K.; Qi, Hongwei; Sweitzer, Thomas; Ward, Paris; Davies, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e98896/1-e98896/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  The protein Keap1 is central to the regulation of the Nrf2-mediated cytoprotective response, and is increasingly recognized as an important target for therapeutic intervention in a range of diseases involving excessive oxidative stress and inflammation.  The BTB domain of Keap1 plays key roles in sensing environmental electrophiles and in mediating interactions with the Cul3/Rbx1 E3 ubiquitin ligase system, and is believed to be the target for several small mol. covalent activators of the Nrf2 pathway.  However, despite structural information being available for several BTB domains from related proteins, there have been no reported crystal structures of Keap1 BTB, and this has precluded a detailed understanding of its mechanism of action and interaction with antagonists.  We report here the first structure of the BTB domain of Keap1, which is thought to contain the key cysteine residue responsible for interaction with electrophiles, as well as structures of the covalent complex with the antagonist CDDO/bardoxolone, and of the constitutively inactive C151W BTB mutant.  In addn. to providing the first structural confirmation of antagonist binding to Keap1 BTB, we also present biochem. evidence that adduction of Cys 151 by CDDO is capable of inhibiting the binding of Cul3 to Keap1, and discuss how this class of compd. might exert Nrf2 activation through disruption of the BTB-Cul3 interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe-yi4jSWD-bVg90H21EOLACvtfcHk0lgs0M3TTOcyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWlsr7I&md5=f9c6542ff2508a74313e996ccdafa0ae</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0098896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0098896%26sid%3Dliteratum%253Aachs%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DYon%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DWilliams%26aufirst%3DP.%2BA.%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DConcha%26aufirst%3DN.%26aulast%3DKerns%26aufirst%3DJ.%2BK.%26aulast%3DQi%26aufirst%3DH.%2BW.%26aulast%3DSweitzer%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26atitle%3DStructure%2520of%2520the%2520BTB%2520domain%2520of%2520keap1%2520and%2520its%2520interaction%2520with%2520the%2520triterpenoid%2520antagonist%2520CDDO%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De98896%26doi%3D10.1371%2Fjournal.pone.0098896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Kensler, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakabayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswal, S.</span><span> </span><span class="NLM_article-title">Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.46.120604.141046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1146%2Fannurev.pharmtox.46.120604.141046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=16968214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1altrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=89-116&author=T.+W.+Kenslerauthor=N.+Wakabayashiauthor=S.+Biswal&title=Cell+survival+responses+to+environmental+stresses+via+the+Keap1-Nrf2-ARE+pathway&doi=10.1146%2Fannurev.pharmtox.46.120604.141046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway</span></div><div class="casAuthors">Kensler, Thomas W.; Wakabayashi, Nobunao; Biswal, Shyam</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-116</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Keap1-Nrf2-ARE signaling plays a significant role in protecting cells from endogenous and exogenous stresses.  The development of Nrf2 knockout mice has provided key insights into the toxicol. importance of this pathway.  These mice are more sensitive to the hepatic, pulmonary, ovarian, and neurotoxic consequences of acute exposures to environmental agents and drugs, inflammatory stresses, as well as chronic exposures to cigarette smoke and other carcinogens.  Under quiescent conditions, the transcription factor Nrf2 interacts with the actin-anchored protein Keap1, largely localized in the cytoplasm.  This quenching interaction maintains low basal expression of Nrf2-regulated genes.  However, upon recognition of chem. signals imparted by oxidative and electrophilic mols., Nrf2 is released from Keap1, escapes proteasomal degrdn., translocates to the nucleus, and transactivates the expression of several dozen cytoprotective genes that enhance cell survival.  This review highlights the key elements in this adaptive response to protection against acute and chronic cell injury provoked by environmental stresses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAmRpcXFLXq7Vg90H21EOLACvtfcHk0lgs0M3TTOcyXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1altrg%253D&md5=eee9260ebe6186b82da647701a10c7e2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.46.120604.141046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.46.120604.141046%26sid%3Dliteratum%253Aachs%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DWakabayashi%26aufirst%3DN.%26aulast%3DBiswal%26aufirst%3DS.%26atitle%3DCell%2520survival%2520responses%2520to%2520environmental%2520stresses%2520via%2520the%2520Keap1-Nrf2-ARE%2520pathway%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2007%26volume%3D47%26spage%3D89%26epage%3D116%26doi%3D10.1146%2Fannurev.pharmtox.46.120604.141046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Shishodia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, B. B.</span><span> </span><span class="NLM_article-title">A synthetic triterpenoid, CDDO-Me, inhibits I kappa B alpha, kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappa B-regulated gene products in human leukemic cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1828</span><span class="NLM_x">–</span> <span class="NLM_lpage">1838</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F1078-0432.CCR-05-2044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=16551868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1CjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1828-1838&author=S.+Shishodiaauthor=G.+Sethiauthor=M.+Konoplevaauthor=M.+Andreeffauthor=B.+B.+Aggarwal&title=A+synthetic+triterpenoid%2C+CDDO-Me%2C+inhibits+I+kappa+B+alpha%2C+kinase+and+enhances+apoptosis+induced+by+TNF+and+chemotherapeutic+agents+through+down-regulation+of+expression+of+nuclear+factor+kappa+B-regulated+gene+products+in+human+leukemic+cells&doi=10.1158%2F1078-0432.CCR-05-2044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB-Regulated Gene Products in Human Leukemic Cells</span></div><div class="casAuthors">Shishodia, Shishir; Sethi, Gautam; Konopleva, Marina; Andreeff, Michael; Aggarwal, Bharat B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1828-1838</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The C-28 Me ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me), a synthetic triterpenoid based on naturally occurring ursolic and oleanolic acids, induces apoptosis in tumor cells, induces differentiation, and inhibits inflammatory response through a poorly understood mechanism.  Because the nuclear transcription factor nuclear factor κB (NF-κB) has been shown to suppress apoptosis and promote proliferation and is linked with inflammation and differentiation, we postulated that CDDO-Me modulates NF-κB activity and NF-κB-regulated gene expression.  Using human leukemia cell lines and patient samples, we show that CDDO-Me potently inhibits both constitutive and inducible NF-κB activated by tumor necrosis factor (TNF), interleukin (IL)-1{szligbeta}, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke.  CDDO-Me was more potent than CDDO and its imidazole deriv.  NF-κB suppression occurred through inhibition of IκBα kinase activation, IκBα phosphorylation, IκBα degrdn., p65 phosphorylation, p65 nuclear translocation, and NF-κB-mediated reporter gene transcription.  This inhibition correlated with suppression of NF-κB-dependent genes involved in antiapoptosis (IAP2, cFLIP, TRAF1, survivin, and bcl-2), proliferation (cyclin d1 and c-myc), and angiogenesis (VEGF, cox-2, and mmp-9).  CDDO-Me also potentiated the cytotoxic effects of TNF and chemotherapeutic agents.  Overall, our results suggest that CDDO-Me inhibits NF-κB through inhibition of IκBα kinase, leading to the suppression of expression of NF-κB-regulated gene products and enhancement of apoptosis induced by TNF and chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8LQa8tIlmE7Vg90H21EOLACvtfcHk0liGYvOQxpUXyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1CjsLY%253D&md5=de5e618ec5bd9c4984aa3894be850610</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2044%26sid%3Dliteratum%253Aachs%26aulast%3DShishodia%26aufirst%3DS.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3DA%2520synthetic%2520triterpenoid%252C%2520CDDO-Me%252C%2520inhibits%2520I%2520kappa%2520B%2520alpha%252C%2520kinase%2520and%2520enhances%2520apoptosis%2520induced%2520by%2520TNF%2520and%2520chemotherapeutic%2520agents%2520through%2520down-regulation%2520of%2520expression%2520of%2520nuclear%2520factor%2520kappa%2520B-regulated%2520gene%2520products%2520in%2520human%2520leukemic%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1828%26epage%3D1838%26doi%3D10.1158%2F1078-0432.CCR-05-2044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Singh, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winocour, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrington, K.</span><span> </span><span class="NLM_article-title">Oxidative stress in early diabetic nephropathy: fueling the fire</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1038/nrendo.2010.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnrendo.2010.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21151200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=176-184&author=D.+K.+Singhauthor=P.+Winocourauthor=K.+Farrington&title=Oxidative+stress+in+early+diabetic+nephropathy%3A+fueling+the+fire&doi=10.1038%2Fnrendo.2010.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress in early diabetic nephropathy: fueling the fire</span></div><div class="casAuthors">Singh, Dhruv K.; Winocour, Peter; Farrington, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">176-184</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This Review summarizes the role of reactive oxygen species and oxidative stress in diabetes mellitus and in the pathogenesis of endothelial cell dysfunction and diabetic nephropathy.  Furthermore, the authors explore possible therapeutic interventions to reduce oxidative stress and endothelial cell dysfunction and retard the progression of diabetic nephropathy.  Diabetic nephropathy is a major microvascular complication of diabetes mellitus and the most common cause of end-stage renal disease worldwide.  The treatment costs of diabetes mellitus and its complications represent a huge burden on health-care expenditures, creating a major need to identify modifiable factors concerned in the pathogenesis and progression of diabetic nephropathy.  Chronic hyperglycemia remains the primary cause of the metabolic, biochem. and vascular abnormalities in diabetic nephropathy.  Promotion of excessive oxidative stress in the vascular and cellular milieu results in endothelial cell dysfunction, which is one of the earliest and most pivotal metabolic consequences of chronic hyperglycemia.  These derangements are caused by excessive prodn. of advanced glycation end products and free radicals and by the subjugation of antioxidants and antioxidant mechanisms.  An increased understanding of the role of oxidative stress in diabetic nephropathy has lead to the exploration of a no. of therapeutic strategies, the success of which has so far been limited.  However, judicious and timely use of current therapies to maintain good glycemic control, adequate blood pressure and lipid levels, along with lifestyle measures such as regular exercise, optimization of diet and smoking cessation, may help to reduce oxidative stress and endothelial cell dysfunction and retard the progression of diabetic nephropathy until more definitive therapies become available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFT_0kFsXLabVg90H21EOLACvtfcHk0liGYvOQxpUXyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlaqtb8%253D&md5=5a72fe9d5cd00587a95276cad81800b6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2010.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2010.212%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%2BK.%26aulast%3DWinocour%26aufirst%3DP.%26aulast%3DFarrington%26aufirst%3DK.%26atitle%3DOxidative%2520stress%2520in%2520early%2520diabetic%2520nephropathy%253A%2520fueling%2520the%2520fire%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D7%26spage%3D176%26epage%3D184%26doi%3D10.1038%2Fnrendo.2010.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucherot, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichinger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitsche, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grone, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlondorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kretzler, M.</span><span> </span><span class="NLM_article-title">Modular activation of nuclear factor-kappa B transcriptional programs in human diabetic nephropathy</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2993</span><span class="NLM_x">–</span> <span class="NLM_lpage">3003</span><span class="refDoi"> DOI: 10.2337/db06-0477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.2337%2Fdb06-0477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2006&pages=2993-3003&author=H.+Schmidauthor=A.+Boucherotauthor=Y.+Yasudaauthor=A.+Hengerauthor=B.+Brunnerauthor=F.+Eichingerauthor=A.+Nitscheauthor=E.+Kissauthor=M.+Bleichauthor=H.+J.+Groneauthor=P.+J.+Nelsonauthor=D.+Schlondorffauthor=C.+D.+Cohenauthor=M.+Kretzler&title=Modular+activation+of+nuclear+factor-kappa+B+transcriptional+programs+in+human+diabetic+nephropathy&doi=10.2337%2Fdb06-0477"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2337%2Fdb06-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb06-0477%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DBoucherot%26aufirst%3DA.%26aulast%3DYasuda%26aufirst%3DY.%26aulast%3DHenger%26aufirst%3DA.%26aulast%3DBrunner%26aufirst%3DB.%26aulast%3DEichinger%26aufirst%3DF.%26aulast%3DNitsche%26aufirst%3DA.%26aulast%3DKiss%26aufirst%3DE.%26aulast%3DBleich%26aufirst%3DM.%26aulast%3DGrone%26aufirst%3DH.%2BJ.%26aulast%3DNelson%26aufirst%3DP.%2BJ.%26aulast%3DSchlondorff%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DC.%2BD.%26aulast%3DKretzler%26aufirst%3DM.%26atitle%3DModular%2520activation%2520of%2520nuclear%2520factor-kappa%2520B%2520transcriptional%2520programs%2520in%2520human%2520diabetic%2520nephropathy%26jtitle%3DDiabetes%26date%3D2006%26volume%3D55%26spage%3D2993%26epage%3D3003%26doi%3D10.2337%2Fdb06-0477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Navarro-Gonzalez, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mora-Fernandez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fuentes, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Perez, J.</span><span> </span><span class="NLM_article-title">Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy</span> <span class="citation_source-journal">Nat. Rev. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1038/nrneph.2011.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnrneph.2011.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21537349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms12lsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=327-340&author=J.+F.+Navarro-Gonzalezauthor=C.+Mora-Fernandezauthor=M.+M.+de+Fuentesauthor=J.+Garcia-Perez&title=Inflammatory+molecules+and+pathways+in+the+pathogenesis+of+diabetic+nephropathy&doi=10.1038%2Fnrneph.2011.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy</span></div><div class="casAuthors">Navarro-Gonzalez, Juan F.; Mora-Fernandez, Carmen; Muros de Fuentes, Mercedes; Garcia-Perez, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Nephrology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">327-340</span>CODEN:
                <span class="NLM_cas:coden">NRNABO</span>;
        ISSN:<span class="NLM_cas:issn">1759-5061</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inflammation has a key role in the pathogenesis and progression of diabetic nephropathy; however, the pathways, ligands and receptors involved in this condition are complex and only partially understood.  The authors of this Review discuss the mol. networks that are implicated in the development of diabetic nephropathy and describe how these pathways function in health and disease, as well as their importance in the identification and development of potential therapeutics.  Many lines of evidence, ranging from in vitro expts. and pathol. examns. to epidemiol. studies, show that inflammation is a cardinal pathogenetic mechanism in diabetic nephropathy.  Thus, modulation of inflammatory processes in the setting of diabetes mellitus is a matter of great interest for researchers today.  The relationships between inflammation and the development and progression of diabetic nephropathy involve complex mol. networks and processes.  This Review, therefore, focuses on key proinflammatory mols. and pathways implicated in the development and progression of diabetic nephropathy: the chemokines CCL2, CX3CL1 and CCL5 (also known as MCP-1, fractalkine and RANTES, resp.); the adhesion mols. intercellular adhesion mol. 1, vascular cell adhesion protein 1, endothelial cell-selective adhesion mol., E-selectin and α-actinin 4; the transcription factor nuclear factor κB; and the inflammatory cytokines IL-1, IL-6, IL-18 and tumor necrosis factor.  Advances in the understanding of the roles that these inflammatory pathways have in the context of diabetic nephropathy will facilitate the discovery of new therapeutic targets.  In the next few years, promising new therapeutic strategies based on anti-inflammatory effects could be successfully translated into clin. treatments for diabetic complications, including diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqeKIeooP0zLVg90H21EOLACvtfcHk0lib7ne9QIilnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms12lsLo%253D&md5=461d682d7bb8a411ea66ba860c029b1e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrneph.2011.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneph.2011.51%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro-Gonzalez%26aufirst%3DJ.%2BF.%26aulast%3DMora-Fernandez%26aufirst%3DC.%26aulast%3Dde%2BFuentes%26aufirst%3DM.%2BM.%26aulast%3DGarcia-Perez%26aufirst%3DJ.%26atitle%3DInflammatory%2520molecules%2520and%2520pathways%2520in%2520the%2520pathogenesis%2520of%2520diabetic%2520nephropathy%26jtitle%3DNat.%2520Rev.%2520Nephrol.%26date%3D2011%26volume%3D7%26spage%3D327%26epage%3D340%26doi%3D10.1038%2Fnrneph.2011.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pergola, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnock, D. G.</span><span> </span><span class="NLM_article-title">Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD</span> <span class="citation_source-journal">Am. J. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span><span class="refDoi"> DOI: 10.1159/000327599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1159%2F000327599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21508635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFyls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=469-476&author=P.+E.+Pergolaauthor=M.+Krauthauthor=J.+W.+Huffauthor=D.+A.+Fergusonauthor=S.+Ruizauthor=C.+J.+Meyerauthor=D.+G.+Warnock&title=Effect+of+bardoxolone+methyl+on+kidney+function+in+patients+with+T2D+and+stage+3b-4+CKD&doi=10.1159%2F000327599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b-4 CKD</span></div><div class="casAuthors">Pergola, Pablo E.; Krauth, Melissa; Huff, J. Warren; Ferguson, Deborah A.; Ruiz, Stacey; Meyer, Colin J.; Warnock, David G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-476</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Bardoxolone Me, a novel synthetic triterpenoid, induces Nrf2, a transcription factor known to play a key role in decreasing oxidative stress and the prodn. of pro-inflammatory mols.  This exploratory multi-center, open-label study assessed the clin. activity and safety of bardoxolone Me in 20 patients with moderate to severe chronic kidney disease and type 2 diabetes.  Patients received 25 mg of bardoxolone Me daily for 28 days, followed by 75 mg daily for another 28 days.  The study achieved its primary efficacy endpoint, as demonstrated by a significant increase from baseline in estd. glomerular filtration rate (eGFR) of 7.2 mL/min/1.73 m2 (p < 0.001).  Improvements were seen in approx. 90% of patients and showed a dose- and time-dependent increase in eGFR.  The eGFR change paralleled a significant redn. in serum creatinine (-0.3 mg/dL) and blood urea nitrogen (-4.9 mg/dL), along with an increase in creatinine clearance (+14.6 mL/min/1.73 m2), without a change in the 24-h creatinine excretion rate.  Markers of vascular injury and inflammation were improved by treatment with bardoxolone.  No life-threatening adverse events or drug-related serious adverse events were reported.  The results describe an apparent increase in kidney function following relatively short-term treatment with bardoxolone Me, a promising new agent that warrants placebo-controlled studies to define its long-term effects on renal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6lXQIYezO97Vg90H21EOLACvtfcHk0lib7ne9QIilnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFyls7w%253D&md5=79cc223ddcc75525c0547f4edbf02de7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1159%2F000327599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000327599%26sid%3Dliteratum%253Aachs%26aulast%3DPergola%26aufirst%3DP.%2BE.%26aulast%3DKrauth%26aufirst%3DM.%26aulast%3DHuff%26aufirst%3DJ.%2BW.%26aulast%3DFerguson%26aufirst%3DD.%2BA.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DC.%2BJ.%26aulast%3DWarnock%26aufirst%3DD.%2BG.%26atitle%3DEffect%2520of%2520bardoxolone%2520methyl%2520on%2520kidney%2520function%2520in%2520patients%2520with%2520T2D%2520and%2520stage%25203b-4%2520CKD%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2011%26volume%3D33%26spage%3D469%26epage%3D476%26doi%3D10.1159%2F000327599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akizawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audhya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakris, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ-Schmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsberry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerspink, H. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parving, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaziri, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrolstad, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chertow, G. M.</span><span> </span><span class="NLM_article-title">Bardoxolone methyl in Type 2 diabetes and stage 4 chronic kidney disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">2492</span><span class="NLM_x">–</span> <span class="NLM_lpage">2503</span><span class="refDoi"> DOI: 10.1056/NEJMoa1306033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa1306033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=24206459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=2492-2503&author=D.+de+Zeeuwauthor=T.+Akizawaauthor=P.+Audhyaauthor=G.+L.+Bakrisauthor=M.+Chinauthor=H.+Christ-Schmidtauthor=A.+Goldsberryauthor=M.+Houserauthor=M.+Krauthauthor=H.+J.+L.+Heerspinkauthor=J.+J.+McMurrayauthor=C.+J.+Meyerauthor=H.+H.+Parvingauthor=G.+Remuzziauthor=R.+D.+Totoauthor=N.+D.+Vaziriauthor=C.+Wannerauthor=J.+Wittesauthor=D.+Wrolstadauthor=G.+M.+Chertow&title=Bardoxolone+methyl+in+Type+2+diabetes+and+stage+4+chronic+kidney+disease&doi=10.1056%2FNEJMoa1306033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease</span></div><div class="casAuthors">de Zeeuw, Dick; Akizawa, Tadao; Audhya, Paul; Bakris, George L.; Chin, Melanie; Christ-Schmidt, Heidi; Goldsberry, Angie; Houser, Mark; Krauth, Melissa; Lambers Heerspink, Hiddo J.; McMurray, John J.; Meyer, Colin J.; Parving, Hans-Henrik; Remuzzi, Giuseppe; Toto, Robert D.; Vaziri, Nosratola D.; Wanner, Christoph; Wittes, Janet; Wrolstad, Danielle; Chertow, Glenn M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2492-2503</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high.  Whether nuclear I factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.  METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estd. glomerular filtration rate [GFR], 15 to <30 mL per min per 1.73 m2 of body-surface area) to bardoxolone Me, at a daily dose of 20 mg, or placebo.  The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes.  RESULTS: The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 mo.  A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone Me and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone Me group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P = 0.92).  In the bardoxolone Me group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed In 51 patients, and 19 patients died from cardiovascular causes.  A total of 96 patients in the bardoxolone Me group were hospitalized for heart failure or died from heart failure, as compared with 55 in the placebo group (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P < 0.001).  Estd. GFR, blood pressure, and the urinary albumin-to-creatinine ratio increased significantly and body wt. decreased significantly in the bardoxolone Me group, as compared with the placebo group.  CONCLUSIONS: Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone Me did not reduce the risk of ESRD or death from cardiovascular causes.  A higher rate of cardiovascular events with bardoxolone Me than with placebo prompted termination of the trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomI6Z9q4C0LLVg90H21EOLACvtfcHk0ljH3EMl2bwuPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKqs74%253D&md5=1bcc997b57ba700423e0549a617231b5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306033%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DAkizawa%26aufirst%3DT.%26aulast%3DAudhya%26aufirst%3DP.%26aulast%3DBakris%26aufirst%3DG.%2BL.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DChrist-Schmidt%26aufirst%3DH.%26aulast%3DGoldsberry%26aufirst%3DA.%26aulast%3DHouser%26aufirst%3DM.%26aulast%3DKrauth%26aufirst%3DM.%26aulast%3DHeerspink%26aufirst%3DH.%2BJ.%2BL.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DMeyer%26aufirst%3DC.%2BJ.%26aulast%3DParving%26aufirst%3DH.%2BH.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DToto%26aufirst%3DR.%2BD.%26aulast%3DVaziri%26aufirst%3DN.%2BD.%26aulast%3DWanner%26aufirst%3DC.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DWrolstad%26aufirst%3DD.%26aulast%3DChertow%26aufirst%3DG.%2BM.%26atitle%3DBardoxolone%2520methyl%2520in%2520Type%25202%2520diabetes%2520and%2520stage%25204%2520chronic%2520kidney%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D2492%26epage%3D2503%26doi%3D10.1056%2FNEJMoa1306033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Pergola, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raskin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audhya, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ-Schmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnock, D. G.</span><span> </span><span class="NLM_article-title">Bardoxolone methyl and kidney function in CKD with type 2 diabetes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1056/NEJMoa1105351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa1105351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21699484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslSnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=327-336&author=P.+E.+Pergolaauthor=P.+Raskinauthor=R.+D.+Totoauthor=C.+J.+Meyerauthor=J.+W.+Huffauthor=E.+B.+Grossmanauthor=M.+Krauthauthor=S.+Ruizauthor=P.+Audhyaauthor=H.+Christ-Schmidtauthor=J.+Wittesauthor=D.+G.+Warnock&title=Bardoxolone+methyl+and+kidney+function+in+CKD+with+type+2+diabetes&doi=10.1056%2FNEJMoa1105351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Bardoxolone methyl and kidney function in CKD with type 2 diabetes</span></div><div class="casAuthors">Pergola, Pablo E.; Raskin, Philip; Toto, Robert D.; Meyer, Colin J.; Huff, J. Warren; Grossman, Eric B.; Krauth, Melissa; Ruiz, Stacey; Audhya, Paul; Christ-Schmidt, Heidi; Wittes, Janet; Warnock, David G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Chronic kidney disease (CKD) assocd. with type 2 diabetes is the leading cause of kidney failure, with both inflammation and oxidative stress contributing to disease progression.  Bardoxolone Me, an oral antioxidant inflammation modulator, has shown efficacy in patients with CKD and type 2 diabetes in short-term studies, but longer-term effects sand dose response have not been detd.  Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned 227 adults with CKD (defined as an estd. glomerular filtration rate [GFR] of 20 to 45 mL per min per 1.73 m2 of body-surface area) in a 1:1:1:1 ratio to receive placebo or bardoxolone Me at a target dose of 25, 75, or 150 mg once daily.  The primary outcome was the change from baseline in the estd. GFR with bardoxolone Me, as compared with placebo, at 24 wk; a secondary outcome was the change at 52 wk.  Results: Patients receiving bardoxolone Me had significant increases in the mean (±SD) estd. GFR, as compared with placebo, at 24 wk (with between-group differences per min per 1.73 m2 of 8.2 ± 1.5 mL in the 25-mg group, 11.4 ± 1.5 mL in the 75-mg group, and 10.4 ± 1.5 mL in the 150-mg group; P < 0.001).  The increases were maintained through week 52, with significant differences per min per 1.73 m2 of 5.8 ± 1.8 mL, 10.5 ± 1.8 mL, and 9.3 ± 1.9 mL, resp.  Muscle spasms, were generally mild and dose-related.  Hypomagnesemia, mild increases in alanine aminotransferase levels, and gastrointestinal effects were more common among patients receiving bardoxolone Me.  Conclusions: Bardoxolone Me was assocd. with improvement in the estd. GFR in patients with advanced CKD and type 2 diabetes at 24 wk.  The improvement persisted at 52 wk, suggesting that bardoxolone Me may have promise for the treatment of CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcbGTG2V2X9LVg90H21EOLACvtfcHk0ljH3EMl2bwuPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslSnsrs%253D&md5=9f4f2bb5e020129e58dc47437fcab8a7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105351%26sid%3Dliteratum%253Aachs%26aulast%3DPergola%26aufirst%3DP.%2BE.%26aulast%3DRaskin%26aufirst%3DP.%26aulast%3DToto%26aufirst%3DR.%2BD.%26aulast%3DMeyer%26aufirst%3DC.%2BJ.%26aulast%3DHuff%26aufirst%3DJ.%2BW.%26aulast%3DGrossman%26aufirst%3DE.%2BB.%26aulast%3DKrauth%26aufirst%3DM.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DAudhya%26aufirst%3DP.%26aulast%3DChrist-Schmidt%26aufirst%3DH.%26aulast%3DWittes%26aufirst%3DJ.%26aulast%3DWarnock%26aufirst%3DD.%2BG.%26atitle%3DBardoxolone%2520methyl%2520and%2520kidney%2520function%2520in%2520CKD%2520with%2520type%25202%2520diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D327%26epage%3D336%26doi%3D10.1056%2FNEJMoa1105351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Varga, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferdinandy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span> </span><span class="NLM_article-title">Drug-induced mitochondrial dysfunction and cardiotoxicity</span> <span class="citation_source-journal">Am. J. Physiol. Heart Circ. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">H1453</span><span class="NLM_x">–</span> <span class="NLM_lpage">H1467</span><span class="refDoi"> DOI: 10.1152/ajpheart.00554.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1152%2Fajpheart.00554.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=26386112" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=H1453-H1467&author=Z.+V.+Vargaauthor=P.+Ferdinandyauthor=L.+Liaudetauthor=P.+Pacher&title=Drug-induced+mitochondrial+dysfunction+and+cardiotoxicity&doi=10.1152%2Fajpheart.00554.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00554.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00554.2015%26sid%3Dliteratum%253Aachs%26aulast%3DVarga%26aufirst%3DZ.%2BV.%26aulast%3DFerdinandy%26aufirst%3DP.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DPacher%26aufirst%3DP.%26atitle%3DDrug-induced%2520mitochondrial%2520dysfunction%2520and%2520cardiotoxicity%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2015%26volume%3D309%26spage%3DH1453%26epage%3DH1467%26doi%3D10.1152%2Fajpheart.00554.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Samudio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurinna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruvolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korchin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span> </span><span class="NLM_article-title">Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1, 9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1130</span><span class="NLM_x">–</span> <span class="NLM_lpage">1139</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F1535-7163.MCT-07-0553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18483301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFanu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1130-1139&author=I.+Samudioauthor=S.+Kurinnaauthor=P.+Ruvoloauthor=B.+Korchinauthor=H.+Kantarjianauthor=M.+Beranauthor=K.+Dunnerauthor=S.+Kondoauthor=M.+Andreeffauthor=M.+Konopleva&title=Inhibition+of+mitochondrial+metabolism+by+methyl-2-cyano-3%2C12-dioxooleana-1%2C+9-diene-28-oate+induces+apoptotic+or+autophagic+cell+death+in+chronic+myeloid+leukemia+cells&doi=10.1158%2F1535-7163.MCT-07-0553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells</span></div><div class="casAuthors">Samudio, Ismael; Kurinna, Svitlana; Ruvolo, Peter; Korchin, Borys; Kantarjian, Hagop; Beran, Miloslav; Dunner, Kenneth, Jr.; Kondo, Seiji; Andreeff, Michael; Konopleva, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1130-1139</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The initial success of the first synthetic bcr-abl kinase inhibitor imatinib has been dampened by the emergence of imatinib-resistant disease in blast crisis chronic myeloid leukemia.  Here, we report that the novel triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me) potently induced cytotoxicity in imatinib-resistant KBM5 cells expressing the T315I mutation of bcr-abl (24-h EC50, 540 nmol/L).  In long-term culture, CDDO-Me abrogated the growth of human parental KBM5 and KBM5-STI cells with 96-h IC50 of 205 and 221 nmol/L, resp.  In addn., CDDO-Me rapidly decreased the viability of murine lymphoid Ba/F3 cells expressing wild-type p210 as well as the imatinib-resistant E255K and T315I mutations of bcr-abl.  The low-dose effects of CDDO-Me are assocd. with inhibition of mitochondrial oxygen consumption, whereas the cytotoxic effects appear to be mediated by a rapid and selective depletion of mitochondrial glutathione that accompanies the increased generation of reactive oxygen species and mitochondrial dysfunction.  Interestingly, the mitochondriotoxic effects of CDDO-Me are followed by the rapid autophagocytosis of intracellular organelles or the externalization of phosphatidylserine in different cell types.  We conclude that alterations in mitochondrial function by CDDO-Me can result in autophagy or apoptosis of chronic myeloid leukemia cells regardless of the mutational status of bcr-abl.  CDDO-Me is in clin. trials and shows signs of clin. activity, with minimal side effects and complete lack of cardiotoxicity.  Studies in leukemias are in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqRX0lPsqvBbVg90H21EOLACvtfcHk0lhVtqJ6es2OzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFanu7g%253D&md5=3600b693af70f14a98b12c04158a083b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0553%26sid%3Dliteratum%253Aachs%26aulast%3DSamudio%26aufirst%3DI.%26aulast%3DKurinna%26aufirst%3DS.%26aulast%3DRuvolo%26aufirst%3DP.%26aulast%3DKorchin%26aufirst%3DB.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DDunner%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKonopleva%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520mitochondrial%2520metabolism%2520by%2520methyl-2-cyano-3%252C12-dioxooleana-1%252C%25209-diene-28-oate%2520induces%2520apoptotic%2520or%2520autophagic%2520cell%2520death%2520in%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1130%26epage%3D1139%26doi%3D10.1158%2F1535-7163.MCT-07-0553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Vannini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cammarota, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noonan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albini, A.</span><span> </span><span class="NLM_article-title">The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3139</span><span class="NLM_x">–</span> <span class="NLM_lpage">3146</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F1535-7163.MCT-07-0451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18065492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3139-3146&author=N.+Vanniniauthor=G.+Lorussoauthor=R.+Cammarotaauthor=M.+Barberisauthor=D.+M.+Noonanauthor=M.+B.+Spornauthor=A.+Albini&title=The+synthetic+oleanane+triterpenoid%2C+CDDO-methyl+ester%2C+is+a+potent+antiangiogenic+agent&doi=10.1158%2F1535-7163.MCT-07-0451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent</span></div><div class="casAuthors">Vannini, Nicola; Lorusso, Girieca; Cammarota, Rosaria; Barberis, Massimo; Noonan, Douglas M.; Sporn, Michael B.; Albini, Adriana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3139-3146</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that the synthetic oleanane triterpenoid, CDDO-Me ester (CDDO-Me; Me 2-cyano-3,12-dioxoolean-1,9-dien-28-oate) is an effective agent for suppressing angiogenesis, both in cell culture and in vivo.  The potency of CDDO-Me is particularly striking when dosed in vivo to inhibit the angiogenic effects of vascular endothelial growth factor and tumor necrosis factor-α in Matrigel sponge assays; activity is seen at i.p. doses of CDDO-Me as low as 0.003 mg/kg of body wt.  If the Matrigel sponges are impregnated with CDDO-Me just before implantation in the mice, picomolar doses of CDDO-Me will suppress angiogenesis.  CDDO-Me also inhibits growth of endothelial cells in monolayer cultures and suppresses neovascular morphogenesis in three-dimensional cultures, but significantly higher doses (50-200 nmol/L) are required.  We also show antiangiogenic effects of CDDO-Me on xenografts of Kaposi's sarcoma cells in immunocompromised mice, using CD31 as a marker.  Several known individual mol. targets of CDDO-Me and related triterpenoids that are relevant to all of these findings include nuclear factor-κB signaling, signal transducers and activators of transcription signaling, and transforming growth factor-β signaling, as well as Keap1, the endogenous inhibitor of the transcription factor Nrf2.  However, the particularly potent antiangiogenic activity seen in vivo in the present expts. suggest that CDDO-Me, as an angioprevention agent, may be interacting with an entire network of mol. and cellular targets, rather than at a single mol. locus or in a single-cell type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqGTbQoBtC7Vg90H21EOLACvtfcHk0lhM-3BCHDHfRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrzE&md5=752a46ca8ece347f695a70652f7b1112</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0451%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DN.%26aulast%3DLorusso%26aufirst%3DG.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DBarberis%26aufirst%3DM.%26aulast%3DNoonan%26aufirst%3DD.%2BM.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DAlbini%26aufirst%3DA.%26atitle%3DThe%2520synthetic%2520oleanane%2520triterpenoid%252C%2520CDDO-methyl%2520ester%252C%2520is%2520a%2520potent%2520antiangiogenic%2520agent%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3139%26epage%3D3146%26doi%3D10.1158%2F1535-7163.MCT-07-0451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orimo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molkentin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komuro, I.</span><span> </span><span class="NLM_article-title">p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1038/nature05602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnature05602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=17334357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2007&pages=444-448&author=M.+Sanoauthor=T.+Minaminoauthor=H.+Tokoauthor=H.+Miyauchiauthor=M.+Orimoauthor=Y.+Qinauthor=H.+Akazawaauthor=K.+Tatenoauthor=Y.+Kayamaauthor=M.+Haradaauthor=I.+Shimizuauthor=T.+Asaharaauthor=H.+Hamadaauthor=S.+Tomitaauthor=J.+D.+Molkentinauthor=Y.+Zouauthor=I.+Komuro&title=p53-Induced+inhibition+of+Hif-1+causes+cardiac+dysfunction+during+pressure+overload&doi=10.1038%2Fnature05602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload</span></div><div class="casAuthors">Sano, Masanori; Minamino, Tohru; Toko, Haruhiro; Miyauchi, Hideyuki; Orimo, Masayuki; Qin, Yingjie; Akazawa, Hiroshi; Tateno, Kaoru; Kayama, Yosuke; Harada, Mutsuo; Shimizu, Ippei; Asahara, Takayuki; Hamada, Hirofumi; Tomita, Shuhei; Molkentin, Jeffrey D.; Zou, Yunzeng; Komuro, Issei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">7134</span>),
    <span class="NLM_cas:pages">444-448</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cardiac hypertrophy occurs as an adaptive response to increased workload to maintain cardiac function.  However, prolonged cardiac hypertrophy causes heart failure, and its mechanisms are largely unknown.  Here we show that cardiac angiogenesis is crucially involved in the adaptive mechanism of cardiac hypertrophy and that p53 accumulation is essential for the transition from cardiac hypertrophy to heart failure.  Pressure overload initially promoted vascular growth in the heart by hypoxia-inducible factor-1 (Hif-1)-dependent induction of angiogenic factors, and inhibition of angiogenesis prevented the development of cardiac hypertrophy and induced systolic dysfunction.  Sustained pressure overload induced an accumulation of p53 that inhibited Hif-1 activity and thereby impaired cardiac angiogenesis and systolic function.  Conversely, promoting cardiac angiogenesis by introducing angiogenic factors or by inhibiting p53 accumulation developed hypertrophy further and restored cardiac dysfunction under chronic pressure overload.  These results indicate that the anti-angiogenic property of p53 may have a crucial function in the transition from cardiac hypertrophy to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8UHX9LdjcrVg90H21EOLACvtfcHk0lhM-3BCHDHfRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1WqsL8%253D&md5=81f9e1bada37ef80a463b3bddee5f6e1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature05602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05602%26sid%3Dliteratum%253Aachs%26aulast%3DSano%26aufirst%3DM.%26aulast%3DMinamino%26aufirst%3DT.%26aulast%3DToko%26aufirst%3DH.%26aulast%3DMiyauchi%26aufirst%3DH.%26aulast%3DOrimo%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DAkazawa%26aufirst%3DH.%26aulast%3DTateno%26aufirst%3DK.%26aulast%3DKayama%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DI.%26aulast%3DAsahara%26aufirst%3DT.%26aulast%3DHamada%26aufirst%3DH.%26aulast%3DTomita%26aufirst%3DS.%26aulast%3DMolkentin%26aufirst%3DJ.%2BD.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DKomuro%26aufirst%3DI.%26atitle%3Dp53-Induced%2520inhibition%2520of%2520Hif-1%2520causes%2520cardiac%2520dysfunction%2520during%2520pressure%2520overload%26jtitle%3DNature%26date%3D2007%26volume%3D446%26spage%3D444%26epage%3D448%26doi%3D10.1038%2Fnature05602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rosengren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosiborod, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawshani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivodic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudbjornsdottir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lind, M.</span><span> </span><span class="NLM_article-title">Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study</span> <span class="citation_source-journal">Lancet Diabetes Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1016/S2213-8587(15)00292-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2FS2213-8587%2815%2900292-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=26388415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A280%3ADC%252BC283ktVKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=876-885&author=A.+Rosengrenauthor=D.+Vestbergauthor=A.+M.+Svenssonauthor=M.+Kosiborodauthor=M.+Clementsauthor=A.+Rawshaniauthor=A.+Pivodicauthor=S.+Gudbjornsdottirauthor=M.+Lind&title=Long-term+excess+risk+of+heart+failure+in+people+with+type+1+diabetes%3A+a+prospective+case-control+study&doi=10.1016%2FS2213-8587%2815%2900292-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study</span></div><div class="casAuthors">Rosengren Annika; Vestberg Daniel; Lind Marcus; Svensson Ann-Marie; Kosiborod Mikhail; Clements Mark; Rawshani Araz; Pivodic Aldina; Gudbjornsdottir Soffia</div><div class="citationInfo"><span class="NLM_cas:title">The lancet. Diabetes & endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">876-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Diabetes is an established risk factor for heart failure, but because nearly all heart failure occurs in older individuals, the excess risk and risk factors for heart failure in individuals with type 1 diabetes are not known.  We aimed to determine the excess risk of heart failure in individuals with type 1 diabetes overall and by different levels of glycaemic control and albuminuria.  METHODS:  In this prospective case-control study, we identified all individuals with type 1 diabetes registered in the Swedish National Diabetes Registry between Jan 1, 1998, and Dec 31, 2011, and five controls randomly selected from the general population for each patient, matched according to age, sex, and county, and compared them with respect to subsequent hospital admissions for heart failure, with hazard ratios calculated with Cox regression.  FINDINGS:  In a cohort of 33 402 patients (mean age at baseline 35 years [SD 14], 15 058 [45%] women, and mean duration of diabetes 20·1 years [SD 14·5]), over a mean follow-up of 7·9 years, 1062 (3%) patients were admitted to hospital with a diagnosis of heart failure, compared with 1325 (1%) of 166 228 matched controls over 8·3 years, giving a HR 4·69 (95% CI 3·64-6·04), after adjustment for time-updated age, sex, time-updated diabetes duration, birth in Sweden, educational level, and baseline comorbidities.  Worse glycaemic control was associated with increased risk of heart failure in a graded fashion, and so was the presence of albuminuria.  Risk of heart failure was also increased among those with well controlled diabetes (adjusted HR 2·16 [95% CI 1·55-3·01]) and in those with no albuminuria (3·38 [2·51-4·57]), but not in the subgroup both well-controlled and with normoalbuminuria (1·59 [0·70-3·58]).  INTERPRETATION:  Individuals with type 1 diabetes had a four-times increase in the risk of being admitted to hospital with heart failure compared with population-based controls.  Poor glycaemic control and impaired renal function substantially increased the risk of heart failure.  FUNDING:  The Swedish state, Swedish Society for Physicians, the Health & Medical Care Committee of the Regional Executive Board (Region Vastra Gotaland, Sweden), the Swedish Heart-Lung Foundation, Diabetes Wellness, Novo Nordisk Foundation (PI M Lind), the Swedish Research Council, and the Swedish Council for working life and social research (Epilife).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgDrp-IV1H8f_I8Jvzw4xCfW6udTcc2eadqszkOFjwOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ktVKgug%253D%253D&md5=cdd5239fb0f9851257ccf972f77d0d2f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2815%2900292-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252815%252900292-2%26sid%3Dliteratum%253Aachs%26aulast%3DRosengren%26aufirst%3DA.%26aulast%3DVestberg%26aufirst%3DD.%26aulast%3DSvensson%26aufirst%3DA.%2BM.%26aulast%3DKosiborod%26aufirst%3DM.%26aulast%3DClements%26aufirst%3DM.%26aulast%3DRawshani%26aufirst%3DA.%26aulast%3DPivodic%26aufirst%3DA.%26aulast%3DGudbjornsdottir%26aufirst%3DS.%26aulast%3DLind%26aufirst%3DM.%26atitle%3DLong-term%2520excess%2520risk%2520of%2520heart%2520failure%2520in%2520people%2520with%2520type%25201%2520diabetes%253A%2520a%2520prospective%2520case-control%2520study%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2015%26volume%3D3%26spage%3D876%26epage%3D885%26doi%3D10.1016%2FS2213-8587%2815%2900292-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gilbert, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krum, H.</span><span> </span><span class="NLM_article-title">Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">2107</span><span class="NLM_x">–</span> <span class="NLM_lpage">2117</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61402-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2FS0140-6736%2814%2961402-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=2107-2117&author=R.+E.+Gilbertauthor=H.+Krum&title=Heart+failure+in+diabetes%3A+effects+of+anti-hyperglycaemic+drug+therapy&doi=10.1016%2FS0140-6736%2814%2961402-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961402-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961402-1%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DR.%2BE.%26aulast%3DKrum%26aufirst%3DH.%26atitle%3DHeart%2520failure%2520in%2520diabetes%253A%2520effects%2520of%2520anti-hyperglycaemic%2520drug%2520therapy%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D2107%26epage%3D2117%26doi%3D10.1016%2FS0140-6736%2814%2961402-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span>The Phase II Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study. <a href="https://www.clinicaltrials.gov/ct2/show/NCT02316821" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02316821</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Phase+II+Study+of+Bardoxolone+Methyl+in+Patients+with+Chronic+Kidney+Disease+and+Type+2+Diabetes%3B+TSUBAKI+Study.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02316821."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Phase%2520II%2520Study%2520of%2520Bardoxolone%2520Methyl%2520in%2520Patients%2520with%2520Chronic%2520Kidney%2520Disease%2520and%2520Type%25202%2520Diabetes%253B%2520TSUBAKI%2520Study" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Yore, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettenbach, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liby, K. T.</span><span> </span><span class="NLM_article-title">Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e22862</span><span class="refDoi"> DOI: 10.1371/journal.pone.0022862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1371%2Fjournal.pone.0022862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=21818401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e22862&author=M.+M.+Yoreauthor=A.+N.+Kettenbachauthor=M.+B.+Spornauthor=S.+A.+Gerberauthor=K.+T.+Liby&title=Proteomic+analysis+shows+synthetic+oleanane+triterpenoid+binds+to+mTOR&doi=10.1371%2Fjournal.pone.0022862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR</span></div><div class="casAuthors">Yore, Mark M.; Kettenbach, Arminja N.; Sporn, Michael B.; Gerber, Scott A.; Liby, Karen T.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e22862</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">New multifunctional drugs that target multiple disease-relevant networks offer a novel approach to the prevention and treatment of many diseases.  New synthetic oleanane triterpenoids (SO), such as CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) and its derivs., are multifunctional compds. originally developed for the prevention and treatment of inflammation and oxidative stress.  However, the protein binding partners and mechanisms of action of these SO are not yet fully understood.  Here we characterize the putative target profile of one SO, CDDO-Imidazolide (CDDO-Im), by combining affinity purifn. with mass spectroscopic proteomic anal. to identify 577 candidate binding proteins in whole cells.  This SO pharmaco-interactome consists of a diverse but interconnected set of signaling networks; bioinformatic anal. of the protein interactome identified canonical signaling pathways targeted by the SO, including retinoic acid receptor (RAR), estrogen receptor (ER), insulin receptor (IR), janus kinase/signal transducers and activators of transcription (JAK/STAT), and phosphatase and tensin homolog (PTEN).  Pull-down studies then further validated a subset of the putative targets.  In addn., we now show for the first time that the mammalian target of rapamycin (mTOR) is a direct target of CDDO-Im.  We also show that CDDO-Im blocks insulin-induced activation of this pathway by binding to mTOR and inhibiting its kinase activity.  Our basic studies confirm that the SO, CDDO-Im, acts on a protein network to elicit its pharmacol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xaGX_jtP5rVg90H21EOLACvtfcHk0lhroFUvjxkaUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbfI&md5=6a92c2cdd3bfa0720a8b80f0f48fd5e7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0022862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0022862%26sid%3Dliteratum%253Aachs%26aulast%3DYore%26aufirst%3DM.%2BM.%26aulast%3DKettenbach%26aufirst%3DA.%2BN.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DGerber%26aufirst%3DS.%2BA.%26aulast%3DLiby%26aufirst%3DK.%2BT.%26atitle%3DProteomic%2520analysis%2520shows%2520synthetic%2520oleanane%2520triterpenoid%2520binds%2520to%2520mTOR%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De22862%26doi%3D10.1371%2Fjournal.pone.0022862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Woods, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieberich, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavanja, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, D. A.</span><span> </span><span class="NLM_article-title">Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as F-19 NMR probes in deuterium-free environments</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7934</span><span class="NLM_x">–</span> <span class="NLM_lpage">7941</span><span class="refDoi"> DOI: 10.1021/jm201114t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201114t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7934-7941&author=J.+R.+Woodsauthor=H.+P.+Moauthor=A.+A.+Bieberichauthor=T.+Alavanjaauthor=D.+A.+Colby&title=Fluorinated+amino-derivatives+of+the+sesquiterpene+lactone%2C+parthenolide%2C+as+F-19+NMR+probes+in+deuterium-free+environments&doi=10.1021%2Fjm201114t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm201114t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201114t%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BR.%26aulast%3DMo%26aufirst%3DH.%2BP.%26aulast%3DBieberich%26aufirst%3DA.%2BA.%26aulast%3DAlavanja%26aufirst%3DT.%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DFluorinated%2520amino-derivatives%2520of%2520the%2520sesquiterpene%2520lactone%252C%2520parthenolide%252C%2520as%2520F-19%2520NMR%2520probes%2520in%2520deuterium-free%2520environments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7934%26epage%3D7941%26doi%3D10.1021%2Fjm201114t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Oakley, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoBello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caccuri, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federici, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M. W.</span><span> </span><span class="NLM_article-title">The three-dimensional structure of the human Pi class glutathione transferase P1–1 in complex with the inhibitor ethacrynic acid and its glutathione</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span><span class="refDoi"> DOI: 10.1021/bi962316i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi962316i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=576-585&author=A.+J.+Oakleyauthor=J.+Rossjohnauthor=M.+LoBelloauthor=A.+M.+Caccuriauthor=G.+Federiciauthor=M.+W.+Parker&title=The+three-dimensional+structure+of+the+human+Pi+class+glutathione+transferase+P1%E2%80%931+in+complex+with+the+inhibitor+ethacrynic+acid+and+its+glutathione&doi=10.1021%2Fbi962316i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi962316i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi962316i%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DA.%2BJ.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLoBello%26aufirst%3DM.%26aulast%3DCaccuri%26aufirst%3DA.%2BM.%26aulast%3DFederici%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DThe%2520three-dimensional%2520structure%2520of%2520the%2520human%2520Pi%2520class%2520glutathione%2520transferase%2520P1%25E2%2580%25931%2520in%2520complex%2520with%2520the%2520inhibitor%2520ethacrynic%2520acid%2520and%2520its%2520glutathione%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D576%26epage%3D585%26doi%3D10.1021%2Fbi962316i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frodin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span><span class="refDoi"> DOI: 10.1038/nchembio.925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Frodinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles&doi=10.1038%2Fnchembio.925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0ljW0I6ReK4etw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFrodin%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476%26doi%3D10.1038%2Fnchembio.925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Couch, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A. C.</span><span> </span><span class="NLM_article-title">Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2215</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.bmcl.2005.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=15837296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlWqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2215-2219&author=R.+D.+Couchauthor=R.+G.+Browningauthor=T.+Hondaauthor=G.+W.+Gribbleauthor=D.+L.+Wrightauthor=M.+B.+Spornauthor=A.+C.+Anderson&title=Studies+on+the+reactivity+of+CDDO%2C+a+promising+new+chemopreventive+and+chemotherapeutic+agent%3A+implications+for+a+molecular+mechanism+of+action&doi=10.1016%2Fj.bmcl.2005.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action</span></div><div class="casAuthors">Couch, Robin D.; Browning, R. Greg; Honda, Tadashi; Gribble, Gordon W.; Wright, Dennis L.; Sporn, Michael B.; Anderson, Amy C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2215-2219</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CDDO, a semi-synthetic triterpenoid derived from oleanolic acid, has the potential to be used as a chemopreventive and chemotherapeutic agent.  The structure of CDDO contains two α,β-unsatd. carbonyl moieties, suggesting a mechanism of action involving a conjugate nucleophilic addn.  Spectroscopic evaluation with thiol nucleophiles illustrates that an addn. does indeed occur, but this addn. is selective and reversible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSEly4KE1L3bVg90H21EOLACvtfcHk0ljW0I6ReK4etw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlWqs78%253D&md5=403474a7b33ce6f42e93ad3f9bbd84b0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DCouch%26aufirst%3DR.%2BD.%26aulast%3DBrowning%26aufirst%3DR.%2BG.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DGribble%26aufirst%3DG.%2BW.%26aulast%3DWright%26aufirst%3DD.%2BL.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DAnderson%26aufirst%3DA.%2BC.%26atitle%3DStudies%2520on%2520the%2520reactivity%2520of%2520CDDO%252C%2520a%2520promising%2520new%2520chemopreventive%2520and%2520chemotherapeutic%2520agent%253A%2520implications%2520for%2520a%2520molecular%2520mechanism%2520of%2520action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2215%26epage%3D2219%26doi%3D10.1016%2Fj.bmcl.2005.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Fleming, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tercek, F.</span><span> </span><span class="NLM_article-title">Unsaturated nitriles: conjugate addition-silylation with grignard reagents</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4883</span><span class="NLM_x">–</span> <span class="NLM_lpage">4885</span><span class="refDoi"> DOI: 10.1021/jo9705430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9705430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=4883-4885&author=F.+F.+Flemingauthor=Y.+F.+Puauthor=F.+Tercek&title=Unsaturated+nitriles%3A+conjugate+addition-silylation+with+grignard+reagents&doi=10.1021%2Fjo9705430"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo9705430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9705430%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DPu%26aufirst%3DY.%2BF.%26aulast%3DTercek%26aufirst%3DF.%26atitle%3DUnsaturated%2520nitriles%253A%2520conjugate%2520addition-silylation%2520with%2520grignard%2520reagents%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D4883%26epage%3D4885%26doi%3D10.1021%2Fjo9705430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Albert, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczuk, A.</span><span> </span><span class="NLM_article-title">Histochemical demonstration of gamma-glutamyl transpeptidase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1961</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1038/191767a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2F191767a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=1961&pages=767-768&author=Z.+Albertauthor=M.+Orlowskiauthor=A.+Szewczuk&title=Histochemical+demonstration+of+gamma-glutamyl+transpeptidase&doi=10.1038%2F191767a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F191767a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F191767a0%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DZ.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DSzewczuk%26aufirst%3DA.%26atitle%3DHistochemical%2520demonstration%2520of%2520gamma-glutamyl%2520transpeptidase%26jtitle%3DNature%26date%3D1961%26volume%3D191%26spage%3D767%26epage%3D768%26doi%3D10.1038%2F191767a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. E.</span><span> </span><span class="NLM_article-title">Human kidney gamma-glutamyl transpeptidase. Catalytic properties, subunit structure, and localization of the gamma-glutamyl binding site on the light subunit</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">252</span><span class="NLM_x">, </span> <span class="NLM_fpage">6042</span><span class="NLM_x">–</span> <span class="NLM_lpage">6045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1977&pages=6042-6045&author=S.+S.+Tateauthor=M.+E.+Ross&title=Human+kidney+gamma-glutamyl+transpeptidase.+Catalytic+properties%2C+subunit+structure%2C+and+localization+of+the+gamma-glutamyl+binding+site+on+the+light+subunit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTate%26aufirst%3DS.%2BS.%26aulast%3DRoss%26aufirst%3DM.%2BE.%26atitle%3DHuman%2520kidney%2520gamma-glutamyl%2520transpeptidase.%2520Catalytic%2520properties%252C%2520subunit%2520structure%252C%2520and%2520localization%2520of%2520the%2520gamma-glutamyl%2520binding%2520site%2520on%2520the%2520light%2520subunit%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1977%26volume%3D252%26spage%3D6042%26epage%3D6045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Worth, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span> </span><span class="NLM_article-title">gamma-L-Glutamyl-L-dopa is a dopamine pro-drug, relatively specific for the kidney in normal subjects</span> <span class="citation_source-journal">Clin. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span><span class="refDoi"> DOI: 10.1042/cs0690207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1042%2Fcs0690207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=3933890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaL2MXltFGqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1985&pages=207-214&author=D.+P.+Worthauthor=J.+N.+Harveyauthor=J.+Brownauthor=M.+R.+Lee&title=gamma-L-Glutamyl-L-dopa+is+a+dopamine+pro-drug%2C+relatively+specific+for+the+kidney+in+normal+subjects&doi=10.1042%2Fcs0690207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">γ-L-Glutamyl-L-dopa is a dopamine prodrug, relatively specific for the kidney in normal subjects</span></div><div class="casAuthors">Worth, D. P.; Harvey, J. N.; Brown, J.; Lee, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-14</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    </div><div class="casAbstract">γ-L-Glutamyl-L-dopa (I)  [52370-58-8] was given by i.v. infusion to normal subjects at doses of 12.5 and 100 μg/min/kg.  Both doses of I resulted in an increase in mean urinary Na+ excretion.  The mean effective renal plasma flow rose at both doses, but mean glomerular filtration rate increased only at the lower dose.  There was a fall in mean plasma renin  [9015-94-5] activity after infusion at both rates.  Mean urine free dopamine  [51-61-6] excretion increased by 280- and 2500-fold at infusion rates of 12.5 and 100 μg/min/kg, resp.  Mean plasma free dopamine rose at both doses but the increase at 12.5 μg/min/kg was not to a level previously assocd. with systemic effects of the catecholamine.  On administration of I at 12.5 μg/min/kg there were no changes in blood pressure or heart rate, but at the higher does there was a fall in diastolic blood pressure.  At a dose of 12.5 μg/min/kg in man, there is kidney-specific conversion of I to dopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7fgPKPPT2uLVg90H21EOLACvtfcHk0ljWTkFiwao7WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltFGqu7s%253D&md5=87b4e0982b8ae5f7bbe88e12a882c0f5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1042%2Fcs0690207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fcs0690207%26sid%3Dliteratum%253Aachs%26aulast%3DWorth%26aufirst%3DD.%2BP.%26aulast%3DHarvey%26aufirst%3DJ.%2BN.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26atitle%3Dgamma-L-Glutamyl-L-dopa%2520is%2520a%2520dopamine%2520pro-drug%252C%2520relatively%2520specific%2520for%2520the%2520kidney%2520in%2520normal%2520subjects%26jtitle%3DClin.%2520Sci.%26date%3D1985%26volume%3D69%26spage%3D207%26epage%3D214%26doi%3D10.1042%2Fcs0690207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milliken, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulczynska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slawin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkby, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botting, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megson, I. L.</span><span> </span><span class="NLM_article-title">Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5321</span><span class="NLM_x">–</span> <span class="NLM_lpage">5334</span><span class="refDoi"> DOI: 10.1021/jm400146r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400146r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5321-5334&author=Q.+Zhangauthor=P.+Millikenauthor=A.+Kulczynskaauthor=A.+M.+Slawinauthor=A.+Gordonauthor=N.+S.+Kirkbyauthor=D.+J.+Webbauthor=N.+P.+Bottingauthor=I.+L.+Megson&title=Development+and+characterization+of+glutamyl-protected+N-hydroxyguanidines+as+reno-active+nitric+oxide+donor+drugs+with+therapeutic+potential+in+acute+renal+failure&doi=10.1021%2Fjm400146r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm400146r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400146r%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMilliken%26aufirst%3DP.%26aulast%3DKulczynska%26aufirst%3DA.%26aulast%3DSlawin%26aufirst%3DA.%2BM.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DKirkby%26aufirst%3DN.%2BS.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DBotting%26aufirst%3DN.%2BP.%26aulast%3DMegson%26aufirst%3DI.%2BL.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520glutamyl-protected%2520N-hydroxyguanidines%2520as%2520reno-active%2520nitric%2520oxide%2520donor%2520drugs%2520with%2520therapeutic%2520potential%2520in%2520acute%2520renal%2520failure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5321%26epage%3D5334%26doi%3D10.1021%2Fjm400146r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Barthelmebs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caillette, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrhardt, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbs, J. L.</span><span> </span><span class="NLM_article-title">Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1414</span><span class="NLM_x">–</span> <span class="NLM_lpage">1422</span><span class="refDoi"> DOI: 10.1038/ki.1990.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fki.1990.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1972967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaK3cXkslSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1990&pages=1414-1422&author=M.+Barthelmebsauthor=A.+Cailletteauthor=J.+D.+Ehrhardtauthor=J.+Vellyauthor=J.+L.+Imbs&title=Metabolism+and+vascular+effects+of+gamma-L-glutamyl-L-dopa+on+the+isolated+rat+kidney&doi=10.1038%2Fki.1990.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney</span></div><div class="casAuthors">Barthelmebs, Mariette; Caillette, Agnes; Ehrhardt, Jean Daniel; Velly, Jeanne; Imbs, Jean Louis</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1414-22</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    </div><div class="casAbstract">Gamma-L-glutamyl-L-dopa (gludopa), a dopamine (DA) prodrug, is selectively metabolized in vivo by the kidney through the sequential action of two renal enzymes, gamma-glutamyl transpeptidase (gamma-GT) and arom. L-amino acid decarboxylase (AADC).  The factors regulating gludopa metab. and its renal vascular effects were studied in vitro.  Rat kidneys were perfused with a buffer contg. 6% bovine serum albumin (BSA).  Adding gludopa (final concn. 10-5 M in the perfusate) led to the release of DA both into urine and perfusate (0.53 and 1.38 nmol/min/g kidney wt., resp., during the first 5 min after substrate addn.).  Total DA release (urine plus perfusate) was 73.7 nmol/g kidney wt. within 30 min of recirculation.  In non-filtering kidneys, the total DA release in the recirculating medium was 12.5 nmol/g kidney wt.  Glomerular filtration and access to the gamma-GT on the brush border membrane of proximal tubular cells are required for the maximal conversion of gludopa.  On filtering kidneys, L-dopa was also converted to DA, but at a higher rate than gludopa (total DA formed within 30 min of recirculation = 131.2 nmol/g kidney wt.) and this rate was not reduced in non-filtering kidneys (224.2 nmol DA/g kidney wt. formed within 30 min).  Metabolic conversion of L-dopa by AADC is thus preserved in the case of an approach via the basolateral side of the proximal tubular cells.  The renal vascular effects of gludopa were studied after vascular tone had been restored by continuous perfusion of PGF2α and after the inhibition of alpha- and beta-adrenoceptors.  Gludopa (3·10-6 to 4·10-5 M) elicited concn.-dependent renal vasodilation.  At 4·10-5 M, the renal response was similar to that elicited by DA and L-dopa at concns. resp. 20- and 2-times lower.  These responses were abolished by the DA-1 receptor antagonist SCH 23390.  Inhibition of gamma-GT by AT-125 (10-6 M) reduced gludopa-induced renal vasodilatation, as did carbidopa (10-4 M), on the L-dopa-induced renal response.  Gludopa- and L-dopa-induced renal vasodilatations are directly linked to endorenal release of DA which interacts with vascular DA-1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_yt5__Og3I7Vg90H21EOLACvtfcHk0lgs-ffjTvikZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslSltb0%253D&md5=c6aadad02db6445c20141c4de78abd93</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fki.1990.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.1990.131%26sid%3Dliteratum%253Aachs%26aulast%3DBarthelmebs%26aufirst%3DM.%26aulast%3DCaillette%26aufirst%3DA.%26aulast%3DEhrhardt%26aufirst%3DJ.%2BD.%26aulast%3DVelly%26aufirst%3DJ.%26aulast%3DImbs%26aufirst%3DJ.%2BL.%26atitle%3DMetabolism%2520and%2520vascular%2520effects%2520of%2520gamma-L-glutamyl-L-dopa%2520on%2520the%2520isolated%2520rat%2520kidney%26jtitle%3DKidney%2520Int.%26date%3D1990%26volume%3D37%26spage%3D1414%26epage%3D1422%26doi%3D10.1038%2Fki.1990.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wilk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizoguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlowski, M.</span><span> </span><span class="NLM_article-title">gamma-Glutamyl dopa: a kidney-specific dopamine precursor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=660553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaE1cXlsVSnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=1978&pages=227-232&author=S.+Wilkauthor=H.+Mizoguchiauthor=M.+Orlowski&title=gamma-Glutamyl+dopa%3A+a+kidney-specific+dopamine+precursor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Glutamyl dopa:  a kidney-specific dopamine precursor</span></div><div class="casAuthors">Wilk, Sherwin; Mizoguchi, Haruko; Orlowski, Marian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">227-32</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">γ-Glutamyl dopa (I)  [52370-58-8] was synthesized both chem. and enzymatically.  Injection of this deriv. into mice led to a selective generation of dopamine  [51-61-6] in the kidney as a consequence of the sequential action of γ-glutamyl transpeptidase and arom. L-amino acid decarboxylase, 2 enzymes which are highly concd. in the kidney.  The concn. of dopamine in the kidney after I was almost 5 times higher than that after an equiv. dose of L-dopa.  Infusion of 10 nmol I/g/30 min to rats produced a 60% increase in renal plasma flow.  By contrast the same dose of L-dopa had no effect on renal plasma flow.  Only a small pressor effect was obsd. after the infusion dose of I was increased 20-fold, indicating that the systemic effects of this prodrug are slight.  Thus, the prodrug I can be used as a specific renal vasodilator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOyxYan2-L07Vg90H21EOLACvtfcHk0lgs-ffjTvikZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXlsVSnsb4%253D&md5=f9d5cb083dacf5f472fdf365f02701c3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilk%26aufirst%3DS.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DOrlowski%26aufirst%3DM.%26atitle%3Dgamma-Glutamyl%2520dopa%253A%2520a%2520kidney-specific%2520dopamine%2520precursor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1978%26volume%3D206%26spage%3D227%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Li Kam Wa, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freestone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span> </span><span class="NLM_article-title">Renal metabolism and effects of the glutamyl derivatives of L-dopa and 5-hydroxytryptophan in man</span> <span class="citation_source-journal">Clin. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1042/cs0910177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1042%2Fcs0910177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=8795441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADyaK28Xltlamsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1996&pages=177-185&author=T.+C.+Li+Kam+Waauthor=S.+Freestoneauthor=R.+R.+Samsonauthor=N.+R.+Johnstonauthor=M.+R.+Lee&title=Renal+metabolism+and+effects+of+the+glutamyl+derivatives+of+L-dopa+and+5-hydroxytryptophan+in+man&doi=10.1042%2Fcs0910177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Renal metabolism and effects of the glutamyl derivatives of L-dopa and 5-hydroxytryptophan in man</span></div><div class="casAuthors">Li Kam Wa, T. C.; Freestone, S.; Samson, R. R.; Johnston, N. R.; Lee, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-185</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    
            (<span class="NLM_cas:orgname">Portland Press</span>)
        </div><div class="casAbstract">Equimolar amts. of γ-L-glutamyl-L-3,4-dihydroxyphenylalanine (gludopa) and γ-L-glutamyl-5-hydroxy-L-tryptophan were infused sep. and together in eight healthy, salt-replete male subjects in a placebo-controlled, cross-over study to investigate whether the administration of one amine precursor affects the renal metab. of the other and to det. whether dopamine or 5-hydroxytryptamine would be generated preferentially.  The overall effect on sodium excretion was also measured when both precursors were administered simultaneously.  Administration of gludopa was assocd. with marked increases in the urinary excretion of L-dopa, dopamine and 3,4-dihydroxyphenylacetic acid, together with a rise in the urinary excretion of sodium.  γ-L-Glutamyl-5-hydroxy-L-tryptophan, produced marked increases in the urinary excretion of 5-hydroxy-L-tryptophan, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid, and this was accompanied by a slight, but non-significant, redn. in sodium excretion.  About 27% of the infused dose of gludopa (on a molar basis) was recovered in the urine as dopamine whereas 15% of the given dose of γ-L-glutamyl-5-hydroxy-L-tryptophan was excreted as 5-hydroxytryptamine.  The urinary excretion values of L-dopa, dopamine and 3,4-dihydroxyphenylacetic acid after the simultaneous infusion of gludopa and γ-L-glutamyl-5-hydroxy-L-tryptophan were not significantly different from those obsd. after infusion of gludopa only.  Similarly, the urinary excretion values of 5-hydroxy-L-tryptophan, 5-hydroxytryptamine and 5-hydroxy-indoleacetic acid during the co-infusion were similar to those measured after administration of γ-L-glutamyl-5-hydroxy-L-tryptophan only.  The net effect of the concomitant infusion of both glutamyl derivs. was an increase in urinary sodium excretion.  The authors' study in salt-replete individuals suggests that dopamine rather than 5-hydroxytryptamine was preferentially produced when equimolar amts. of their precursors were provided and that the natriuretic effect of dopamine, generated intrarenally from gludopa, was greater than the sodium retaining action of 5-hydroxytryptamine derived from γ-L-glutamyl-5-hydroxy-L-tryptophan.  Comparison of the urinary metabolite data after the sep. and concomitant infusion of the two glutamyl compds. provided no evidence of competitive inhibition of synthesis of either amine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn7Aez3H3jK7Vg90H21EOLACvtfcHk0liPXSc-ksLzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xltlamsr0%253D&md5=677471b4d08bcac85bf61fe9accb5729</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1042%2Fcs0910177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fcs0910177%26sid%3Dliteratum%253Aachs%26aulast%3DLi%2BKam%2BWa%26aufirst%3DT.%2BC.%26aulast%3DFreestone%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DR.%2BR.%26aulast%3DJohnston%26aufirst%3DN.%2BR.%26aulast%3DLee%26aufirst%3DM.%2BR.%26atitle%3DRenal%2520metabolism%2520and%2520effects%2520of%2520the%2520glutamyl%2520derivatives%2520of%2520L-dopa%2520and%25205-hydroxytryptophan%2520in%2520man%26jtitle%3DClin.%2520Sci.%26date%3D1996%26volume%3D91%26spage%3D177%26epage%3D185%26doi%3D10.1042%2Fcs0910177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Yasushi, Y.; Keiko, S.; Setsuko, N.</span><span> </span><span class="NLM_article-title">Novel glutamic acid derivative and use thereof</span>. W.O. Patent 2,015,178,265, November 26,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Yasushi&author=S.+Keiko&author=N.+Setsuko&title=Novel+glutamic+acid+derivative+and+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYasushi%26aufirst%3DY.%26atitle%3DNovel%2520glutamic%2520acid%2520derivative%2520and%2520use%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Tranoy-Opalinski, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papot, S.</span><span> </span><span class="NLM_article-title">Design of self-immolative linkers for tumour-activated prodrug therapy</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span><span class="refDoi"> DOI: 10.2174/187152008785133065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.2174%2F187152008785133065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18690826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ogsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=618-637&author=I.+Tranoy-Opalinskiauthor=A.+Fernandesauthor=M.+Thomasauthor=J.+P.+Gessonauthor=S.+Papot&title=Design+of+self-immolative+linkers+for+tumour-activated+prodrug+therapy&doi=10.2174%2F187152008785133065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design of self-immolative linkers for tumour-activated prodrug therapy</span></div><div class="casAuthors">Tranoy-Opalinski, I.; Fernandes, A.; Thomas, M.; Gesson, J.-P.; Papot, S.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">618-637</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The main drawback of most cancer chemotherapy is its relatively low ability to target tumor cells vs. normal cells.  As a consequence, chemotherapy is usually connected with severe side effects due to the toxicity of traditional cytostatic agents towards normal tissues.  A few years ago, the site-specific activation of nontoxic prodrugs in tumors has been proposed in order to enhance the selectivity for the killing of cancer cells.  Within this framework, most of the prodrugs that have been designed were three part compds. comprising trigger, linker and effector units.  The main function of the linker is to release the effector unit after selective trigger activation via a spontaneous chem. breakdown.  However, its structure also affects significantly many prodrug properties such as stability, pharmacokinetic, organ distribution, bioavailability or trigger activation.  This review, focussed on the linker unit, is an update of the previous article published in 2002.  It deals with recent advances in the design of prodrug linkers including new delivery systems such as elongated linkers or self-immolative dendrimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeb-2jcsWQx7Vg90H21EOLACvtfcHk0liPXSc-ksLzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ogsr8%253D&md5=c11a530c32537ef25c5789e0a8573d91</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2174%2F187152008785133065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152008785133065%26sid%3Dliteratum%253Aachs%26aulast%3DTranoy-Opalinski%26aufirst%3DI.%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DGesson%26aufirst%3DJ.%2BP.%26aulast%3DPapot%26aufirst%3DS.%26atitle%3DDesign%2520of%2520self-immolative%2520linkers%2520for%2520tumour-activated%2520prodrug%2520therapy%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D618%26epage%3D637%26doi%3D10.2174%2F187152008785133065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Dong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surana, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, R. B.</span><span> </span><span class="NLM_article-title">Solubilization and preformulation of poorly water soluble and hydrolysis susceptible N-epoxymethyl-1,8-naphthalimide (ENA) compound</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.ijpharm.2008.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=18282672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2008&pages=130-136&author=Y.+Dongauthor=W.+K.+Ngauthor=U.+Suranaauthor=R.+B.+Tan&title=Solubilization+and+preformulation+of+poorly+water+soluble+and+hydrolysis+susceptible+N-epoxymethyl-1%2C8-naphthalimide+%28ENA%29+compound&doi=10.1016%2Fj.ijpharm.2008.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Solubilization and preformulation of poorly water soluble and hydrolysis susceptible N-epoxymethyl-1,8-naphthalimide</span></div><div class="casAuthors">Dong, Yuancai; Ng, Wai Kiong; Surana, Uttam; Tan, Reginald B. H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">130-136</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-Epoxymethyl-1,8-naphthalimide (ENA) is a novel antiproliferative drug candidate with potent anticancer and antifungal activity.  It has an aq. soly. of 0.0116 mg/mL and also exhibits hydrolytic instability with a first-order hydrolysis rate of 0.051 h-1.  The present preformulation study aimed to characterize the physicochem. properties of ENA and develop an early injectable soln. formulation for preclin. studies.  To minimize hydrolysis, ENA is proposed to be formulated as either lyophilized powders or nonaq. solns. followed by solubilization/reconstitution prior to administration.  ENA solubilization was investigated in both aq. media (by cosolvency, micellization and complexation) and nonaq. solns. (mixt. of Cremophor EL and ethanol).  It is found that none of the solubilization techniques in aq. media could increase ENA soly. to a desired level of several hundreds μg/mL at pharmaceutically acceptable excipient concns. (≤10%).  In contrast, a combination of 70% Cremophor EL and 30% ethanol (vol./vol.) proved effective in solubilizing ENA at 4 mg/mL, which exhibited good phys. and chem. stability on storage at both 4° and room temp. over 4 mo.  No pptn. was obsd. upon 5-20 times diln. by the saline; in addn., less than 5% of ENA was hydrolyzed in 4 h for the saline-dild. aq. solns.  This nonaq. ENA formulation is thus proposed for further preclin. studies, which can be reconstituted, prior to administration, by the 5-20 times infusion fluids (saline, 5% dextrose, etc.) to the desired drug dosing concn. at the acceptable excipient level.  The approach used in this work could serve as a useful ref. in formulating nonpolar drugs with hydrolytic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYu7dPcI3t77Vg90H21EOLACvtfcHk0ljIO9FQf6uFNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFClurc%253D&md5=fa221971b1689f088b7b11246a3061b9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DW.%2BK.%26aulast%3DSurana%26aufirst%3DU.%26aulast%3DTan%26aufirst%3DR.%2BB.%26atitle%3DSolubilization%2520and%2520preformulation%2520of%2520poorly%2520water%2520soluble%2520and%2520hydrolysis%2520susceptible%2520N-epoxymethyl-1%252C8-naphthalimide%2520%2528ENA%2529%2520compound%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D356%26spage%3D130%26epage%3D136%26doi%3D10.1016%2Fj.ijpharm.2008.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Ahmad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharbanda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufe, D.</span><span> </span><span class="NLM_article-title">Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">35764</span><span class="NLM_x">–</span> <span class="NLM_lpage">35769</span><span class="refDoi"> DOI: 10.1074/jbc.M607160200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1074%2Fjbc.M607160200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=35764-35769&author=R.+Ahmadauthor=D.+Rainaauthor=C.+Meyerauthor=S.+Kharbandaauthor=D.+Kufe&title=Triterpenoid+CDDO-Me+blocks+the+NF-kappaB+pathway+by+direct+inhibition+of+IKKbeta+on+Cys-179&doi=10.1074%2Fjbc.M607160200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M607160200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M607160200%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DRaina%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DKufe%26aufirst%3DD.%26atitle%3DTriterpenoid%2520CDDO-Me%2520blocks%2520the%2520NF-kappaB%2520pathway%2520by%2520direct%2520inhibition%2520of%2520IKKbeta%2520on%2520Cys-179%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D35764%26epage%3D35769%26doi%3D10.1074%2Fjbc.M607160200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Sharma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, S. R.</span><span> </span><span class="NLM_article-title">Diabetic kidney disease in the db/db mouse</span> <span class="citation_source-journal">Am. J. Physiol. Renal Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">F1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">F1144</span><span class="refDoi"> DOI: 10.1152/ajprenal.00315.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1152%2Fajprenal.00315.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=12736165" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=F1138-F1144&author=K.+Sharmaauthor=P.+McCueauthor=S.+R.+Dunn&title=Diabetic+kidney+disease+in+the+db%2Fdb+mouse&doi=10.1152%2Fajprenal.00315.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00315.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00315.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DMcCue%26aufirst%3DP.%26aulast%3DDunn%26aufirst%3DS.%2BR.%26atitle%3DDiabetic%2520kidney%2520disease%2520in%2520the%2520db%252Fdb%2520mouse%26jtitle%3DAm.%2520J.%2520Physiol.%2520Renal%2520Physiol.%26date%3D2003%26volume%3D284%26spage%3DF1138%26epage%3DF1144%26doi%3D10.1152%2Fajprenal.00315.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Alpers, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, K. L.</span><span> </span><span class="NLM_article-title">Mouse models of diabetic nephropathy</span> <span class="citation_source-journal">Curr. Opin. Nephrol. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1097/MNH.0b013e3283451901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1097%2FMNH.0b013e3283451901" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=278-284&author=C.+E.+Alpersauthor=K.+L.+Hudkins&title=Mouse+models+of+diabetic+nephropathy&doi=10.1097%2FMNH.0b013e3283451901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1097%2FMNH.0b013e3283451901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMNH.0b013e3283451901%26sid%3Dliteratum%253Aachs%26aulast%3DAlpers%26aufirst%3DC.%2BE.%26aulast%3DHudkins%26aufirst%3DK.%2BL.%26atitle%3DMouse%2520models%2520of%2520diabetic%2520nephropathy%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2011%26volume%3D20%26spage%3D278%26epage%3D284%26doi%3D10.1097%2FMNH.0b013e3283451901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Sporn, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liby, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yore, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopchuk, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, G. W.</span><span> </span><span class="NLM_article-title">New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1021/np100826q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np100826q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVWisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=537-545&author=M.+B.+Spornauthor=K.+T.+Libyauthor=M.+M.+Yoreauthor=L.+Fuauthor=J.+M.+Lopchukauthor=G.+W.+Gribble&title=New+synthetic+triterpenoids%3A+potent+agents+for+prevention+and+treatment+of+tissue+injury+caused+by+inflammatory+and+oxidative+stress&doi=10.1021%2Fnp100826q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress</span></div><div class="casAuthors">Sporn, Michael B.; Liby, Karen T.; Yore, Mark M.; Fu, Liangfeng; Lopchuk, Justin M.; Gribble, Gordon W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">We review the original rational for the development and the chem. of a series of new synthetic oleanane triterpenoids (SO), based on oleanolic acid (I) as a starting material.  Many of the new compds. that have been made, such as 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ["CDDO", (II; R = H)], are highly potent (activities found at levels below 1 nM) anti-inflammatory agents, as measured by their ability to block the cellular synthesis of the enzyme inducible nitric oxide synthase (iNOS) in activated macrophages.  Details of the org. synthesis of new SO and their chem. mechanisms of biol. activity are reviewed, as is formation of biotin conjugates for investigation of protein targets.  Finally, we give a brief summary of important biol. activities of SO in many organ systems in numerous animal models.  Clin. investigation of a new SO [Me 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate, "CDDO-Me", bardoxolone Me, (II; R = Me)] is currently in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWMDf2Fxc3LVg90H21EOLACvtfcHk0liY9-ZL6ZaBaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVWisrg%253D&md5=a6b2efe5faaba6151472b0f5f654940e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fnp100826q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp100826q%26sid%3Dliteratum%253Aachs%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DLiby%26aufirst%3DK.%2BT.%26aulast%3DYore%26aufirst%3DM.%2BM.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLopchuk%26aufirst%3DJ.%2BM.%26aulast%3DGribble%26aufirst%3DG.%2BW.%26atitle%3DNew%2520synthetic%2520triterpenoids%253A%2520potent%2520agents%2520for%2520prevention%2520and%2520treatment%2520of%2520tissue%2520injury%2520caused%2520by%2520inflammatory%2520and%2520oxidative%2520stress%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2011%26volume%3D74%26spage%3D537%26epage%3D545%26doi%3D10.1021%2Fnp100826q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2452</span><span class="NLM_x">–</span> <span class="NLM_lpage">2464</span><span class="refDoi"> DOI: 10.1021/jm5019302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2452-2464&author=Y.+Aiauthor=F.+Kangauthor=Z.+Huangauthor=X.+Xueauthor=Y.+Laiauthor=S.+Pengauthor=J.+Tianauthor=Y.+Zhang&title=Synthesis+of+CDDO-amino+acid-nitric+oxide+donor+trihybrids+as+potential+antitumor+agents+against+both+drug-sensitive+and+drug-resistant+colon+cancer&doi=10.1021%2Fjm5019302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm5019302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019302%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520CDDO-amino%2520acid-nitric%2520oxide%2520donor%2520trihybrids%2520as%2520potential%2520antitumor%2520agents%2520against%2520both%2520drug-sensitive%2520and%2520drug-resistant%2520colon%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2452%26epage%3D2464%26doi%3D10.1021%2Fjm5019302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Fermini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossa, A. A.</span><span> </span><span class="NLM_article-title">The impact of drug-induced qt interval prolongation on drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1038/nrd1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fnrd1108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=439-447&author=B.+Ferminiauthor=A.+A.+Fossa&title=The+impact+of+drug-induced+qt+interval+prolongation+on+drug+discovery+and+development&doi=10.1038%2Fnrd1108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrd1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1108%26sid%3Dliteratum%253Aachs%26aulast%3DFermini%26aufirst%3DB.%26aulast%3DFossa%26aufirst%3DA.%2BA.%26atitle%3DThe%2520impact%2520of%2520drug-induced%2520qt%2520interval%2520prolongation%2520on%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fnrd1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Nogueira, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souto, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho-Braga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, D.</span><span> </span><span class="NLM_article-title">Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease</span> <span class="citation_source-journal">Horm-Int. J. Endocrino.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.14310/horm.2002.1436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.14310%2Fhorm.2002.1436" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=483-494&author=C.+Nogueiraauthor=S.+B.+Soutoauthor=E.+Vinhaauthor=D.+Carvalho-Bragaauthor=D.+Carvalho&title=Oral+glucose+lowering+drugs+in+type+2+diabetic+patients+with+chronic+kidney+disease&doi=10.14310%2Fhorm.2002.1436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.14310%2Fhorm.2002.1436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14310%252Fhorm.2002.1436%26sid%3Dliteratum%253Aachs%26aulast%3DNogueira%26aufirst%3DC.%26aulast%3DSouto%26aufirst%3DS.%2BB.%26aulast%3DVinha%26aufirst%3DE.%26aulast%3DCarvalho-Braga%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DD.%26atitle%3DOral%2520glucose%2520lowering%2520drugs%2520in%2520type%25202%2520diabetic%2520patients%2520with%2520chronic%2520kidney%2520disease%26jtitle%3DHorm-Int.%2520J.%2520Endocrino.%26date%3D2013%26volume%3D12%26spage%3D483%26epage%3D494%26doi%3D10.14310%2Fhorm.2002.1436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Klahr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caggiula, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsicker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusek, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Striker, G.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The effects of dietary-protein restriction and blood-pressure control on the progression of chronic renal-disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">877</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span><span class="refDoi"> DOI: 10.1056/NEJM199403313301301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJM199403313301301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=8114857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A280%3ADyaK2c7lvFSisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1994&pages=877-884&author=S.+Klahrauthor=A.+S.+Leveyauthor=G.+J.+Beckauthor=A.+W.+Caggiulaauthor=L.+Hunsickerauthor=J.+W.+Kusekauthor=G.+Striker&title=The+effects+of+dietary-protein+restriction+and+blood-pressure+control+on+the+progression+of+chronic+renal-disease&doi=10.1056%2FNEJM199403313301301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group</span></div><div class="casAuthors">Klahr S; Levey A S; Beck G J; Caggiula A W; Hunsicker L; Kusek J W; Striker G</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">877-84</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Restricting protein intake and controlling hypertension delay the progression of renal disease in animals.  We tested these interventions in 840 patients with various chronic renal diseases.  METHODS:  In study 1, 585 patients with glomerular filtration rates of 25 to 55 ml per minute per 1.73 m2 of body-surface area were randomly assigned to a usual-protein diet or a low-protein diet (1.3 or 0.58 g of protein per kilogram of body weight per day) and to a usual- or a low-blood-pressure group (mean arterial pressure, 107 or 92 mm Hg).  In study 2, 255 patients with glomerular filtration rates of 13 to 24 ml per minute per 1.73 m2 were randomly assigned to the low-protein diet (0.58 g per kilogram per day) or a very-low-protein diet (0.28 g per kilogram per day) with a keto acid-amino acid supplement, and a usual- or a low-blood-pressure group (same values as those in study 1).  An 18-to-45-month follow-up was planned, with monthly evaluations of the patients.  RESULTS:  The mean follow-up was 2.2 years.  In study 1, the projected mean decline in the glomerular filtration rate at three years did not differ significantly between the diet groups or between the blood-pressure groups.  As compared with the usual-protein group and the usual-blood-pressure group, the low-protein group and the low-blood-pressure group had a more rapid decline in the glomerular filtration rate during the first four months after randomization and a slower decline thereafter.  In study 2, the very-low-protein group had a marginally slower decline in the glomerular filtration rate than did the low-protein group (P = 0.07).  There was no delay in the time to the occurrence of end-stage renal disease or death.  In both studies, patients in the low-blood-pressure group who had more pronounced proteinuria at base line had a significantly slower rate of decline in the glomerular filtration rate.  CONCLUSIONS:  Among patients with moderate renal insufficiency, the slower decline in renal function that started four months after the introduction of a low-protein diet suggests a small benefit of this dietary intervention.  Among patients with more severe renal insufficiency, a very-low-protein diet, as compared with a low-protein diet, did not significantly slow the progression of renal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBn-_i3rXoj3qj_yg7twvpfW6udTcc2eb6V5AcQ1Vsrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7lvFSisg%253D%253D&md5=aec46f8160446b4fe98810b34260db13</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1056%2FNEJM199403313301301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199403313301301%26sid%3Dliteratum%253Aachs%26aulast%3DKlahr%26aufirst%3DS.%26aulast%3DLevey%26aufirst%3DA.%2BS.%26aulast%3DBeck%26aufirst%3DG.%2BJ.%26aulast%3DCaggiula%26aufirst%3DA.%2BW.%26aulast%3DHunsicker%26aufirst%3DL.%26aulast%3DKusek%26aufirst%3DJ.%2BW.%26aulast%3DStriker%26aufirst%3DG.%26atitle%3DThe%2520effects%2520of%2520dietary-protein%2520restriction%2520and%2520blood-pressure%2520control%2520on%2520the%2520progression%2520of%2520chronic%2520renal-disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1994%26volume%3D330%26spage%3D877%26epage%3D884%26doi%3D10.1056%2FNEJM199403313301301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdmann, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckardt, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyzi, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanovich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kewalramani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levey, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parfrey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parving, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R.</span><span> </span><span class="NLM_article-title">A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">2019</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1056/NEJMoa0907845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa0907845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=19880844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A280%3ADC%252BD1MjmslSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=2019-2032&author=M.+A.+Pfefferauthor=E.+A.+Burdmannauthor=C.+Y.+Chenauthor=M.+E.+Cooperauthor=D.+de+Zeeuwauthor=K.+U.+Eckardtauthor=J.+M.+Feyziauthor=P.+Ivanovichauthor=R.+Kewalramaniauthor=A.+S.+Leveyauthor=E.+F.+Lewisauthor=J.+B.+McGillauthor=J.+J.+V.+McMurrayauthor=P.+Parfreyauthor=H.+H.+Parvingauthor=G.+Remuzziauthor=A.+K.+Singhauthor=S.+D.+Solomonauthor=R.+Toto&title=A+trial+of+darbepoetin+alfa+in+type+2+diabetes+and+chronic+kidney+disease&doi=10.1056%2FNEJMoa0907845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease</span></div><div class="casAuthors">Pfeffer Marc A; Burdmann Emmanuel A; Chen Chao-Yin; Cooper Mark E; de Zeeuw Dick; Eckardt Kai-Uwe; Feyzi Jan M; Ivanovich Peter; Kewalramani Reshma; Levey Andrew S; Lewis Eldrin F; McGill Janet B; McMurray John J V; Parfrey Patrick; Parving Hans-Henrik; Remuzzi Giuseppe; Singh Ajay K; Solomon Scott D; Toto Robert</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2019-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease.  Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested.  METHODS:  In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter.  The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease.  RESULTS:  Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17; P=0.41).  Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (hazard ratio, 1.06; 95% CI, 0.95 to 1.19; P=0.29).  Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68; P<0.001).  Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo (P<0.001).  There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group.  CONCLUSIONS:  The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke.  For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQNrRccr0OgNthSDZx9hyjKfW6udTcc2eb6V5AcQ1Vsrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjmslSltw%253D%253D&md5=904a3c1f4ae9a82d4476c9d3a1753a8b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0907845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0907845%26sid%3Dliteratum%253Aachs%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DBurdmann%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DEckardt%26aufirst%3DK.%2BU.%26aulast%3DFeyzi%26aufirst%3DJ.%2BM.%26aulast%3DIvanovich%26aufirst%3DP.%26aulast%3DKewalramani%26aufirst%3DR.%26aulast%3DLevey%26aufirst%3DA.%2BS.%26aulast%3DLewis%26aufirst%3DE.%2BF.%26aulast%3DMcGill%26aufirst%3DJ.%2BB.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DParfrey%26aufirst%3DP.%26aulast%3DParving%26aufirst%3DH.%2BH.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DToto%26aufirst%3DR.%26atitle%3DA%2520trial%2520of%2520darbepoetin%2520alfa%2520in%2520type%25202%2520diabetes%2520and%2520chronic%2520kidney%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D2019%26epage%3D2032%26doi%3D10.1056%2FNEJMoa0907845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Mann, J. F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamerson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruilope, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuranoff, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viberti, G.</span><span> </span><span class="NLM_article-title">Avosentan for overt diabetic nephropathy</span> <span class="citation_source-journal">J. Am. Soc. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">535</span><span class="refDoi"> DOI: 10.1681/ASN.2009060593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1681%2FASN.2009060593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=20167702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFClu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=527-535&author=J.+F.+E.+Mannauthor=D.+Greenauthor=K.+Jamersonauthor=L.+M.+Ruilopeauthor=S.+J.+Kuranoffauthor=T.+Littkeauthor=G.+Viberti&title=Avosentan+for+overt+diabetic+nephropathy&doi=10.1681%2FASN.2009060593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Avosentan for overt diabetic nephropathy</span></div><div class="casAuthors">Mann, Johannes F. E.; Green, Damian; Jamerson, Kenneth; Ruilope, Luis M.; Kuranoff, Susan J.; Littke, Thomas; Viberti, Giancarlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-535</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">In the short term, the endothelin antagonist avosentan reduces proteinuria, but whether this translates to protection from progressive loss of renal function is unknown.  We examd. the effects of avosentan on progression of overt diabetic nephropathy in a multicenter, multinational, double-blind, placebo-controlled trial.  We randomly assigned 1392 participants with type 2 diabetes to oral avosentan (25 or 50 mg) or placebo in addn. to continued angiotensin-converting enzyme inhibition and/or angiotensin receptor blockade.  The composite primary outcome was the time to doubling of serum creatinine, ESRD, or death.  Secondary outcomes included changes in albumin-to-creatinine ratio (ACR) and cardiovascular outcomes.  We terminated the trial prematurely after a median follow-up of 4 mo (max. 16 mo) because of an excess of cardiovascular events with avosentan.  We did not detect a difference in the frequency of the primary outcome between groups.  Avosentan significantly reduced ACR: In patients who were treated with avosentan 25 mg/d, 50 mg/d, and placebo, the median redn. in ACR was 44.3, 49.3, and 9.7%, resp.  Adverse events led to discontinuation of trial medication significantly more often for avosentan than for placebo (19.6 and 18.2 vs. 11.5% for placebo), dominated by fluid overload and congestive heart failure; death occurred in 21 (4.6%; P = 0.225), 17 (3.6%; P = 0.194), and 12 (2.6%), resp.  In conclusion, avosentan reduces albuminuria when added to std. treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDkVksju9Z7Vg90H21EOLACvtfcHk0li67tznoO9Utw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFClu7k%253D&md5=65f0963d275019e74b10e0d59e259808</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1681%2FASN.2009060593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2009060593%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DJ.%2BF.%2BE.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DJamerson%26aufirst%3DK.%26aulast%3DRuilope%26aufirst%3DL.%2BM.%26aulast%3DKuranoff%26aufirst%3DS.%2BJ.%26aulast%3DLittke%26aufirst%3DT.%26aulast%3DViberti%26aufirst%3DG.%26atitle%3DAvosentan%2520for%2520overt%2520diabetic%2520nephropathy%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2010%26volume%3D21%26spage%3D527%26epage%3D535%26doi%3D10.1681%2FASN.2009060593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Parving, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolaides, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span> </span><span class="NLM_article-title">Cardiorenal end points in a trial of aliskiren for type 2 diabetes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2204</span><span class="NLM_x">–</span> <span class="NLM_lpage">2213</span><span class="refDoi"> DOI: 10.1056/NEJMoa1208799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1056%2FNEJMoa1208799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=23121378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVakt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2204-2213&author=H.+H.+Parvingauthor=B.+M.+Brennerauthor=J.+J.+McMurrayauthor=D.+de+Zeeuwauthor=S.+M.+Haffnerauthor=S.+D.+Solomonauthor=N.+Chaturvediauthor=F.+Perssonauthor=A.+S.+Desaiauthor=M.+Nicolaidesauthor=A.+Richardauthor=Z.+Xiangauthor=P.+Brunelauthor=M.+A.+Pfeffer&title=Cardiorenal+end+points+in+a+trial+of+aliskiren+for+type+2+diabetes&doi=10.1056%2FNEJMoa1208799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiorenal end points in a trial of aliskiren for type 2 diabetes</span></div><div class="casAuthors">Parving, Hans-Henrik; Brenner, Barry M.; McMurray, John J. V.; de Zeeuw, Dick; Haffner, Steven M.; Solomon, Scott D.; Chaturvedi, Nish; Persson, Frederik; Desai, Akshay S.; Nicolaides, Maria; Richard, Alexia; Xiang, Zhihua; Brunel, Patrick; Pfeffer, Marc A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2204-2213</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">This study was undertaken to det. whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.  In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker.  The primary end point was a composite of the time to cardiovascular death or a 1st occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline blood serum creatinine level.  The trial was stopped prematurely after the 2nd interim efficacy anal.  After a median follow-up of 32.9 mo, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20).  Effects on 2ndary renal end points were similar.  Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, resp.) and the mean redn. in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17).  The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per L) was significantly higher in the aliskiren group than in the placebo group (11.2 vs. 7.2%), as was the proportion with reported hypotension (12.1 vs. 8.3%).  The addn. of aliskiren to std. therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXET5pl999drVg90H21EOLACvtfcHk0li67tznoO9Utw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVakt73F&md5=16882cb81d7f60e93f44b3cad9deca0b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1208799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1208799%26sid%3Dliteratum%253Aachs%26aulast%3DParving%26aufirst%3DH.%2BH.%26aulast%3DBrenner%26aufirst%3DB.%2BM.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DHaffner%26aufirst%3DS.%2BM.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DChaturvedi%26aufirst%3DN.%26aulast%3DPersson%26aufirst%3DF.%26aulast%3DDesai%26aufirst%3DA.%2BS.%26aulast%3DNicolaides%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DBrunel%26aufirst%3DP.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26atitle%3DCardiorenal%2520end%2520points%2520in%2520a%2520trial%2520of%2520aliskiren%2520for%2520type%25202%2520diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2204%26epage%3D2213%26doi%3D10.1056%2FNEJMoa1208799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Thomas, M. C.</span><span> </span><span class="NLM_article-title">Emerging drugs for managing kidney disease in patients with diabetes</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1517/14728214.2013.762356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1517%2F14728214.2013.762356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=23330907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=55-70&author=M.+C.+Thomas&title=Emerging+drugs+for+managing+kidney+disease+in+patients+with+diabetes&doi=10.1517%2F14728214.2013.762356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for managing kidney disease in patients with diabetes</span></div><div class="casAuthors">Thomas, Merlin C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-70</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The need for new approaches to manage the increasing nos. of patients with diabetes and their burden of complications is urgent.  Of these, chronic kidney disease imposes some of the highest costs, both in dollars and in terms of human suffering.  In individuals with diabetes, the presence and severity of kidney disease adversely affects their well-being, contributes to disease morbidity and increases their risk of a premature death.Areas covered: To collect information for the strategies previously or currently under investigation for managing kidney disease in patients with diabetes, a literature search was performed through the search engines PubMed and ClinicalTrials.gov.Expert opinion: Despite advancing knowledge on the pathogenesis of diabetic kidney disease, and promising effects in exptl. models, at present there are no new drugs that come close to providing the solns. we desire for our patients.  Even when used in combination with std. care, renal complications are at best only modestly reduced, at the considerable expense of addnl. pill burden and exposure to serious off-target effects.  Some of the most exciting advances over the last decade, including thiazolidinediones, direct renin inhibitors, endothelin antagonists and most recently bardoxolone Me have all fallen at this last hurdle.  Better targeted ( smarter') drugs appear to be the best hope for renoprotective therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokZWmPIkMpALVg90H21EOLACvtfcHk0lh0-0b8LvFXAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKktbY%253D&md5=4c2caa89f6672ce3c2bce7162ef2a1ed</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1517%2F14728214.2013.762356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2013.762356%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BC.%26atitle%3DEmerging%2520drugs%2520for%2520managing%2520kidney%2520disease%2520in%2520patients%2520with%2520diabetes%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2013%26volume%3D18%26spage%3D55%26epage%3D70%26doi%3D10.1517%2F14728214.2013.762356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Ai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel olean-28,13beta-lactams as potential antiprostate cancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4506</span><span class="NLM_x">–</span> <span class="NLM_lpage">4520</span><span class="refDoi"> DOI: 10.1021/jm5020023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5020023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4506-4520&author=Y.+Aiauthor=Y.+Huauthor=F.+Kangauthor=Y.+Laiauthor=Y.+Jiaauthor=Z.+Huangauthor=S.+Pengauthor=H.+Jiauthor=J.+Tianauthor=Y.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+olean-28%2C13beta-lactams+as+potential+antiprostate+cancer+agents&doi=10.1021%2Fjm5020023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Novel Olean-28,13β-lactams as Potential Antiprostate Cancer Agents</span></div><div class="casAuthors">Ai, Yong; Hu, Yang; Kang, Fenghua; Lai, Yisheng; Jia, Yanju; Huang, Zhangjian; Peng, Sixun; Ji, Hui; Tian, Jide; Zhang, Yihua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4506-4520</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">γ-Lactam is an important structural motif in a large no. of biol. active natural products and synthetic small pharmaceutical mols.  However, there is currently no effective approach to construct γ-lactam ring directly from natural rigid polycyclic amides.  Herein, we report a facile methodol. for synthesis of a new group of olean-28,13β-lactams from their corresponding amides, promoted by an easily available reagent 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), through an intramol. dehydrogenative C-N coupling reaction via a radical ion mechanism.  Biol. evaluation indicated that the most active lactam I displayed potent antiproliferative activity against human cancer cells but 13.84- to 16.92-fold less inhibitory activity on noncancer cells in vitro.  In addn., I significantly inhibited the growth of implanted prostate cancer in vivo.  Furthermore, I induced cell cycle arrest and apoptosis and down-regulated the AKT/mTOR signaling in DU-145 cells.  Finally, I was more stable in rat plasma and human liver microsomes than CDDO-Me and had little hERG channel inhibitory activity.  Collectively, I may be a potential antiprostate cancer agent for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFMGyzOutkVrVg90H21EOLACvtfcHk0lh0-0b8LvFXAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVSntrc%253D&md5=2ba7a93f8fdec6be8156d01922f85338</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm5020023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5020023%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520olean-28%252C13beta-lactams%2520as%2520potential%2520antiprostate%2520cancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4506%26epage%3D4520%26doi%3D10.1021%2Fjm5020023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span> </span><span class="NLM_article-title">The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1016/j.intimp.2015.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.intimp.2015.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=25614226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ohsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=55-64&author=T.+Chenauthor=Y.+Mouauthor=J.+Tanauthor=L.+Weiauthor=Y.+Qiaoauthor=T.+Weiauthor=P.+Xiangauthor=S.+Pengauthor=Y.+Zhangauthor=Z.+Huangauthor=H.+Ji&title=The+protective+effect+of+CDDO-Me+on+lipopolysaccharide-induced+acute+lung+injury+in+mice&doi=10.1016%2Fj.intimp.2015.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice</span></div><div class="casAuthors">Chen, Tong; Mou, Yi; Tan, Jiani; Wei, Linlin; Qiao, Yixue; Wei, Tingting; Xiang, Pengjun; Peng, Sixun; Zhang, Yihua; Huang, Zhangjian; Ji, Hui</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-64</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CDDO-Me, initiated in a phase II clin. trial, is a potential useful therapeutic agent for cancer and inflammatory dysfunctions, whereas the therapeutic efficacy of CDDO-Me on LPS-induced acute lung injury (ALI) has not been reported as yet.  The purpose of the present study was to explore the protective effect of CDDO-Me on LPS-induced ALI in mice and to investigate its possible mechanism.  BalB/c mice received CDDO-Me (0.5 mg/kg, 2 mg/kg) or dexamethasone (5 mg/kg) i.p. 1 h before LPS stimulation and were sacrificed 6 h later.  W/D ratio, lung MPO activity, no. of total cells and neutrophils, pulmonary histopathol., IL-6, IL-1β, and TNF-α in the BALF were assessed.  Furthermore, we estd. iNOS, IL-6, IL-1β, and TNF-α mRNA expression and NO prodn. as well as the activation of the three main MAPKs, AkT, IκB-α and p65.  Pretreatment with CDDO-Me significantly ameliorated W/D ratio, lung MPO activity, inflammatory cell infiltration, and inflammatory cytokine prodn. in BALF from the in vivo study.  Addnl., CDDO-Me had beneficial effects on the intervention for pathogenesis process at mol., protein and transcriptional levels in vitro.  These anal. results provided evidence that CDDO-Me could be a potential therapeutic candidate for treating LPS-induced ALI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjLNCxbpkw7LVg90H21EOLACvtfcHk0lhDZgEUzFZTtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ohsbo%253D&md5=06625d74528d5c4fe5d3733edcd8c5d9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2015.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2015.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DMou%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DP.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DJi%26aufirst%3DH.%26atitle%3DThe%2520protective%2520effect%2520of%2520CDDO-Me%2520on%2520lipopolysaccharide-induced%2520acute%2520lung%2520injury%2520in%2520mice%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2015%26volume%3D25%26spage%3D55%26epage%3D64%26doi%3D10.1016%2Fj.intimp.2015.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Petronelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannitteri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, U.</span><span> </span><span class="NLM_article-title">Triterpenoids as new promising anticancer drugs</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e328330fd90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1097%2FCAD.0b013e328330fd90" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=880-892&author=A.+Petronelliauthor=G.+Pannitteriauthor=U.+Testa&title=Triterpenoids+as+new+promising+anticancer+drugs&doi=10.1097%2FCAD.0b013e328330fd90"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e328330fd90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e328330fd90%26sid%3Dliteratum%253Aachs%26aulast%3DPetronelli%26aufirst%3DA.%26aulast%3DPannitteri%26aufirst%3DG.%26aulast%3DTesta%26aufirst%3DU.%26atitle%3DTriterpenoids%2520as%2520new%2520promising%2520anticancer%2520drugs%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2009%26volume%3D20%26spage%3D880%26epage%3D892%26doi%3D10.1097%2FCAD.0b013e328330fd90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Liby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royce, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risingsong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yore, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dmitrovsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sporn, M. B.</span><span> </span><span class="NLM_article-title">The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2414</span><span class="NLM_x">–</span> <span class="NLM_lpage">2419</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1158%2F0008-5472.CAN-06-4534" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2414-2419&author=K.+Libyauthor=D.+B.+Royceauthor=C.+R.+Williamsauthor=R.+Risingsongauthor=M.+M.+Yoreauthor=T.+Hondaauthor=G.+W.+Gribbleauthor=E.+Dmitrovskyauthor=T.+A.+Spornauthor=M.+B.+Sporn&title=The+synthetic+triterpenoids+CDDO-methyl+ester+and+CDDO-ethyl+amide+prevent+lung+cancer+induced+by+vinyl+carbamate+in+A%2FJ+mice&doi=10.1158%2F0008-5472.CAN-06-4534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4534%26sid%3Dliteratum%253Aachs%26aulast%3DLiby%26aufirst%3DK.%26aulast%3DRoyce%26aufirst%3DD.%2BB.%26aulast%3DWilliams%26aufirst%3DC.%2BR.%26aulast%3DRisingsong%26aufirst%3DR.%26aulast%3DYore%26aufirst%3DM.%2BM.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DGribble%26aufirst%3DG.%2BW.%26aulast%3DDmitrovsky%26aufirst%3DE.%26aulast%3DSporn%26aufirst%3DT.%2BA.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26atitle%3DThe%2520synthetic%2520triterpenoids%2520CDDO-methyl%2520ester%2520and%2520CDDO-ethyl%2520amide%2520prevent%2520lung%2520cancer%2520induced%2520by%2520vinyl%2520carbamate%2520in%2520A%252FJ%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D2414%26epage%3D2419%26doi%3D10.1158%2F0008-5472.CAN-06-4534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span> </span><span class="NLM_article-title">Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">19278</span><span class="NLM_x">–</span> <span class="NLM_lpage">19281</span><span class="refDoi"> DOI: 10.1021/ja2073824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja2073824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=19278-19281&author=Y.+Kuangauthor=K.+Balakrishnanauthor=V.+Gandhiauthor=X.+Peng&title=Hydrogen+peroxide+inducible+DNA+cross-linking+agents%3A+targeted+anticancer+prodrugs&doi=10.1021%2Fja2073824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs</span></div><div class="casAuthors">Kuang, Yunyan; Balakrishnan, Kumudha; Gandhi, Varsha; Peng, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">19278-19281</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The major concern for anticancer chemotherapeutic agents is the host toxicity.  The development of anticancer prodrugs targeting the unique biochem. alterations in cancer cells is an attractive approach to achieve therapeutic activity and selectivity.  We designed and synthesized a new type of nitrogen mustard prodrug that can be activated by high level of reactive oxygen species (ROS) found in cancer cells to release the active chemotherapy agent.  The activation mechanism was detd. by NMR anal.  The activity and selectivity of these prodrugs toward ROS was detd. by measuring DNA interstrand cross-links and/or DNA alkylations.  These compds. showed 60-90% inhibition toward various cancer cells, while normal lymphocytes were not affected.  To the best of our knowledge, this is the first example of H2O2-activated anticancer prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY5EVvl5gaabVg90H21EOLACvtfcHk0lg0BiRCb0vYng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqsLvE&md5=d907a75fa0e9c33185187cdfb85fda29</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja2073824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja2073824%26sid%3Dliteratum%253Aachs%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DBalakrishnan%26aufirst%3DK.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPeng%26aufirst%3DX.%26atitle%3DHydrogen%2520peroxide%2520inducible%2520DNA%2520cross-linking%2520agents%253A%2520targeted%2520anticancer%2520prodrugs%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D19278%26epage%3D19281%26doi%3D10.1021%2Fja2073824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Noh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span> </span><span class="NLM_article-title">Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">6907</span><span class="refDoi"> DOI: 10.1038/ncomms7907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1038%2Fncomms7907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=25892552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6907&author=J.+Nohauthor=B.+Kwonauthor=E.+Hanauthor=M.+Parkauthor=W.+Yangauthor=W.+Choauthor=W.+Yooauthor=G.+Khangauthor=D.+Lee&title=Amplification+of+oxidative+stress+by+a+dual+stimuli-responsive+hybrid+drug+enhances+cancer+cell+death&doi=10.1038%2Fncomms7907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death</span></div><div class="casAuthors">Noh, Joungyoun; Kwon, Byeongsu; Han, Eunji; Park, Minhyung; Yang, Wonseok; Cho, Wooram; Yoo, Wooyoung; Khang, Gilson; Lee, Dongwon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6907</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells, compared with normal cells, are under oxidative stress assocd. with the increased generation of reactive oxygen species (ROS) including H2O2 and are also susceptible to further ROS insults.  Cancer cells adapt to oxidative stress by upregulating antioxidant systems such as glutathione to counteract the damaging effects of ROS.  Therefore, the elevation of oxidative stress preferentially in cancer cells by depleting glutathione or generating ROS is a logical therapeutic strategy for the development of anticancer drugs.  Here we report a dual stimuli-responsive hybrid anticancer drug QCA, which can be activated by H2O2 and acidic pH to release glutathione-scavenging quinone methide and ROS-generating cinnamaldehyde, resp., in cancer cells.  Quinone methide and cinnamaldehyde act in a synergistic manner to amplify oxidative stress, leading to preferential killing of cancer cells in vitro and in vivo.  We therefore anticipate that QCA has promising potential as an anticancer therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmpSt8k04fybVg90H21EOLACvtfcHk0lg0BiRCb0vYng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlaisrY%253D&md5=0f796d502d10b7e63a54cdab05287893</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fncomms7907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms7907%26sid%3Dliteratum%253Aachs%26aulast%3DNoh%26aufirst%3DJ.%26aulast%3DKwon%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DCho%26aufirst%3DW.%26aulast%3DYoo%26aufirst%3DW.%26aulast%3DKhang%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DAmplification%2520of%2520oxidative%2520stress%2520by%2520a%2520dual%2520stimuli-responsive%2520hybrid%2520drug%2520enhances%2520cancer%2520cell%2520death%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D6907%26doi%3D10.1038%2Fncomms7907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Lampiasi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzolina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervello, M.</span><span> </span><span class="NLM_article-title">The novel NF-kappaB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1016/j.canlet.2012.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2Fj.canlet.2012.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=22343223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Kjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2012&pages=35-44&author=N.+Lampiasiauthor=A.+Azzolinaauthor=K.+Umezawaauthor=G.+Montaltoauthor=J.+A.+McCubreyauthor=M.+Cervello&title=The+novel+NF-kappaB+inhibitor+DHMEQ+synergizes+with+celecoxib+to+exert+antitumor+effects+on+human+liver+cancer+cells+by+a+ROS-dependent+mechanism&doi=10.1016%2Fj.canlet.2012.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism</span></div><div class="casAuthors">Lampiasi, Nadia; Azzolina, Antonina; Umezawa, Kazuo; Montalto, Giuseppe; McCubrey, James A.; Cervello, Melchiorre</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In a previous work of ours dehydroxymethyl-epoxyquinomicin (DHMEQ), an inhibitor of NF-κB, was shown to induce apoptosis through Reactive Oxygen Species (ROS) prodn. in hepatoma cells.  The present study demonstrated that DHMEQ cooperates with Celecoxib (CLX) to decrease NF-κB DNA binding and to inhibit cell growth and proliferation more effectively than treatment with these single agents alone in the hepatoma cell lines HA22T/VGH and Huh-6.  ROS prodn. induced by the DHMEQ-CLX combination in turn generated the expression of genes involved in endoplasmic reticulum (ER) stress and silencing TRB3 mRNA significantly decreased DHMEQ-CLX-induced cell growth inhibition.  Moreover, the DHMEQ-CLX combination was assocd. with induction of PARP cleavage and down-regulation of the anti-apoptotic proteins Bcl-2, Mcl-1 and survivin, as well as activated Akt.  CD95 and CD95 ligand expression increased synergistically in the combination treatment, which was reversed in the presence of NAC.  Knockdown of CD95 mRNA expression significantly decreased DHMEQ-CLX-induced cell growth inhibition in both cell lines.  These data suggest that the DHMEQ-CLX combination kills hepatoma cells via ROS prodn., ER stress response and the activation of intrinsic and extrinsic apoptotic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN2Ybg0SJpHLVg90H21EOLACvtfcHk0liw4OF7rDryeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Kjtbk%253D&md5=6868d6ae8280e6294997393dbe8e3ed2</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DLampiasi%26aufirst%3DN.%26aulast%3DAzzolina%26aufirst%3DA.%26aulast%3DUmezawa%26aufirst%3DK.%26aulast%3DMontalto%26aufirst%3DG.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DCervello%26aufirst%3DM.%26atitle%3DThe%2520novel%2520NF-kappaB%2520inhibitor%2520DHMEQ%2520synergizes%2520with%2520celecoxib%2520to%2520exert%2520antitumor%2520effects%2520on%2520human%2520liver%2520cancer%2520cells%2520by%2520a%2520ROS-dependent%2520mechanism%26jtitle%3DCancer%2520Lett.%26date%3D2012%26volume%3D322%26spage%3D35%26epage%3D44%26doi%3D10.1016%2Fj.canlet.2012.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Keillor, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castonguay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lherbet, C.</span><span> </span><span class="NLM_article-title">Gamma-glutamyl transpeptidase substrate specificity and catalytic mechanism</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1016/S0076-6879(05)01027-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;key=10.1016%2FS0076-6879%2805%2901027-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=2005&pages=449-467&author=J.+W.+Keillorauthor=R.+Castonguayauthor=C.+Lherbet&title=Gamma-glutamyl+transpeptidase+substrate+specificity+and+catalytic+mechanism&doi=10.1016%2FS0076-6879%2805%2901027-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2805%2901027-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252805%252901027-X%26sid%3Dliteratum%253Aachs%26aulast%3DKeillor%26aufirst%3DJ.%2BW.%26aulast%3DCastonguay%26aufirst%3DR.%26aulast%3DLherbet%26aufirst%3DC.%26atitle%3DGamma-glutamyl%2520transpeptidase%2520substrate%2520specificity%2520and%2520catalytic%2520mechanism%26jtitle%3DMethods%2520Enzymol.%26date%3D2005%26volume%3D401%26spage%3D449%26epage%3D467%26doi%3D10.1016%2FS0076-6879%2805%2901027-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00971">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33375"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00971">10.1021/acs.jmedchem.7b00971</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic and experimental details; <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HRMS spectra of new compounds; crystallographic data for <b>9</b>; and additional biological data of <b>2</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_001.pdf">jm7b00971_si_001.pdf (1.6 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00971/suppl_file/jm7b00971_si_002.csv">jm7b00971_si_002.csv (0.74 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00971&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-21%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00971%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00971" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b14ceee691995","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
